Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 1 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL   
44-02219-000 A Randomized, Sham- Controlled Trial Evaluating the Safety and Effectiveness of 
NeuroStar Transcranial Magnetic Stimulation  (TMS) Therapy  in Depressed Adolescents  
 
 
 
Regulatory Sponsor : Neuronetics, Inc  
3222 Phoenixville Pike Malvern, PA  19355 
Principal Investigator : 
   
 
 Dr. Paul E. Croarkin  
Assistant Professor of Psychiatry  
Child and Adolescent Psychiatry Mayo Clinic  
200 First Street SW  
Rochester, MN 55905 
 
Study Product: NeuroStar TMS TherapyÂ® System using NeuroStar  XPLORÂ® 
research configuration  
  
 Rev A:  June 8, 2015 
Rev B:  June 19, 2015 
Rev C: August 3 1, 2015  
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI
5HYLVLRQ&$XJ
&21),'(17,$/7DEOHRI&RQWHQWV
 &217$&7,1)250$7, 21$33529$/6   
 (0(5*(1&< &217$&7   
 $'',7,21$/ &217$&76   
 0(',&$/021,725 6,*1$785(   
 ,19(67,*$725$ *5((0(17   
 ,167,787,21$/5(9 ,(:%2$5' ,5%   
 ',6&/2685(6 7$7(0(1 7   
 /,672)$%%5(9,$7,216   
 678'<680 0$5<    
 ,1752'8&7,21    
 %$&.*5281'    
1HXUR6WDU7067KHUDS\6\VWHP0HFKDQLVPRI$FWLRQ    
(IILFDF\DQG6DIHW\RI706DQGWKH1HXUR6WDU7067KHUDS\ÂŠ6\VWHPLQ0DMRU'HSUHVVLRQLQ$GXOW3DWLHQWV  
(IILFDF\DQG6DIHW\RI706DQGWKH1HXUR6WDU7067KHUDS\ÂŠ6\VWHPLQ0DMRU'HSUHVVLRQLQ$GROHVFHQW3DWLHQWV  
 ,19(67,*$7,21$/ '(9,&(   
 &/,1,&$/'$7$72'$7(   
 678'<5$7,21$/($1' 5,6.%(1(),76   
6WXG\5DWLRQDOH    
$QWLFLSDWHG5LVNV    
3RWHQWLDO%HQHILWV    
 678'<2%-(& 7,9(6    
 35,0$5<2%-(&7,9(3+$6(,   
 6(&21'$5<2%-(&7,9(6    
3KDVH,    
3KDVH,,    
3KDVH,,,    
 678'<'(6 ,*1    
 *(1(5$/'(6,*1   
6FUHHQLQJ    
7067UHDWPHQW    
6WUXFWXUDO+HDG05,6XEVHW/LPLWHGVWXG\VLWHV  
 ()),&$&<$1' 6$)(7<$66(660(176    
3KDVH,    
3KDVH,,    
3KDVH,,,    
 6758&785$/ +($'05,/,0,7('678'<6,7(6    
 68%-(&76(/(&7,21(152 //0(17$1':, 7+'5$:$/   
 ,1&/86,21 &5,7(5,$   
 (;&/86,21 &5,7(5,$   
 68%-(&75(&58,70(17 (152//0(17$1' 6&5((1,1*  
6XEMHFW5HFUXLWPHQW    
6XEMHFW(QUROOPHQW    
6XEMHFW6FUHHQLQJ  
 ($5/<:,7+'5$:$/2) 68%-(&76   
:KHQDQG+RZWR:LWKGUDZ6XEMHFWV    
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI
5HYLVLRQ&$XJ
&21),'(17,$/ 678'<'(9 ,&(    
 '(6&5,37,21    
 68%-(&7,'(17,),&$7,21    
 5$1'20,=$7,21    
 0$6.,1*    
 35(3$5$7,21$1'$'0,1,675$7,212),19(67,*$7,21$/'(9,&(   
 027257+5(6+2/' '(7(50,1$7,21 352&('85( Â±3(51(85267$586(50$18$/  
 75($70(17    
 3$&.$*,1*$1' /$%(/,1*   
 %/,1',1*2) 678'<   
 5(&(,9,1*6725$*(',675,%87,21$1' 5(7851  
5HFHLSWRI,QYHVWLJ DWLRQDO' HYLFHV    
6WRUDJH    
'LVWULEXWLRQRI6WXG\'HYLFH  
5HWXUQRU'HVWUXFWLRQRI6WXG\'HYLFH    
 678'<352 &('85( 6    
 678'<29(59,(:   
 68%-(&7&203/,$1&( 021,725,1*    
 35,25$1'&21&20,7$17 7+(5$3<   
3HUPLWWHG&RQFRPLWDQW7KHUDS\    
3URKLELWHG&RQFRP LWDQW7KHUDS\    
 3+$6(6Â±5$1'20,=(' 75,3/(%/,1'('   
 67$7,67,&$/ 3/$1    
 6$03/(6,=($1'32:(5&$/&8/$7,21    
 $1$/<6,63/$1   
 6$)(7<$1'$'9(56 ((9(176   
 $'9(56((9(17'(),1,7,216    
 7,0,1*)25 5(3257,1*2) 6(5,286$'9(56((9(176  
 5(3257$%/( (9(176   
5(3257,1*352&('85(6  
 $'9(56((9(175(3257,1*3(5,2'   
 81%/,1',1* 352&('85(6 %5($.,1*7+( %/,1'   
 67233,1*58/(6   
 0(',&$/021,725,1*    
'DWDDQG6DIHW\0RQLWRULQJ%RDUG    
 '$7$+$1'/,1*$1'5 (&25'.( (3,1*   
 &21),'(17,$/,7<    
 6285&('2&80(176    
 &$6(5(3257)2506   
 5(&25'65(7(17,21   
 678'<021,725,1*$8',7, 1*$1',163 (&7,1*   
 678'<021,725,1* 3/$1   
 $8',7,1*$1' ,163(&7,1*    
 (7+,&$/&216, '(5$7,2 16   
 5()(5( 1&(6    
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 4 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  APPENDIX A. PHASE I SCHEDULE OF EVENTS ........................................................................................ 53 
APPENDIX B. PHASE II SCHEDULE OF EVENTS ....................................................................................... 55 
APPENDIX C. PHASE III SCHEDULE OF EVENTS ...................................................................................... 56 
APPENDIX D. ........................................................................................................................................... 57 
 CONCOMITANT MEDICATION LIST ........................................................................................................ 57 
 
 
 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI
5HYLVLRQ&$XJ
&21),'(17,$/&RQWDFW,QIRUPDWLRQ$SSURYDOV
(PHUJHQF\&RQWDFW
&RQWDFWWKHIROORZLQJIRUDOOVHULRXVDGYHUVHHYHQWVHPHUJHQFL HVDQGRWKHULQTXLULHVDQGLQIRUPDWLRQ
DERXWWKLVVWXG\
$VVRFLDWH'LUHFWRU&OLQLFDO'HYHORSPHQW 
1DPH   $QJHOD:DOWPDQ
&RXQWU\  86$
3KRQH  H[W
)D[   
'LUHFWRU0HGLFDO2SHUDWLRQV 
1DPH   .DUHQ+HDUW
&RXQWU\  86$
3KRQH  H[W
)D[   
(PHUJHQF\7HOHSKRQH1XPEHU,I WKHSHUVRQQDPHGDERYHFDQQRWEH UHDFKHGFDOODQG
LQGLFDWHWKDW\RXKDYHDVWXG\GHYLFHUHODWHGHPHUJHQF\
$GGLWLRQDO&RQWDFWV
0HGLFDO0RQLWRU
1DPH  0DUN$'HPLWUDFN0'
&RXQWU\ 86$ 
3KRQH H[W)D[  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 6 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  2 Medical Monitor Signature  
I have read and approve this protocol. This study will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality.  
 
 
Medical Monitorâ€™s Signature   Date of Signature  
(DD Mmm YYYY)  
   
   
Mark A. Demitrack, MD    
Medical Monitorâ€™s Name (print)    
   
 
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 7 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  3 Investigator  Agreement  
I have read this protocol and agree that it contains all necessary details for conducting the study as 
described.  
I will conduct this investigation in accordance with the agreement, the investigational plan, Part 812 and 
other applicable FDA regulations, and any conditions of approval imposed by the Institutional Review 
Board (IRB) and FDA. 
I will provide a copy of my current curriculum vitae.  
I will provide a summary of my relevant clinical experience (including dates, location, extent and type of 
experience) for the conduct of this trial.  
By signing this document, I attest to the fact that I have not been involved in an investigation or other 
research that was terminated, or if so, I will provide an explanation of the circumstances that led to termination.  
I will maintain all confidentiality.  
I will supervise all testing of the device involving human subjects. 
I will ensure that all stud y personnel are appropriately trained and that they have access to all relevant 
documents related to the investigations, as furnished by the sponsor. 
I will discuss all relevant study -related information with study personnel to ensure that they are fully 
informed about the device and the studies.  
I will assure that all requirements of informed consent are met for subjects participating in these studies.  
I understand that this study may be terminated or enrollment suspended at any time by the sponsor, with 
or without cause, or by me if it becomes necessary to protect the best interests of the study subjects.  
 
 
Investigatorâ€™s Signature   Date of Signature  
(DD Mmm YYYY)  
   
Investigatorâ€™s Name (print)    
 
 
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 8 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  4 Institutional Review Board (IRB ) 
The name, address,  and phone number of the IRB used by each site participating in this study is identified 
below. 
 
IRB:   
 
Address:   
 
   
 
Phone No.:    
 
 
IRB:   
 
Address:   
 
   
 
Phone No.:    
 
 
IRB:   
 
Address:   
 
   
 
Phone No.:    
 
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 9 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  5 Disclosure  Statement  
This protocol contains information that is confidential and proprietary to the sponsor. It is being provided 
to you for the sole purpose of evaluating and/or conducting a clinical trial for the sponsor. You may 
disclose the contents of this document only to study personnel under your supervision, IRBs, or duly 
authorized representatives of the U.S. FDA or other regulatory authority for this purpose under the 
condition that they maintain confidentiality.  
The contents of this protocol may not be used in any other device trial, disclosed to any other person or 
entity, and/or published without the prior written permission of the sponsor. The foregoing shall not apply 
to disclosure required by any regulations; however, you will give prompt notice to the sponsor of any 
such disclosure. 
Any information that may be added to this protocol is also confidential and proprietary to the sponsor and 
must be kept in confidence in the same manner as the contents of this protocol. 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 10 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  6 List of Abbreviations  
1H-MRS Proton Magnetic  Resonance Spectroscopy  
3T 3 Tesla 
AC Anterior Cingulate  
AE Adverse Event/Adverse Experience  
AMI Autobiographical Memory Interview  
APB Abductor Pollicis Brevis  
ATHF Antidepressant Treatment History Form  
ATR Antidepressant Treatment Record  
CDRS-R Childhood Depression Rating Scale â€“ Revised 
CFR Code of Federal Regulations  
CGI-S Clinical Global Impression â€“ Severity of Illness  
CRF Case Report Form  
CSF Cerebrospinal Fluid  
C-SSRS Columbia â€“ Suicide Severity Rating Scale  
DSMB Data and Safety Monitoring Board  
DSM-5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
eCRF Electronic Case Report Form  
ECT Electroconvulsive Therapy  
EDC Electronic Data Capture  
EMR Electronic Medical Record  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HAMD Hamilton Depression Rating Scale  
HIPAA Health Insurance Portability and Accountability Act  
Hz Hertz 
IDE Investigational Device Exemption  
IRB Institutional Review Board  
ITT Intention-to-Treat 
L-DLPFC Left Dorsolateral Prefrontal Cortex  
MADRS Montgomery Asberg Depression Rating Scale  
M.I.N.I. Mini International Neuropsychiatric Interview  
M.I.N.I. KID Mini International Neuropsychiatric Interview for Children and Adolescents  
MDD Major Depressive Disorder  
MRI Magnetic  Resonance Imaging  
MRS Magnetic Resonance Spectroscopy  
NIH National Institute s of Health 
PHI Protected Health Information  
PI Principal Investigator  
QIDS-A17-SR Quick Inventory of Depressive Symptoms â€“ Adolescent Version â€“ Self Report  
TMS Transcranial  Magnetic Stimulation  
SAE Serious Adverse Event/Serious Adverse Experience  
SOP Standard Operating Procedure  
SSRI Selective Serotonin Reuptake Inhibitor  
TASS Transcranial Magnetic Stimulation Adult Safety Screen  
TEEQ Treatment Expectations and Experience Questionnaire  
YMRS Young Mania Rating Scale  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 11 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  7 Study Summary  
 
Title A Randomized, Sham- Controlled Trial of the Safety and Effectiveness of 
NeuroStar Transcranial Magnetic Stimulation  (TMS) Therapy in Depressed 
Adolescents  
Running Title NeuroStarÂ® TMS Adolescent MDD RCT 
Protocol Number  44-02219-000  
Methodology  Randomized, sham-controlled, triple -blinded; crossover open-label acute 
treatment and post treatment follow up. (Investigator Blinded to criteria for 
eligibility to entry into crossover study phase) 
Overall Study 
Duration 42 months   
Subject Participation 
Duration Screening to Randomization:  1 week 
 Phase I (Randomized, B linded): 6 weeks ( Active TMS vs. Sham)  
 Phase II (Non-Randomized, Open -label): 6 weeks of open -label acute treatment 
(for Phase I subjects who did not receive protocol-defined clinical benefit ). 
(Note:  The definition of protocol defined clinical benefit is concealed from study staff.) 
 
Taper (End of Phase I or Phase II):  After acute treatment is completed  (prior to 
exit of study at end of phase or prior to entry into Phase III), subject  will receive 
3 weeks of taper treatments (week 1:3, week 2:2, week 3:1 
 
Phase III (Long term follow up): 6 month follow up with retreatment course for 
symptom re- emergence (for Phase I and II subjects who received protocol-
defined clinical benefit ) 
Objectives  Primary:   
To evaluate the antidepressant effects of daily, active TMS (when compared with 
sham treatment) in adolescents meeting criteria for Major Depressive Disorder, 
single or recurrent episode (Phase I).   
 Secondary:   
To evaluate the acute and long term safety of TMS treatment in adolescent MDD subjects. 
 To evaluate the durability of benefit of TMS treatment over the course of 6 
months in subjects who received clinical benefit from acute treatment course(s)  
(Phase III). 
 
To evaluate the benefit of daily, active, open -label TMS in Phase I subjects who 
did not receive  protocol -defined clinical benefit; as new acute treatment (sham 
to active) or as extend ed treatment course (blinded active to open label active)  
(Phase II)  
 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 12 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Structural MRI (conducted at specific sites only):   To utilize standard 
morphometric measures to determine structural changes in the brain associated 
with TMS treatment.  
Number of Subjects  Phase I: Total of 100 enrolled (50 Active/ 50 Sham) across sites 
 
Phase II: Subjects from phase I who did not receive protocol -defined clinical 
benefit from acute treatment will be offered open-label treatment  (estimated to 
be 42 subjects)  
 Phase III: Subject who did meet protocol-defined clinical benefit after acute treatment in Phase I or Phase II will be followed for 6 months post taper 
(estimated to be 37 subjects)  
 
Structural MRI subset:  Approximately 25% of subjects of the  Phase I popul ation.  
 
 
Diagnosis and Main 
Inclusion Criteria â€¢ Male or female outpatients, age 12 -21, meeting DSM-5 diagnosis of Major 
Depressive Disorder, single or recurrent  course of illness, of moderate or 
greater symptom severity  
â€¢ CGI-S score â‰¥ 4 
â€¢ HAMD 24, item 1 â‰¥ 2 and total score at least 20 at screening  
â€¢ At the end of the baseline visit, subject must have a HAMD 24 score of â‰¥ 18 
and change in score may not be â‰¥ 25% decrease from that seen at the screening visit  
â€¢ Duration of current episode of depression â‰¥ 4 weeks an d â‰¤ 3 years 
â€¢ Resistance to antidepressant treatment in a discrete illness episode defined by the Antidepressant Treatment Record (ATR):  
- Resistance to treatment defined by ATR level 1  through 4 in current 
episode.  If insufficient number of trials in the cur rent episode, then 
must also have failed  â‰¥1 and â‰¤ 4 trials in a previous ep isode 
- Subjects who have been unable to complete an  antidepressant trial of 
adequate dose and duration due to intolerance to antidepressant 
therapy may be included if they have demonstrated intolerance to â‰¥ 4 
antidepressant medications within one discrete illness episo de 
(current or a previous episode as defined above)  
â€¢ For any subject  currently receiving antidepressant medication, the clinician 
must determine that insufficient benefit is being received from this treatment 
and it is clinically appropriate to discontinue the existing antidepressant . 
Exclusion Criteria â€¢ Subjects associated directly with this study or indirectly by a parent or 
sibling being affiliated with the study.  
â€¢ Subjects diagnosed by the investigator with one or more of the following 
conditions (current, unless otherwise stated):  depression secondary to a 
general medical condition or substance- induced; seasonal pattern of 
depression; history of substance abuse or dependence within the past year (except nicotine or caffeine); any psychotic disord er (lifetime), including 
schizoaffective disorder, or major depression with psychotic features in this or previous episodes; amnestic disorder, mental retardation, bipolar disorder; 
eating disorder ( lifetime); obsessive compulsive disorder  (lifetime); or 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 13 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  posttraumatic stress disorder ( lifetime) 
â€¢ Any psychiatric diso rder, which in the judgement of the Investigator may 
hinder the subject  in completing the procedures required by the study 
protocol. 
â€¢ Subject with a clinically defined neurological disorder or insult including, 
but not limited to any condition likely increase the risk of seizure; such as,  
space occupying brain lesion; any history or family history of epilepsy ; 
history of cerebrovascular accident; tran sient ischemic attack within two 
years; cerebral aneurysm; dementia; brain surgery  or history of stroke .  
â€¢ Increased risk of seizure for any reason, including prior diagnosis of 
increased intracranial pressure or history of significant head trauma w ith loss 
of consciousness for â‰¥ 5 minutes. 
â€¢ A true positive response to any question on the TASS 
â€¢ Inability to locate and quantify a motor threshold as defined in the protocol 
â€¢ History of treatment with ECT or TMS Therapy for any disorder 
â€¢ Use of any investiga tional drug within 4 weeks of the baseline visit  
â€¢ Use of any excluded medication(s) listed on the Concomitant Medication  
List (Appendix D) within 1 week of the baseline visit  
â€¢ Significant acute suicide risk, defined as follows:  Suicide attempt within the previous 6 months that required medical treatment or â‰¥ 2 attempts in the past 
12 months, or has a clear cut plan for suicide and states that he/she cannot 
guarantee that he/she  will inform a family member or call his/her psychiatrist 
or the investigator if the im pulse to implement the plan becomes substantia l 
during the study; or, in the investigatorâ€™s opinion, is likely to attempt suicide within the next 6 months. 
â€¢ Conductive, ferromagnetic, or other magnetic- sensitive metals implanted in 
the subjectâ€™s head within 30 cm of the treatment coil excluding the mouth 
that cannot safely be removed.  Examples include cochlear implants, 
implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet 
fragments, jewelry and hair barrettes.  
â€¢ Active or inactive implants (including device leads), including deep brain 
stimulators, cochlear implants, and vagus nerve stimulators.  
â€¢ Cardiac pacemakers, implanted medication pumps, intracard iac lines, or 
acute, unstable cardiac disease  
â€¢ Known or suspected pregnancy 
â€¢ If sexually active female, not on an approved method of birth control. 
â€¢ Unstable psychotherapy ( therapy must be for at least 3 months prior to entry 
into the study, with no anticipation of change in the frequency or treatment focus of the therapeutic sessions over the duration of the study ) 
â€¢ Positive urine drug screen ( a positive screen at screening may be repeated 
once prior to randomization upon approval from the Sponsor) 
â€¢ Clinically significant laboratory abnormality  or medical condition, in the 
opinion of the Investigator would hinder the subject in completing the 
procedures required by the study.  
Study Device  NeuroStar TMS TherapyÂ® System using NeuroStar XPLORÂ® research 
configuration 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 14 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Duration of Exposure Phase I (Randomized, Blinded) : 
For subjects randomized to the active treatment, stimulation will occur at a 
maximum of 120% magnetic field intensity relative to the subjectâ€™s resting 
motor threshold (MT), at 10 pulses per second (10 Hz) for 4 seconds, with an 
intertrain interval of 26 seconds.  Repositioning of coil, per NeuroStar User 
Manual, and prophylactic use of acetaminophen or ibuprofen will be allowed for 
subjects reporting sensations at or near the stim ulation site which are 
uncomfortable.  During the first week of treatment only, in the event that the 
subject cannot tolerate the treatment at these dose parameters, dose intensity may 
be titrated downward to 110% of the motor threshold, with all other dos e 
parameters remaining the same.  Treatment sessions will last for 37.5 minutes 
(75 trains) to provide a total of 3,000 pulses per treatment session.  A maximum 
total of 36 treatments will be completed within 9 weeks of  Phase I (including the 
6 treatment s administered during the 3 week taper  phase).  If the subject meets 
criteria (blinded to Site personnel) to enter Phase II, they will not complete the 3 week taper phase, resulting in a maximum total of 30 treatments. 
 
Phase II (Non-Randomized, Open -label): 
Subjects who d o not achieve ;protocol-defined clinical benefit to treatment in 
Phase I will be offered the opportunity to undergo acute  TMS treatment using 
the known- active therapy coil in Phase II.  A maximum total of 36 treatments 
will be completed within 9 weeks of Phase II (including the 6 treatments 
administered during the 3 week taper  phase).   
 
Therefore, subjects who are randomized to active treatment during Phase I and subsequently enroll in to Phase II will receive up to a total of 66 active treatments 
using stated study parameters within the 15 week combined timeframe (including one taper phase) .  
 Subjects who are randomized to sham treatment during Phase I and subsequently 
enroll in Phase II will receive up to a total of 3 6 active treatments using stated 
study parameters within the 15 week combined timeframe (including one taper 
phase). 
 
Phase III (Long Term Follow up) :  
Subjects who achieve protocol-defined clinical benefit from treatment in Phase I 
or Phase II will be followed for 6 months after treatment . 
 
If a subject experiences re-emergence of depressive symptoms, an acute TMS 
retreatment  course will be initiated .  The TMS retreatment course will continue 
up to 6 weeks until symptom score is at or below Phase III entry score.  Each 
successful retreatment  is followed by a 3 week taper.  Subjects could receive 
retreatment on more than one occasion; therefore, any subject could receive up 
to 72 treatments in Phase III over 6 months, in addition to Phase I and II 
exposure. 
Reference Therapy Subjects in Phase I who are randomized to sham treatments will have schedules, 
systematic assessments, and treatment approaches that are identical to subjects 
randomized to active treatments.  Subjects, treaters, and clinical raters will not 
know whether the treatment is active or sh am in nature ( triple-blinded).  The 
sham coil is identical in its appearance to the active coil.  Furthermore, the sham 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 15 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  coil operates with  an acoustic ally matched profile that renders the auditory 
experience of the treatments virtually indistinguishable to  subjects or 
researcher s.  The sham coil  also creates a mild percussive sensation that may be 
felt by the subject and further assists in simulating the active condition.  The 
blinded randomization of patients in the Phase I acute phase to the active or 
sham condition will remain blinded for the duration of all study phases including 
Phases II and III .  
Concomitant Therapy  Permitted: Zaleplon, zolpidem, or zopiclone (1 dose nightly) as needed for 
treatment emergent insomnia or lorazepam (up to 2 mg daily) for treatment 
emergent anxiety , may be administered for up to 14 doses during Phase I and an 
additional 14 doses during Phase II.  For Phase III, these medications may be 
administered for up to 10 days , on â‰¤5 occasions. The use of alternative hypnot ics 
or anxiolytic compounds requires prior approval from the Sponsor.  Hormonal contraceptives are allowed if the subject has been on a stable dose for at least 3 
months. The use of alternative hypnotics or anxiolytic compounds requires prior approval from  the Sponsor.  Short- term treatments for headaches, allergies, 
colds, or flu-like symptoms  require prior approval from the Sponsor. 
 
Prohibited: Any medication administered for the treatment of any psychiatric or 
neurologic disorder or any other known CNS-active drugs, including herbal, over-the-counter, and homeopathic medications, MAOIs, other antidepressants, 
antipsychotics, stimulants and mood stabilizers. 
Statistical 
Methodology  Statistical analysis plan for Primary objective and secondary  objective s :  
â€¢ Primary efficacy outcome, HAMD24 , will be examined in a frequentist 
analysis (i.e., meta-analysis) combining the data obtained in this study 
with data borrowed from two prior randomized controlled trials 
conducted in adults tested using the same procedures outlines in this 
protocol (Oâ€™Reardon, et al., 2007; George, et al., 2010). 
â€¢ The model for this analysis will include the following terms: treatment (active vs. sham), baseline score (continuous), medication resistance 
level as determined using the Antidepressant Treatment Record (ATR), 
(ATR=1 â€˜Loâ€™ vs. ATR =2-4 â€˜Hiâ€™), and Study (adolescent study, and adult 
studies Oâ€™Reardon, et al, 2007 and George, et al, 2010) as fixed effects, and, interaction terms for â€œstudy- by-treatmentâ€ and â€œATHF medication 
resistance level -by-treatmentâ€.  A random effect of â€œsite nested within 
studyâ€ will also be included to assess any potential site effects.  
â€¢ In the absence of a statistically significant interaction between Study and 
Treatment on the primary efficacy outcome variable at a pre -specified 
alpha level = 0.10 , the continuity of efficacy across the age range 12 to 
70 will be  established , and the main effect for treatment is statistically 
significant at the alpha level = 0.05 . 
â€¢ A sample size of 50 patients per treatment condition in the adolescent study and an alpha level of 0.10 to test the Study by Treatment interaction, will detect a statistically significant Study by Treatment 
interaction if the mean treatment group difference, in favor of active, is 
greater than the upper bound of 5.5 points or less than the lower bound 
of -0.8 points.  In the absence of a statistically significant interaction 
between Study and Treatment, the lower bound of the observed 
treatment group differ ence must be greater than 1. 7 in favor of the active 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/WUHDWPHQWLQRUGHUWRERUURZGDWDIURPWKHDGXOWVWXGLHVLQDP HWD
DQDO\VLVZLWKWKHGDWDIURPWKHDGROHVFHQWVWXG\ 
,QWURGXFWLRQ
7KLVGRFXPHQWLVDSURWRFROIRU DKXPDQUHVHDUFKVWXG\7KLVVW XG\ZLOOEHFDUULHGRXWLQDFFRUGDQFHZLWK
WKHSURFHGXUHVGHVFULEHGLQWKLVSURWRFRODSSOLFDEOH8QLWHG6W DWHVDQG&DQDGLDQJRYHUQPHQWUHJXODWLRQV
DQG*RRG&OLQLFDO3UDFWLFHVDVGRFXPHQWHGLQWKHVWXG\UHIHUHQ FHPDQXDO
%DFNJURXQG
1HXUR6WDU7067KHUDS\6\VWHP0HFKDQLVPRI$FWLRQ
7KH1HXUR6WDU7067KHUDS\ÂŠ6\VWHPLVDFRPSXWHUL]HGHOHFWURPHFKDQLFDOLQVWUXPHQWWKDWSUR GXFHVDQG
GHOLYHUVEULHIGXUDWLRQUDSLGO\DOWHUQDWLQJSXOVHGPDJQHWLF ILHOGVWRLQGXFHHOHFWULFDOFXUUHQWVLQ
ORFDOL]HGUHJLRQVRIWKHFHUHEUDOFRUWH[6LQFHWKH1HXUR6WDU 7067KHUDS\6\VWHPSURGXFHVDWLPH
YDU\LQJPDJQHWLFILHOGLWVLQWHQGHGHIIHFWGHULYHVIXQGDPHQWDO O\IURP)DUDGD\Â¶V/DZZKLFKDVVHUWVWKDW
DWLPHYDU\LQJPDJQHWLFILHOGSURGXFHVDQHOHFWULFDOFXUUHQWLQ DQDGMDFHQWFRQGXFWLYHVXEVWDQFH'XULQJ
706WKHFRQGXFWLYHVXEVWDQFHRILQWHUHVWLVWKHEUDLQLQSDUW LFXODUWKHUHJLRQRIWKHFRUWH[WKDWOLHV
EHQHDWKWKH1HXUR6WDU7067KHUDS\6\VWHPWUHDWPHQWFRLO
7KHHOHFWULFFXUUHQWLQGXFHGLQWKLVUHJLRQRIWKHFRUWH[WUDYH OVLQDSDWKRUWKRJRQDOWRWKHGLUHFWLRQRIWKH
DOWHUQDWLQJPDJQHWLFILHOGZLWKWKHSRLQWRIPD[LPXPILHOGVWUH QJWKDQGJUHDWHVWFXUUHQWORFDWHGGLUHFWO\
EHQHDWKWKHFHQWHURIWKHFRLOZKLFKLVWKH1HXUR6WDU7067KHU DS\6\VWHPFRPSRQHQWWKDWUHVWVDJDLQVW
WKHSDWLHQWÂ¶VKHDGDQGWUDQVPLWVPDJQHWLFSXOVHVWRWKHSDWLHQW Â¶VEUDLQ7KHLQGXFHGFXUUHQWLVWDQJHQWLDO
WRWKHVFDOSDWWKHFRUWLFDOVXUIDFHDQGGLPLQLVKHVLQPDJQLWX GHZLWKLQFUHDVLQJGHSWK
,QWKHWDUJHWHGDUHDRIWKHPRWRUFRUWH[ZKHUHILHOGVWUHQJWK DFKLHYHVWKHVWLPXODWLRQWKUHVKROGLWLV
SRVWXODWHGWKDWQHXURQDOGHSRODUL]DWLRQRFFXUV7KLVW\SHRIPD JQHWLFILHOGLVQRWLQWHQGHGWRLQGXFHD
VHL]XUHGXULQJWKHUDSHXWLFXVH7KHSHDNPDJQHWLFILHOGVWUHQJ WKDFKLHYHGZLWKHDFKSXOVHLQWKHFRUWH[LV
DSSUR[LPDWHO\7HVOD
$OWKRXJKWKHPHFKDQLVPRIDFWL RQLVXQNQRZQLWLVK\SRWKHVL]HG WKDWWKH1HXUR6WDU7067KHUDS\
6\VWHPFDXVHVGLUHFWQHXURQDOGHSRODUL]DWLRQLQEUDLQUHJLRQVL PPHGLDWHO\DGMDFHQWWRWKHPDJQHWLFFRLO
DQGDOVRUHVXOWVLQFKDQJHVLQIXQFWLRQDODFWLYLW\LQDUHDVRI WKHEUDLQWKDWDUHV\QDSWLFDOO\FRQQHFWHGWRWKH
EUDLQUHJLRQVH[SHULHQFLQJGLUHFWQHXURQDOGHSRODUL]DWLRQ,W LVWKRXJKWWKDWWKHVHDFWLRQVPD\FDXVH
YDULRXVSK\VLRORJLFFKDQJHVLQWKHEUDLQZKLFKDUHDVVRFLDWHGZ LWKWKHV\PSWRPDWLFUHOLHIRIGHSUHVVLRQ
LQSDWLHQWV
(IILFDF\DQG6DIHW\RI706DQGWKH1HXUR6WDU7067KHUDS\ÂŠ6\VWHPLQ0DMRU'HSUHVVLRQLQ
$GXOW3DWLHQWV
7KHHIILFDF\DQGVDIHW\RIWKH1HXUR6WDU7067KHUDS\6\VWHPLQ DGXOWSDWLHQWVZLWKPDMRUGHSUHVVLYH
GLVRUGHU0''ZKRIDLOHGWRUHFHLYHVDWLVIDFWRU\LPSURYHPHQWI URPSULRUDQWLGHSUHVVDQWPHGLFDWLRQZDV
HVWDEOLVKHGLQWZRUDQGRPL]HGFRQWUROOHGWULDOV2Â¶5HDUGRQ -DQLFDN*HRUJH
&OLQLFDOHIILFDF\RXWFRPHVRIWKHXVHRI1HXUR6WDU7067KHUDS\ LQDGXOWSDWLHQWVZLWKPDMRUGHSUHVVLRQ
LQUHDOZRUOGFOLQLFDOSUDFWLFH ZDVGHPRQVWUDWHGLQDPXOWLVLWH QDWXUDOLVWLFVWXG\LQ86FHQWHUVXQGHU
FRQGLWLRQVRIJHQHUDOFOLQLFDOXVH&DUSHQWHU-DQLFDN 

Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 17 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  A company- independent, randomized controlled trial funded by the National Institute of Mental Health, 
evaluated the safety and efficacy of TMS using a clinical  trial version of the NeuroStar TMS Therapy 
System in adult patients (N=197, 4 sites) with moderate to severe major depressive disorder and wh o 
failed to benefit from 1 through 4 adequate antidepressant medication trials, as defined using the 
Antidepressant Treatment History Form (ATHF), or who could not tolerate 3 or more antidepressant 
medications (George 2010).  
The study evaluated 197 outpat ients across 4 sites, ages 21 -70 years, most with a recurrent course of 
major depression (~97%), with the maximum duration of the current episode of depression of â‰¤3 years. Patients had received a median of 1.6 total prior antidepressant medications at an adequate dose and 
duration in the current episode or a median of 4 treatment attempts at any dose and duration.   
 
The primary outcome measure was remission using the HAMD24 (HAMD24 total score â‰¤3 or 2 
consecutive HAMD24 total scores <10) through 6 weeks of acute treatment. A statistically significant 
benefit of active TMS as compared to sham treatment for the HAMD24 remission outcome (Active TMS: 
13.4% vs Sham TMS: 5.0%, P=0. 0173) was observed in the ITT study population (N=197).  An adjusted 
odds ratio o f achieving remission with active TMS was 4.05 (95% confidence interval (CI), 1.28-12.83) 
as compared to sham TMS. The baseline to endpoint change score outcome using the HAMD24 also 
favored active TMS compared to sham treatment ( -2.11, 95% CI: -4.30, 0.08; P=0.0588).  Baseline to 
endpoint outcomes for patients treated with active TMS were statistically significant as compared to sham 
treatment as measured using the MADRS (P=0.0136), CGI-S (P=0.0181) and the patient- rated IDS -SR 
(P=0.0008). For the categorical endpoints, higher rates of remission were observed for patients receiving 
active TMS as compared to sham treatment as  measured using the MADRS (P=0.0170) and the patient -
rated IDS -SR (P=0.1199), and for response (50% improvement from baseline) for all three measures 
(HAMD24, P=0.0104; MADRS, P=0.0063; IDS-SR, P=0.0145). Standardized effect size estimates for the continuous outcome endpoints range from 0.43 to 0.67, indicating a moderate to large effect size in this 
patient population.  Study 101 evaluated the safety and efficacy of NeuroStar TMS Therapy in 301 adult outpatients across 23 sites with moderate to severe major depressive disorder and who failed to benefit from 1 through 4 prior antidepressant medication trials administered at an adequate dose and duration, 
and verified using the ATHF (Oâ€™Reardon2007; Janicak, 2008). The patient population was similar to 
patients enrolled in the independent NIMH-funded trial.  Outcome on the primary efficacy endpoint 
(MADRS change from baseline at 4 weeks) fav ored NeuroStar TMS Therapy (P=0.057) ove r sham 
treatment for the ATHF 1 through 4 population. A subgroup analysis of the overall study population demonstrated that the device was safe and effective for patients who had failed to achieve satisfactory 
improvement from one prior antidepressant medication (N=164 patients, P=0.0006, MADRS, primary 
efficacy endpoint) in the current episode.  
Study 19- 50001 was a multisite naturalistic study in 42 US centers that evaluated the acute efficacy and 
12-month durability of NeuroStar TMS Therapy under conditions of general clinical use (Carpenter, 
2012; Janicak, 2013; Dunner 2014).  This study enrolled adult patients (N=307) with MDD who failed to 
benefit from any number of antidepressant medications administered at an adequate dose and duration 
(mean of 2.5, range 0-14) in the current episode. 
 
There was a statistically significant improvement from baseline in CGI -S total score (CGI -S, âˆ’1.9 Â± 1.4, 
P < .0001, primary efficacy outcome) at end of acute treatment. A similar  pattern and magnitude of 
clinical improvement was observed in the two patient self- reported outcome measures, the PHQ -9 (âˆ’8.7 Â± 
7.2, P <0.0001) and the IDS-SR (âˆ’18.3 Â± 14.9, P<0.0001). Categorical response and remission rates were 
consistent in clinical m agnitude on all three outcome measures i.e., CGI -S (58.0% response; 37.1% 
remission), PHQ -9 (56.4% response; 28.7% remission), and IDS-SR (41.5% response; 26.5% remission). 
 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/6WXG\DOVRHYDOXDWHGWKHGXUDELOLW\RIDFXWHEHQHILWZ LWK1HXUR6WDU7067KHUDS\ÂŠGXULQJ
PRQWKVRIIROORZXSLQSDWLHQWVPDLQWDLQHGRQDQWLGHSUHVVDQWPH GLFDWLRQDQGRUZLWKSHULRGLF706
UHLQWURGXFWLRQIRUV\PSWRPZRUVH QLQJ'XQQHU2YHUDOO RISDWLHQWVUHTXLUHGUHWUHDWPHQW
ZLWK706RYHUPRQWKV$PRQJDFXWHWUHDWPHQWUHPLWWHUV RISDWLHQWVH[SHULHQFHGUHODSVHRYHU
WKHVXEVHTXHQWPRQWKVRIIROORZXS
7KHVDIHW\RIWKH1HXUR6WDU7066\VWHPIRUWKHWUHDWPHQWRISDW LHQWVZLWK0''ZDVGHPRQVWUDWHGLQ
1HXURQHWLFVVWXGLHVDVUHSRUWHGE\-DQLFDNDQGFROOHDJXHV 7KHVHVWXGLHVHYDOXDWHGVDIHW\E\WKH
DQDO\VLVRIVSRQWDQHRXVO\UHSRUWHGDGYHUVHHYHQWVDVZHOODVWD UJHWHGPHDVXUHVRIFRJQLWLYHIXQFWLRQDQG
DXGLWRU\WKUHVKROG7KHPRVWIUHTXHQWGHYLFHUHODWHGDGYHUVHH YHQWUHSRUWHGZDVFXWDQHRXVGLVFRPIRUWDW
WKHVLWHRIDSSOLFDWLRQZKLFKZDVUHSRUWHGLQDSSUR[LPDWHO\ RISDWLHQWV7KHUHZHUHQRQHJDWLYH
HIIHFWVRQFRJQLWLYHRUDXGLWRU\IXQFWLRQ*HRUJHDQGFROOHDJXH V*HRUJHUHSRUWHGVDIHW\GDWDLQ
WKHLUVWXG\WKDWZHUHFRQVLVWHQWZLWKWKHLQIRUPDWLRQUHSRUWHG E\-DQLFDN
(IILFDF\DQG6DIHW\RI706DQGWKH1HXUR6WDU7067KHUDS\
ÂŠ6\VWHPLQ0DMRU'HSUHVVLRQLQ
$GROHVFHQW3DWLHQWV
7KLVUHVHDUFKSURSRVDOLVLQWHQGHGWRSURYLGHWKHILUVWUDQGRPL ]HGEOLQGHGVKDPFRQWUROOHGVWXG\RI
UHSHWLWLYHWUDQVFUDQLDOPDJQHWLFVWLPXODWLRQ706LQGHSUHVVHG DGROHVFHQWV7KLVVWXG\ZLOOEHWKHILUVW
WRFRPSDUHDFWLYHWUHDWPHQWZLWKDSODFHERVKDPWUHDWPHQWFRQ GLWLRQLQDGROHVFHQWVZKRKDYHQRW
UHVSRQGHGWRDWOHDVWRQHDGHTXDWHFRXUVHRIDQWLGHSUHVVDQWSKD UPDFRWKHUDS\7KXVIDU706KDVSURYHQ
WREHDVDIHWUHDWPHQWDSSURDFKZLWKHDUO\SURPLVHDVDQHIIHFW LYHDQGZHOOWROHUDWHGWUHDWPHQWRSWLRQLQ
\RXWKEXWLWKDVQRW\HWEHHQWHVWHGXQGHUWKHVFLHQWLILFULJR URIDEOLQGHGVKDPFRQWUROOHGWULDO

$OWKRXJKWKHH[DFWPHFKDQLVPRI DFWLRQUHPDLQVXQNQRZQ706VWL PXODWHVFRUWLFDOQHXURQVXVLQJSXOVHG
PDJQHWLFILHOGVJHQHUDWHGE\UDSLGO\FKDQJLQJFXUUHQWVLQDFRL ORIZLUHSODFHGRQWKHVFDOS%\XVLQJ
DGYDQFHGLPDJLQJWHFKQLTXHVWKDWDQDO\]HWKHPDJQHWLFUHVRQDQFH VSHFWURVFRS\056SDWWHUQVRI706
UHVSRQVHLQGHSUHVVHGDGROHVFHQWVWKLVSURSRVDOZLOOVHUYHDV DODQGPDUNLQDGYDQFLQJWKHVFLHQWLILF
XQGHUVWDQGLQJRIWZRILHOGVÂ±QHXURVWLPXODWLRQDQGWKHSUDFWLFH RIFKLOGDQGDGROHVFHQWSV\FKLDWU\7KLV
UHVHDUFKSURWRFROZLOOIXQGDPHQ WDOO\FKDQJHKRZ706LVYLHZHGD VDWUHDWPHQWLQWHUYHQWLRQLQGHSUHVVHG
DGROHVFHQWV

&URDUNLQDQGFROOHDJXHV:DOOKDYHSXEOLVKHGSUHYLRXVWU LDOGDWDGHPRQVWUDWLQJWKHVDIHW\DQG
HIILFDF\RIRSHQODEHO706LQGHSUHVVHGDGROHVFHQWVXVLQJWKH1 HXUR6WDU7067KHUDS\6\VWHP7RGDWH
WKLVLVWKHODUJHVWNQRZQWULDOLQWKH8QLWHG6WDWHVGHPRQVWUDW LQJWKHWROHUDELOLW\DQGWKHUDSHXWLFSRWHQWLDO
RI706LQGHSUHVVHGDGROHVFHQWV'DWDRQWKHHIILFDF\DQGVDIH W\RI706LQDGROHVFHQWGHSUHVVLRQLV
GLVFXVVHGIXUWKHULQ6HFWLRQEHORZ
,QYHVWLJDWLRQDO'HYLFH
7KH1HXUR6WDU;3/25ÂŠ7067KHUDS\6\VWHPLVDFOLQLFDOUHVHDUFKRSWLRQIRUWKH1HXUR 6WDU706
7KHUDS\ÂŠ6\VWHPWKDWSURYLGHVIHDWXUHVQHFHVVDU\WRFRQGXFWUDQGRPL]HG FRQWUROOHGWULDOVDQGRWKHU706
UHVHDUFK7KH;3/25UHVHDUFKFRQILJXUDWLRQFRQVLVWVRIWKUHHF RLOVDNQRZQDFWLYHFRLOLGHQWLFDOWRWKH
1HXUR6WDU7067KHUDS\6\VWHPWUH DWPHQWFRLODQGWZRLGHQWLFDO Â³EOLQGHGÂ´FRLOV2QHRIWKHEOLQGHG
FRLOVSURYLGHVDFWLYHWUHDWPHQWLGHQWLFDOWRWKHNQRZQDFWLYH1 HXUR6WDU7067KHUDS\6\VWHPWUHDWPHQW
FRLOWKHVKDPFRLOSURYLGHVDFRXVWLFDOO\LQGLVWLQJXLVKDEOHIU RPDFWLYHSXOVHVDQGDJHQWOHSHUFXVVLYH
VHQVDWLRQWKDWVLPXODWHVVFDOSVHQVDWLRQVSURGXFHGGXULQJDFWLY HWUHDWPHQW
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/
&OLQLFDO'DWDWR'DWH
(IILFDF\RI706IRUWKHWUHDWPHQWRIDGROHVFHQWGHSUHVVLRQIRU DOO706GHYLFHVLQFOXGLQJWKH1HXUR6WDU
7067KHUDS\ÂŠ6\VWHPKDVEHHQUHSRUWHGLQWZ RSLORWFOLQLFDOVWXGLHVDQGLQ PXOWLSOHFDVHUHSRUWV
:DOWHU%ORFK:DOO7KHVHRSHQODEHOVWXGLHV GHVFULEHWKHWUHDWPHQWRISDWLHQWV
DJHV7KH:DOOHWDORSHQODEHOWULDOLVWKHRQO\ VWXG\WKDWXVHGWKH1HXUR6WDU7067KHUDS\
6\VWHP7KLVVWXG\UHSRUWHGRQWKHWUHDWPHQWRIDQWLGHSUHVVD QWUHVLVWDQWDGROHVFHQWVDQGGHPRQVWUDWHG
DUREXVWUHVSRQVHUDWHQRWHGE\RIVXEMHFWVDFKLHYLQJUHPLV VLRQRIGHSUHVVLRQDVUDWHGXVLQJWKH
&KLOGKRRG'HSUHVVLRQ5DWLQJ6FDOH Â±5HYLVHG&'565)XUWKHUP RUH&'565PHDQGHSUHVVLRQ
VHYHULW\VFRUHVZHUHVLJQLILFDQWE\WUHDWPHQWDVFRPSDUHGWR EDVHOLQHZLWKVLPLODUHIILFDF\
GHPRQVWUDWHGXVLQJWKHSDWLHQWUHSRUWHG4XLFN,QYHQWRU\RI'HSU HVVLYH6\PSWRPVÂ± $GROHVFHQW9HUVLRQ
4,'6$65)LJXUH3ODFHERHIIHFWVLQRSHQODEHOWULDOV RIDGROHVFHQWVDUHDZHOONQRZQ
SKHQRPHQRQ+RZHYHUDVVKRZQLQ)LJXUHWKHDGROHVFHQWVWUH DWHGLQWKLVSURWRFROZHUHVKRZQWR
GHPRQVWUDWHHQGXULQJPRRGLPSURYHPHQWIRUDWOHDVWPRQWKVIRO ORZLQJWKHLUILQDODFXWHWUHDWPHQW
VHVVLRQ)XUWKHUPRUHRIVXEMHFWVFRPSOHWHGWKHHQWLU HWUHDWPHQWFRXUVHZLWKSDWLHQWH[LWLQJ
WKHVWXG\DIWHURQO\PLQXWHVRIWUHDWPHQWGXHWRVFDOSGLVFRP IRUWDQGDSHUFHLYHGODFNRILPSURYHPHQW



)LJXUHÂ±&'565DQG4,'6$650HDQ6FRUH&KDQJHIURP%DVHOL QHLQ
'HSUHVVHG$GROHVFHQWVLQDQ2SHQODEHO7067ULDO:DOOHWDO -&OLQ3V\FKLDWU\
S









3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/
6WXG\5DWLRQDOHDQG5LVN%HQHILWV
6WXG\5DWLRQDOH
$ODUJHSHUFHQWDJHRIDGROHVFHQWVVXIIHULQJIURP0DMRU'HSUHVVL YH'LVRUGHU0''GRQRWDGHTXDWHO\
EHQHILWIURPFXUUHQWO\DYDLODEOHPHGLFDWLRQVSV\FKRWKHUDS\DQ GRUVRFLDOVXSSRUWWUHDWPHQWV,QIDFWLWLV
HVWLPDWHGWKDWFXUUHQWWUHDWPHQWDSSURDFKHVFRQVLGHUHGVHSDUDW HO\IDLOWRSURYLGHDGHTXDWHFOLQLFDO
LPSURYHPHQWLQRIDGROHVFHQWVZLWK0''0RUHRYHUWKHVHWUH DWPHQWDSSURDFKHVSURGXFHFRPSOHWH
UHPLVVLRQLQRQO\RIDGROHVFHQWSDWLHQWV0DUFK0DUFK %UHQW:DONXS
8QIRUWXQDWHO\DGROHVFHQWVZLWKSHUVLVWHQWV\PSWRPVRIGHSUHVVL RQDUHPRUHOLNHO\WRH[SHULHQFHLQSDWLHQW
SV\FKLDWULFKRVSLWDOL]DWLRQSV\FKRVRFLDOPDODGMXVWPHQWDQGVX LFLGDOLW\&URDUNLQ&RQVHTXHQWO\
WKH\DUHPRUHOLNHO\WRUHFHLYHDGGLWLRQDOSV\FKRSKDUPDFRORJLF DJHQWVWKDWJHQHUDOO\RIIHUOLWWOHDGGLWLRQDO
EHQHILWDQGLQFUHDVHWKHULVNRIDGYHUVHHIIHFWV
7KHFXUUHQWOLWHUDWXUHLQFOXVLYHRIHYLGHQFHDFURVVDOO706GHY LFHVGHVFULEHVDWRWDORIDSSUR[LPDWHO\
DGXOWVXEMHFWVVDIHO\WUHDWHGZLWK706,QWKLVSXEOLVKH GOLWHUDWXUHWKHWZRODUJHVWVKDP
FRQWUROOHGUDQGRPL]HGFOLQLFDOWULDOVZLWKDFRPELQHGVDPSOH RIDERXWSDWLHQWVXVHGWKH1HXUR6WDU
7067KHUDS\
ÂŠ6\VWHPLQVLPLODUSDWLHQWSRSXODWLRQVDQGZLWKWKHLGHQWLFDO WUHDWPHQWSDUDPHWHUVDQG
UHJLRQDOEUDLQORFDOL]DWLRQIRUSODFHPHQWRIWKHGHYLFHRQWKH KHDG7KHVHVWXGLHVERWKGHPRQVWUDWHGWKH
VDIHW\DQGHIILFDF\RI1HXUR6WDU706PRQRWKHUDS\DSSOLHGWRWKH OHIWGRUVRODWHUDOSUHIURQWDOFRUWH[/
'/3)&LQGHSUHVVHGDGXOWV2 
5HDUGRQ*HRUJH$VG LVFXVVHGDERYH706KDVEHHQDSSOLHG
WRDPXFKVPDOOHUQXPEHURIDGROHVFHQWGHSUHVVHGSDWLHQWV,Q IRXUVHSDUDWHVWXGLHVXVLQJYDU\LQJFOLQLFDO
FKDUDFWHULVWLFVGHYLFHVDQGVWLPXOXVGRVLQJVLJQLILFDQWLPSU RYHPHQWZDVGHPRQVWUDWHGLQRI
SDWLHQWVZLWKQRHYLGHQFHRIVLJQLILFDQWWUHDWPHQWUHODWHGDGYH UVHHYHQWVRWKHUWKDQVFDOSGLVFRPIRUW
ERUHGRPGXULQJWKHWUHDWPHQWDQGPLOGKHDGDFKHV:DOWHU /RR%ORFK:DOO,Q
UHFHQW\HDUV706WUHDWPHQWSDUDPHWHUVKDYHDGYDQFHGZLWKUHJDU GWRDQLQFUHDVHLQWKHQXPEHURI
VWLPXODWLRQVSHUVHVVLRQDQGLQWKHSHUFHQWDJHRIPRWRUWKUHVKR OGDWZKLFKWKHVWLPXODWLRQVDUHDSSOLHGWR
WKHFXUUHQWVWDQGDUGLQFOLQLFDOFDUHZKHUHDVSHFLILHGWUHDWPH QWSDUDPHWHUVHWKDVEHHQHVWDEOLVKHGIRU
URXWLQHFOLQLFDOFDUHZLWKDWUHDWPHQWVLWHRYHUWKHOHIWGRUV RODWHUDOSUHIURQWDOFRUWH[

$QWLFLSDWHG5LVNV
6HL]XUHV
5HSHWLWLYHWUDQVFUDQLDOPDJQHWLFVWLPXODWLRQLVJHQHUDOO\UHJDU GHGDVVDIHDQGZLWKRXWDQ\ VHULRXVRU
ODVWLQJDGYHUVHHIIHFWV:DVVHUPDQ5RVVL,QDGYHUW HQWLQGXFWLRQRIDVHL]XUHLVWKHPRVW
PHGLFDOO\VLJQLILFDQWSRWHQWLDOVDIHW\FRQFHUQ+RZHYHUZLWK WKHDGRSWLRQDQGZLGHVSUHDGXVHRI
UHFRPPHQGDWLRQVGHOLQHDWLQJDVDIHPDUJLQIRUERWKLQWHUWUDLQL QWHUYDOVDQGIRURWKHUUHOHYDQW706
GRVLQJSDUDPHWHUVDVGLVVHPLQDWHGLQWKH706FRQVHQVXVVDI HW\JXLGHOLQHIURPWKH1DWLRQDO
,QVWLWXWHRI1HXURORJLFDO'LVRUGHUVDQG6WURNH1,1'6WKHULVNIRUVHL]XUHVLVVLJQLILFDQWO\PLWLJDWHGLQ
URXWLQHFOLQLFDOSUDFWLFH,Q1HXURQHWLFVÂ¶SRVWPDUNHWVXUYHLO ODQFHH[SHULHQFHWKHLQFLGHQFHRI
LQDGYHUWHQWVHL]XUHLQGXFWLRQLVSHUSDWLHQW1HXURQHWLFV GDWDRQILOH7KLVVWXG\ZLOOFRPSO\
ZLWK1,1'6JXLGHOLQHVWDQGDUGV IRU706:DVVHUPDQ5RVVL DQGFXUUHQWSUDFWLFHHVWDEOLVKHG
IRUWKH)'$FOHDUHGODEHOHGXVHRIWKH1HXUR6WDU7067KHUDS\ÂŠ6\VWHP,WLVLPSRUWDQWWRQRWHWKDW
WKHUHLVQRHYLGHQFHLQWKHO LWHUDWXUHRULQ1HXURQHWLFVÂ¶SRVW PDUNHWVXUYHLOODQFHGDWDWRLQGLFDWHWKDWD
VLQJOHVHL]XUHGXULQJ706PDNHVVXEVHTXHQWVHL]XUHVPRUHOLNHO\ LQDQRWKHUZLVHQRQVHL]XUHSURQH
LQGLYLGXDO1HYHUWKHOHVVLWLVWUXHWKDWWKHUHDUHSRWHQWLDO FRQVHTXHQFHVRIDVHL]XUHUHJDUGLQJ
HPSOR\PHQWRULQVXUDELOLW\LQW KHIXWXUH,IDVXEMHFWGRHVH[ SHULHQFHDVHL]XUHUHODWHGWRWKLV
LQYHVWLJDWLRQDOHWWHUIURPWKHVLWH3ULQFLSDO,QYHVWLJDWRUZL OOQRWHWKDWWKHVHL]XUHZDVSURGXFHGXQGHU
H[SHULPHQWDOFRQGLWLRQVDQGWKHUHLVQRUHDVRQWRH[SHFWWKHV XEMHFWWRH[SHULHQFHDQRWKHUVHL]XUHLQWKH
IXWXUH
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 21 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Safety Monitoring for Potential Seizure Risk  
Safety monitoring for the potential risk of seizure is addressed in several ways in this protocol. 
All subjects will be assessed during the screening phase for neurologic disease, concurrent 
medication use, or other clinical factors that may contribute to the risk of seizure.  The 
Transcranial Magnetic Stimulation Adult Safety Screen (TASS ) will be used as a screening tool 
to assure rigorous review of these clinical factors.  Stimulation parameters have been selected to 
optimize the likelihood of clinical efficacy, while maintaining a safety level within the guidelines consistent with the 1998 NINDS workshop recommendations (Wasserman 1998). 
 
All clinical personnel involved in the motor threshold determinations and the TMS treatment 
sessions will be familiar  with the ISTS Consensus Statement on Managing the Risks of Repetitive 
Transcranial Magnetic Stimulation, with specific attention to the requirements of medical supervision and first -responder capability in the event of a seizure as outlined in that document. 
Specifically, all personnel will be familiar with the procedures for subject  screening for risk 
factors prior to treatment, individual risks and potential benefits for specific subject s, appropriate 
discussion of the risks and potential benefits of stu dy participation as outlined in the informed 
consent document, the stimulation parameters to be used in this study, monitoring subject s for the 
potential development of seizures by continuous visual inspection during the course of each 
treatment session (especially the more subtle signs and symptoms of frontal lobe seizures), and 
first responder management in the event of a seizure. All sites will be required to have immediate 
(i.e., within minutes) availability of more sophisticated medical support, includ ing access to an 
emergency room, in the event that a seizure is not a self -limited event, access to antiepileptic 
medications, and to life support equipment including oxygen, suction, blood pressure monitoring and cardiopulmonary (CPR) equipment. 
 
As stated above, f or all subjects who may experience a seizure during the study, the Investigator 
will provide a letter documenting that the seizure was experimentally produced.  All personnel involved in the administration of TMS in this study will be required to participate 
in individual site initiation visits and/or complete other sponsor training requirements and be able 
to demonstrate understanding of these issues to  sponsor study personnel prior to initiation of 
subject enrollment at that site.  
 
If a seizure occurs during the active treatment phase of the study, that subject will be discontinued 
from the study. 
Mood considerations  
There is a risk that the TMS treatment may not be effective for some subjects and that their depression 
may worsen.  Concerns for theoretical mood destabilization, including induction of mania or worsening of suicidality, will be carefully considered throughout the course of treatment ( at every treatment visit ); and 
subjects, their families, and investigators may elect to  discontinue the treatment protocol and withdraw 
from the study at any point.  Furthermore, safety considerations consistent with current standard of care in 
child and adolescent psychiatric practice will be employed including contacting the primary mental  health 
care provider, referral to on -call child and adolescent psychiatric services, referral to the emergency room, 
and/or hospitalization if necessary.  
 Several studies in the adult population and limited studies in the adolescent population have so fa r 
demonstrated the feasibility of TMS to treat depression without any indicators of exacerbation of 
depression or suicidality (Loo 2006; Janicak 2008; George 2010; Wall 2011) .  However, pediatric use of 
antidepressant pharmacotherapy has corresponded with warnings about increases in suicidal ideation and 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 22 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  behavior in youths and young adults.  No compelling data are available to indicate whether the net result 
of treatment of depressed youths with these compounds is an overall increase or an overall decrease in the 
hazard of completed suicide; there is limited and inconclusive evidence in either  direction  (Rapaport 
2006; Gibbons 2007; Libby 2007; Cheung 2008; Maalouf 2010). 
 
Exacerbation of depression that results in hospitalization or increased suicidality, or any emergent 
symptoms that are deemed clinically significant by the treating physician, will be considered a Serious 
Adverse Event (SAE), regardless of  relatedness to TMS treatment.  
 
Management plan for treatment- emergent mania, exacerbation of depression, and/or 
suicidality   
During the consent process, subjects and families will be educated about the possibility of significant changes in mood, suicidal thinking, and/or behaviors during the treatment.  These 
changes could include emergence of mania, worsening of depression, and/or suicidal thinking and 
behaviors. Both the subject  and parent(s) will be told to initiate contact with their study doctor, if 
they experience any significant mood or behavior changes including suicidal ideation.  Principal Investigator contact information is included in each siteâ€™s consent/assent document.  Furthermore, 
during the active treatment phase s of the protocol, subjects will have assessments weekly where 
changes of psycholog ical symptoms will be queried ( see Appendix A-C for schedules of events ).  
Ongoing monitoring for worsening of depression and emergence of suicidal ideation and/or 
behaviors will be evaluated using the HAMD, C-SSRS, and CGI- S. 
 Suspected treatment -induced mania will be evaluated using the Young Mania Rating Scale 
(YMRS).  A YMRS score of â‰¥ 20 will prompt administration of the M.I.N.I. /M.I.N.I. KID to 
determine whether or not the subject meets the Diagnostic and Statistical Manual  of Mental 
Disorders, Fifth Edition (DSM- 5) criteria for mania.  A YMRS score of 20 or greater will be 
considered an adverse event (AE) and will be monitored using the YMRS; the emergence of DSM-5 verified mania will be treated as a serious adverse event ( SAE) and will also be 
monitored using the YMRS.   
 
 
Exacerbation of depression, suicidality or induction of mania would constitute an SAE and the 
subject would be discontinued from the study.  See Section 17 for SAE handling.  Subject  would 
then be referred for clinical follow-up outside of the study. 
 
Other potential side effects of TMS that may be experienced  during treatment  
In the adult controlled registration studie s using the NeuroStar TMS TherapyÂ® System, the adverse event 
verbatim terms were collected at each clinical visit and subsequently coded using the current version of the Medical Dictionary for Regulatory Activities (MedDRA) and reported by MedDRA preferred terms.  
The most commonly occurring adverse events in the randomized controlled trial described in Oâ€™Reardon, 
et al (2007) are shown in Table 1, for those events occurring with an incidence of 5% or greater in the 
active TMS treatment group and twice the rate for the sham TMS treatment group.  Headache occurred 
equally in subject s in both treatment groups.  Similar rates of adverse events were reported in the 
controlled trial using the NeuroStar TMS Therapy System described in George, et al., 2010.  Post market 
surveillance has been consistent with these events reported, with no a dditional types of events reported for 
adolescent subjects. 
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 23 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Table 1.  Adverse Events with an Incidence in Active TMS at a Rate of > 5% and at Least 
2x Sham in the Safety Exposure Study Population  
Body System  
- Preferred Term  
 Active TMS  
(N=165) 
N (%) Sham TMS 
(N=158) 
N (%) 
Eye disorders  
-  Eye pain  
10 (6.1)  
3 (1.9) 
Gastrointestinal disorders  
-  Toothache   
12 (7.3)  
1 (0.6) 
General disorders and site administration conditions  
-  Application site discomfort  
-  Application site pain  
-  Facial pain   
18 (10.9) 
59 (35.8) 
11 (6.7)  
2 (1.3) 
6 (3.8) 
5 (3.2) 
Musculoskeletal and connective tissue disorders  
-  Muscle twitching   
34 (20.6)  
5 (3.2) 
Skin and subcutaneous tissue disorders  
-  Pain of skin   
14 (8.5)  
1 (0.6) 
 
There is the p otential risk of alteration in auditory threshold.  As a result of the rapid changes in the 
magnetic field during TMS administration, the coil produces an audible, high -energy click ing sound, 
which may be associated with temporary increases in auditory threshold.  During previous studies with 
the NeuroStar TMS TherapyÂ® System (Oâ€™Reardon 2007; George 2010; Carpenter 2012), all subjects were 
required to use hearing protection at a protection rating of â‰¥30 db.  No change in hearing was found with 
air conduction threshold testing in the two randomiz ed clinical studies (Janicak 2008 and George 2010)  
when this method of ear protection was used .  As a safety precaution, auditory assessments will be 
conducted during this study per the schedule of events  
Treatment plan for other side effects of TMS experienced during treatment : 
Repositioning of coil, consistent with the guidelines in the  NeuroStar User Manual, and 
prophylactic use of acetaminophen or ibuprofen will be allowed for subjects reporting sensations 
at or near the stimulation site which are uncomfortable or painful. During the first week of 
treatment only, in the event that the participant cannot tolerate the treatment at the  stipulated 
study dose parameters, dose intensity may be titrated downward to 110% of the motor threshold, 
with all o ther dose parameters remaining the same. 
Treatment plan for other potential side effects experienced following treatment : 
Subjects reporting headaches during or following study treatment will be encouraged to take acetaminophen or ibuprofen prior to the daily treatment.  To reduce the risk of temporary or 
permanent hearing loss due to noise emitted from the stimulator, subjec ts will wear protective ear 
plugs during treatment.  All subject s will be monitored, and appropriate treatment will be 
recommended including the possibility of stopping TMS .  Any other potential side effects will be 
managed symptomatically with treatment(s) deemed appropriate by the study site Principal 
Investigator .  All symptomatic interventions will be recorded in the subjectâ€™s case file and, if 
applicable, adverse event CRF.  
 
**Treatment with the Neurostar TMS Therapy  System may involve other risks that are not known 
at the present time.  The long -term effects of TMS are not known. ** 
 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/6WUXFWXUDO+HDG05,
$VWKLVVWXG\RQO\LQYROYHVXSWRIRXU05VFDQV3KDVH,%DVHOL QH(QGRI3KDVH,3KDVH,,%DVHOLQH(QG
RI3KDVH,,(QGRI3KDVH,,,>/7)8@WKHULVNLVDVVHVVHGDV PLQLPDO1RFRQWUDVWPDWHULDORUH[SRVXUH
WRLRQL]LQJUDGLDWLRQZLOORFFXU IRUWKHFRQGXFWRIWKLVSURWRF RO

7RPLQLPL]HDQ\SRWHQWLDOULVNVIURPWKHVFDQVWKHSK\VLFLDQZ LOOHQVXUHWKDWWKHVXEMHFWGRHVQRWPHHW
DQ\FRQWUDGLFWLRQVIRUDQ05, 6XEMHFWVZKRDUHXQFRPIRUWDEOH LQHQFORVHGSODFHVFODXVWURSKRELFPD\
H[SHULHQFHVRPHGLVFRPIRUW7KH05,VWDIIZLOOEHLQFRQWDFWZ LWKVXEMHFWVDWDOOWLPHVWKURXJKRXWWKH
VFDQQLQJSURFHVVDQGLIQHFHVVDU\WKHVFDQFDQEHVWRSSHGDWD Q\WLPH7KHWRWDOVFDQQLQJWLPHZLOOEH
DSSUR[LPDWHO\PLQXWHV SHUVFDQQLQJVHVVLRQ
2YHUDOO5LVN$QDO\VLV6WDWHPHQW
%DVHGRQDYDLODEOHGDWDWKHSRWHQWLDOEHQHILWVRIWKLVVWXG\R XWZHLJKWKHULVNV'HSUHVVHGDGROHVFHQWV
ZKRIDLOWRUHVSRQGWRPHGLFDWLRQDUHDWLQFUHDVHGULVNIRUVXL FLGHDQGSURORQJHGGLVDELOLW\UHODWHGWR
GHSUHVVHGPRRGGXULQJDFULWLFDOGHYHORSPHQWDOVWDJH7KHSUHO LPLQDU\GDWDVXJJHVWWKDW706KDV
DQWLGHSUHVVDQWHIIHFWVÂ±LQERWKWKHDGXOWDQGWKHSHGLDWULFSR SXODWLRQV7KHULVNVRI706DUHVOLJKW
UHODWLYHWRHOHFWURFRQYXOVLYHWKHUDS\(&7DWUHDWPHQWVRPHWL PHVXVHGLQWKLVSRSXODWLRQRU
SKDUPDFHXWLFDOWKHUDS\ZLWKPXOWLSOHPHGLFDWLRQV,I706SURYH VWREHDQHIIHFWLYHDOWHUQDWLYHWR(&7
DQGRUFRPELQDWLRQSKDUPDFHXWLFDOWKHUDS\GHSUHVVHGDGROHVFHQW VQRWUHVSRQGLQJWRPHGLFDWLRQZRXOG
KDYHDQHIIHFWLYHWUHDWPHQWDOWHUQDWLYHZLWKIHZHUVLGHHIIHFWV DQGULVNV7KHSURWRFROSURFHGXUHVDUH
FRQVLGHUHGWREHVDIHDQGDUHZHOOZLWKLQSUHYLRXVO\ HVWDEOLVKHG706JXLGHOLQHV
3RWHQWLDO%HQHILWV
7KH1HXUR6WDU7067KHUDS\ÂŠ6\VWHPWKDWGHOLYHUVUHSHWLWLYHWUDQVFUDQLDOPDJQHWLFVWLPXODW LRQLVD
PHGLFDOGHYLFHWKDWZDVFOHDUHGE\WKH8QLWHG6WDWHV)'$VLQFH 2FWREHUIRUWKHWUHDWPHQWRI0''
LQDGXOWVZKRIDLOWRDFKLHYHVDWLVIDFWRU\LPSURYHPHQWIURPSUL RUDQWLGHSUHVVDQWPHGLFDWLRQ,WLVD
SURPLVLQJDOWHUQDWLYHWRWUHDWPHQWVVXFKDV(&7RUSKDUPDFRWKHU DS\IRUVXEMHFWVSUHVHQWLQJZLWK
WUHDWPHQWUHVLVWDQWFDVHVRI0''7KH706SURFHGXUHLVQRQLQYD VLYHGRHVQRWUHTXLUHDQHVWKHVLDDQG
PD\EHGHOLYHUHGLQDQRXWSDWLHQWVHWWLQJ
6WXG\2EMHFWLYHV
3ULPDU\2EMHFWLYH3KDVH,
7KHSULPDU\REMHFWLYHRIWKLVVWXG\LVWRHYDOXDWHWKHVDIHW\D QGHIILFDF\RI706DVDPRQRWKHUDS\
DQWLGHSUHVVDQWLQDSURVSHFWLYHUDQGRPL]HGVKDPFRQWUROOHGVW XG\LQDGROHVFHQWVZLWK0''ZKRKDYH
QRWUHVSRQGHGVXIILFLHQWO\WRDWOHDVWRQHDQWLGHSUHVVDQWPHGLF DWLRQWULDODGPLQLVWHUHGDWDFOLQLFDOO\
DGHTXDWHGRVHDQGGXUDWLRQ
6HFRQGDU\REMHFWLYHV
3KDVH,
7RHYDOXDWHWKHDFXWHVDIHW\RI706LQDGROHVFHQWVXEMHFWV
3KDVH,,
7RHYDOXDWHWKHEHQHILWRIGDLO\DFWLYHRSHQODEHO706LQ3KD VH,VXEMHFWVZKRGLGQRWUHFHLYHSURWRFRO
GHILQHGFOLQLFDOEHQHILWIURPWKHLUDVVLJQHGWUHDWPHQWFRQGLWLR QLQ3KDVH,HLWKHUDVQHZDFXWHWUHDWPHQW
VKDPWRDFWLYHRUDVH[WHQGHGWUHDWPHQWFRXUVHEOLQGHGDFWLY HWRRSHQODEHODFWLYH
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/3KDVH,,,
7RHYDOXDWHWKHORQJWHUPVDIHW\RI706LQDGROHVFHQWVXEMHFWV 

7RHYDOXDWHWKHGXUDELOLW\RIWKHDFXWHFOLQLFDOEHQHILWRI706 WUHDWPHQWRYHUWKHFRXUVHRIPRQWKV
DPRQJVXEMHFWVZKRUHFHLYHGSURWRFROGHILQHGFOLQLFDOEHQHILWI URPWKHLULQLWLDODFXWHWUHDWPHQWFRXUVHV
6WXG\'HVLJQ
*HQHUDO'HVLJQ
6FUHHQLQJ
6XEMHFWVZLOOXQGHUJRPHGLFDO SV\FKRORJLFDODQGQHXURSV\FKRORJ LFDODVVHVVPHQWVWRDVVXUHFRPSOLDQFH
ZLWKDOOLQFOXVLRQDQGH[FOXVLRQFULWHULD(OLJLEOHVXEMHFWVZ LOOHQWHU3KDVH,UDQGRPL]HGDFXWHWUHDWPHQW
6HH$SSHQGL[$IRUVFKHGXOHRIHYHQWV
7067UHDWPHQW
$OOWUHDWPHQWVDQGPRWRUWKUHVKROGGHWHUPLQDWLRQVZLOOEHFRPSO HWHGE\SK\VLFLDQVRURWKHUKHDOWKFDUH
SURYLGHUVZKRKDYHEHHQWUDLQHGWRWKHSURFHVVEDVHGRQWKH1HX UR6WDU8VHU0DQXDODQGFHUWLILHGE\WKH
1HXURQHWLFVVWXG\VWDII$OOSURFHVVHVDUHFRQVLVWHQWZLWKWKH FOLQLFDOXVHRIWKH1HXUR6WDU706
7KHUDS\ÂŠ6\VWHP
0RWRU7KUHVKROG07'HWHUPLQDWLRQ07/RFDWLRQDQG07/HYHO
7KHPRWRUWKUHVKROGORFDWLRQZLOOEHGHWHUPLQHGE\YLVXDOFRQIL UPDWLRQRIWKHORFDWLRQRQWKHPRWRU
FRUWH[WKDWFRQWUROVWKHDEGXFWRUSROOLFLVEUHYLV$3%PXVFOH RIWKHWKXPE7KHUHVWLQJ07OHYHOLVWKH
PLQLPXPSRZHUWRSURGXFHDVWLPXOD WLRQUHVSRQVHRIWKHWLPH 
3KDVH,5DQGRPL]HG7ULSOH%OLQGHG$FWLYH7UHDWPHQW
6WLPXODWLRQZLOORFFXURYHUWKHOHIWGRUVRODWHUDOSUHIURQWDOFR UWH[DWPDJQHWLFILHOGLQWHQVLW\UHODWLYH
WRWKHVXEMHFWÂ¶VUHVWLQJPRWRUWKUHVKROGDWSXOVHVSHUVHFR QGIRUVHFRQGVZLWKDQRIIWLPHRU
LQWHUWUDLQLQWHUYDORIVHFRQGV5HSRVLWLRQLQJRIWKHFRLO SHUWKH1HXUR6WDU8VHU0DQXDODQG
SURSK\ODFWLFXVHRIDFHWDPLQRSKHQRULEXSURIHQZLOOEHDOORZHG IRUVXEMHFWVUHSRUWLQJVHQVDWLRQVDWRU
QHDUWKHVWLPXODWLRQVLWHZKLFKDUHXQFRPIRUWDEOHRUSDLQIXO' XULQJWKHILUVWZHHNRIWUHDWPHQWRQO\LQ
WKHHYHQWWKDWWKHVXEMHFWFDQQRWWROHUDWHWKHWUHDWPHQWDWWKH VHGRVHSDUDPHWHUVGRVHLQWHQVLW\PD\EH
WLWUDWHGGRZQZDUGWRRIWK HPRWRUWKUHVKROGZLWKDOORWKH UGRVHSDUDPHWHUVUHPDLQLQJWKHVDPH
7UHDWPHQWVHVVLRQVZLOOODVWIRUPLQXWHVWUDLQVWRSU RYLGHDWRWDORISXOVHVSHUWUHDWPHQW
VHVVLRQ$WRWDORIWUHDWPHQW VZLOOEHFRPSOHWHGZLWKLQZ HHNVRIWUHDWPHQWLQLWLDWLRQ
3KDVH,5DQGRPL]HG7ULSOH%OLQGHG6KDP7UHDWPHQW
6XEMHFWVUDQGRPL]HGWRVKDPWUHDWPHQWVZLOOKDYHLGHQWLFDOVFKH GXOHVV\VWHPDWLFDVVHVVPHQWVDQG
WUHDWPHQWDSSURDFKHVWRWKHLUDFWLYHWUHDWPHQWFRXQWHUSDUWV1 HLWKHUWKHDGROHVFHQWVQRUWKHLQYHVWLJDWRUV
FOLQLFDOUDWHUVRUWUHDWHUVZLOONQRZZKHWKHUWKHWUHDWPHQWL VDFWLYHRUVKDPLQQDWXUH7KHVKDPFRLOLV
LGHQWLFDOLQLWVDSSHDUDQFHWRWKHDFWLYHFRLO)XUWKHUPRUH1 HXURQHWLFV,QFKDVFUHDWHGDQDFRXVWLF
PDWFKLQJSURILOHWKDWUHQGHUVWKHÂ³VRXQGÂ´RIWKHWUHDWPHQWVYLU WXDOO\LQGLVWLQJXLVKDEOHWRVXEMHFWVRU
UHVHDUFKHUV7KHDFRXVWLFVLJQDOFUHDWHVDSDLQOHVVSHUFXVVLYH VHQVDWLRQWKDWZLOOEHIHOWE\WKHVXEMHFWDQG
ZLOODVVLVWLQVLPXODWLQJWKHDFWLYHFRQGLWLRQ

3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/6WUXFWXUDO+HDG05,6XEVHW/LPLWHGVWXG\VLWHV
6WUXFWXUDO05,FRPSDULVRQVZLOOEHDFTXLUHGIRUVXEMHFWV$FRQ VLVWHQW05,WHFKQLFLDQDWHDFKVWXG\VLWH
ZLOOEHUHTXHVWHGIRUHDFKRIWKHVWXG\VFDQV(DFKVXEMHFWZL OOKDYHDEDVHOLQHVFDQDQGDGGLWLRQDOVFDQV
DWWKHFRPSOHWLRQRIHDFKWUHDWPHQWSKDVH3KDVH,DQG3KDVH,, LIDSSOLFDEOHDQGDWVL[PRQWKVSRVW
WUHDWPHQWHQGRI3KDVH,,,RUDWVWXG\GLVFRQWLQXDWLRQZKLFKH YHUFRPHVILUVW7KHPD[LPXPQXPEHURI
VFDQVGXULQJWKHVWXG\ZLOOEHIRXU


3KDVH,,1RQ5DQGRPL]HG2SHQODEHO
6XEMHFWVZKRGRQRWPHHW,QYHVWLJDWRUVLWHEOLQGHGFULWHULDIRU SURWRFROGHILQHGWUHDWPHQWEHQHILW
IROORZLQJ3KDVH,WUHDWPHQWZ LOOEHRIIHUHGWKHRSSRUWXQLW\IRU WUHDWPHQWVXVLQJWKHNQRZQDFWLYHFRLO
7KHWUHDWPHQWSDUDPHWHUVDQGPHWKRGVRIDVVHVVPHQWLQ3KDVH,, ZLOOEHLGHQWLFDOWRWKRVHLQ3KDVH,7KH
RQO\GLIIHUHQFHZLOOEHWKDWWKHFRLOXVHGIRU3KDVH,,ZLOOEH DFWLYHDQGNQRZQWRWKHVXEMHFWDQG
LQYHVWLJDWRUV6HH$SSHQGL[%IRUVFKHGXOHRIHYHQWV7KHEOL QGZLOOQRWEHEURNHQIURP3KDVH,DWHQWU\
LQWR3KDVH,,
7DSHU3KDVH
$WFRPSOHWLRQRIDFXWHWUHDWPHQ W3KDVH,RU,,DQGIROORZLQJ HDFKUHWUHDWPHQWLQ3KDVH,,,HDFKVXEMHFW
ZLOOXQGHUJRWDSHULQJRIWKH706WUHDWPHQWFRXUVHRYHUWKUHHZH HNV'XULQJZHHNWKHVXEMHFWZLOO
KDYHWUHDWPHQWVHJ0RQ :HG)UL'XULQJZHHNWKHVXE MHFWZLOOKDYHWUHDWPHQWVHJ0RQ)UL
DQGGXULQJZHHNWKHVXEMHFWZLOOKDYHWUHDWPHQWHJ)UL 
3KDVH,,,1RQ5DQGRPL]HG 2SHQÂ±/DEHO)ROORZXS
6XEMHFWVZKRDWWKHFRPSOHWLRQRI3KDVH,RU,,PHHWEOLQGHGFU LWHULDIRUSURWRFROGHILQHGWUHDWPHQW
EHQHILWZLOOEHIROORZHGIRUPRQWKV,IV\PSWRPZRUVHQLQJR FFXUVDVGHILQHGE\LQFUHDVHLQ&*,6E\
RUPRUHSRLQWVIURP 3KDVH,,,HQWU\VFRUHIRUFRQVHFXWLYH ZHHNVDQDFXWHFRXUVHRINQRZQDFWLYH
706ZLOOEHRIIHUHGIRUXSWRZHHNVXQWLOV\PSWRPVUHWXUQWR WKHOHYHOUHFRUGHGDWHQWU\LQWR3KDVH,,,
&OLQLFDODVVHVVPHQWVZLOORFFXUELZHHNO\RYHUWKHSKRQHDQGPRQ WKO\DWWKHVWXG\VLWHWKURXJKRXWWKH
GXUDWLRQRIWKHIROORZXSSKDVH6HH$SSHQGL[&IRUVFKHGXOHR IHYHQWV
(IILFDF\DQG6DIHW \$VVHVVPHQWV
3KDVH,
6HH$SSHQGL[$IRUVFKHGXOHRIHYHQWV
2XWFRPH$VVHVVPHQWV
7UDLQHGSK\VLFLDQVDQGUDWHUVZLOODGPLQLVWHUDOOGLDJQRVWLFDV VHVVPHQWVDQGFOLQLFDOLQWHUYLHZV
GHWHUPLQLQJVWXG\HOLJLELOLW\GXULQJVFUHHQLQJDQGSULRUWRUDQ GRPL]DWLRQ$OOVWXG\VWDIIZLOOEHWUDLQHG
RQVWXG\SURFHGXUHVE\1HXURQHWLFVVWDII
2XWFRPHVFUHHQLQJZLOORFFXUDIWHUERWKWKH,QIRUPHG$VVHQW&RQ VHQW'RFXPHQWDQGWKH+,3$$
$XWKRUL]DWLRQDUHVLJQHG%DVHOLQHDVVHVVPHQWVZLOORFFXUSULR UWRWKHILUVW706WUHDWPHQWVHVVLRQ
2XWFRPHPHDVXUHVLQ3KDVH,ZLOOEHDVVHVVHGDWWKHHQGRIWUHD WPHQWZHHNVDQG7KHIROORZLQJ
RXWFRPHDVVHVVPHQWVZLOOEHFRPSOHWHG+$0'0$'56VWUXFWXUHGLQ WHUYLHZ&'565&*,6DQG
4,'6$65
6DIHW\$VVHVVPHQWV
$SK\VLFDODQGFRPSOHWHPHGLFDODQGSV\FKLDWULFKLVWRU\ZLOOEH REWDLQHGDWWKHVFUHHQLQJYLVLW
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 27 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL   
Vital signs  including height, weight , blood pressure and heart rate will be collected at the baseline visit 
and at week 6 . 
 
Laboratory determination will be measured at screening and include: Blood chemistry, hematology, urine 
drug screen, and urine pregnancy for female subjects.  
Subjects will be evaluated clinically for adverse events at each visit.  Serious adverse events ( SAEs) will 
be recorded as they occur and reported to Neuronetics by the study site within one business day of 
notification. 
 Cognitive function assessments will be conducted at the baseline visit and at week 6 .  The following tests 
from the NIH Toolbox Cognition Battery are used for this study:  
â€¢ Education 
â€¢ Handedness 
â€¢ Attention  
o Flanker Inhibitory Control and Attention Test  
â€¢ Episodic Memory  
o Picture Sequence Memory Test  
o Auditory Verbal Learning Test  (Rey) 
â€¢ Executive Function 
o Dimensional Change Card Sort Test  
o Flanker Inhibitory Control and Attention Test 
â€¢ Language  
o Picture Vocabulary Test  
o Oral Reading Recognition Test  
â€¢ Processing Speed  
o Pattern Comparison Processing Speed Test  
â€¢ Memory 
o List Sorting Working Memory Test  
 
The C-SSRS will be completed weekly during TMS treatment to assess worsening of illness and 
suicidality .  The YMRS will be completed at baselin e and will be repeated based on reported change in 
symptoms. 
 Air conduction thresholds will be assessed for both left and right ears at the baseline visit and at week 6 . 
Phase II 
See Appendix B for schedule of events .  The schedule of efficacy and safety measures for Phase II will be 
identical to that of Phase I .  
Phase III 
See Appendix C for schedule of events . 
 Outcome measures for Follow up Phase I II, including HAMD/MADRS structured interview, QIDS -A17-
SR, CDRS -R, and CGI- S, will be assessed per schedule of events .  
 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/6XEMHFWVZLOOEHHYDOXDWHGFOLQLFDOO\IRUDGYHUVHHYHQWVDWHDF KYLVLWDQGDWWKHELZHHNO\SKRQHFDOO7KH
ELZHHNO\FDOOVDUHGRQHDVDVDIHW\FKHFNWRDVVHVVZRUVHQLQJ RILOOQHVVEHWZHHQPRQWKO\YLVLWV7KH
SKRQHFDOOZLOOEHGRFXPHQWHGDVDSURJUHVVQRWHDQGSODFHGZLW KWKHVXEMHFWVÂ¶VRXUFHGRFXPHQWDWLRQ
6$(VZLOOEHUHFRUGHGDVWKH\RFFXUDQGUHSRUWHGWR1HXURQHWLFV E\WKHVWXG\VLWHZLWKLQRQHEXVLQHVVGD\
RIQRWLILFDWLRQ
7KH&6656ZLOOEHFRPSOHWHGZHHNO\GXULQJ706UHWUHDWPHQWVHVV LRQV7KH<056ZLOOEH
FRPSOHWHGLIWKHLQWHUYDODVVHVVPHQWRIVSRQWDQHRXVDGYHUVHHYH QWVLQGLFDWHVWKHSRWHQWLDORFFXUUHQFHRI
V\PSWRPVRIPDQLDRUK\SRPDQLD,QDGGLWLRQLQDOOVXEMHFWVU HFHLYLQJ706UHWUHDWPHQWDLUFRQGXFWLRQ
WKUHVKROGVZLOOEHDVVHVVHGIRUERWKOHIWDQGULJKWHDUVDWEDV HOLQHDQGDWWKHHQGRIWKHUHWUHDWPHQWEORFN
9LWDOVLJQVLQFOXGLQJKHLJKWZHLJKWEORRGSUHVVXUHDQGKHDUW UDWHFRJQLWLYHIXQFWLRQDVVHVVPHQWVDQG
DLUFRQGXFWLRQWKUHVKROGVIRUERWKHDUVZLOOEHDVVHVVHGDWWKH HQGRIVL[PRQWKIROORZXS
6WUXFWXUDO+HDG05, /LPLWHGVWXG\VLWHV
$QDO\]HGE\VWDQGDUGPRUSKRPHWULF PHDVXUHVWRGHWHUPLQHVWUXFWX UDOFKDQJHVLQWKHEUDLQDVVRFLDWHG
ZLWK706WUHDWPHQW6HH$SSHQGL[$&IRUVFKHGXOHRIHYHQWV

6XEMHFW6HOHFWLRQ(QUROOPHQWDQG:LWKGUDZDO
$OODGROHVFHQWVDQGWKHLUJXDUGLDQVLIDSSOLFDEOHZLOOEHSUR YLGHGDFDUHIXODVVHQWDQGFRQVHQW
GLVFXVVLRQSULRUWRHQUROOPHQW6LQFHWKLVLVDVKDPFRQWUROOH GWULDODOOVXEMHFWVZRXOGQHHGWRXQGHUVWDQG
WKDWGXULQJ3KDVH,RIWKHWULDOWKH\ZLOOEHUDQGRPL]HGWRHL WKHUWKHDFWLYHWUHDWPHQWFRQGLWLRQRUWKH
VKDPWUHDWPHQWFRQGLWLRQ7KH\ZLOODOVREHLQIRUPHGDERXWWKH RSSRUWXQLW\WRUHFHLYHRSHQDFWLYH706
WUHDWPHQWGXULQJ3KDVH,,LIWKH\GLGQRWUHFHLYHSURWRFROGH ILQHGFOLQLFDOEHQHILWGXULQJ3KDVH,
,QFOXVLRQ&ULWHULD

,QFOXVLRQ&ULWHULD 'HWHUPLQDQW
3ULPDU\GLDJQRVLVRIXQLSRODUPDMRUGHSUHVVLYHGLVRUGHULQDF XUUHQW
PDMRUGHSUHVVLYHHSLVRGHZLWKRXWSV\FKRWLFIHDWXUHV0,1,0,1,.,'DJHVXSWR
RUDJHV!WRFRQILUP
'60FULWHULD
'XUDWLRQRIFXUUHQWHSLVRGHRIGHSUHVVLRQÂ•ZHHNVDQGÂ”\HDUV WKH
GHILQLWLRQRIDQHSLVRGHLVGHPDUFDWHGE\DSHULRGRIÂ•PRQW KVZKHQ
WKHVXEMHFWGLGQRWPHHWIXOOFULWHULDIRUWKH'60GHILQLWLRQ RIPDMRU
GHSUHVVLYHHSLVRGH3K\VLFLDQHYDOXDWLRQ
0,1,0,1,.,'
&*,6Â• &*,6
$JHLVDWOHDVWDQGOHVVWKDQ\HDUV 6HOIUHSRUWDQGUHYLH ZRIPHGLFDO
UHFRUG
5HVLVWDQFHWRDQWLGHSUHVVDQWWUHDWPHQWLQDGLVFUHWHLOOQHVVHS LVRGHDV
GHILQHGE\WKH$QWLGHSUHVVDQW 7UHDWPHQW5HFRUG$75
x5HVLVWDQFHWRWUHDWPHQWGHILQHGE\$75OHYHOLQFXUUHQW
HSLVRGH,ILQVXIILFLHQWQXPEHURIWULDOVLQWKHFXUUHQWHSLVR GH
WKHQPXVWDOVRKDYHIDLOHG!DQGWULDOVLQDSUHYLRXV
HSLVRGH3K\VLFLDQHYDOXDWLRQDQGUHYLHZRI
PHGLFDOUHFRUG7DEOHÂ±,QFOXVLRQ&ULWHULD
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/x6XEMHFWVZKRKDYHEHHQXQDEOHWRFRPSOHWHDQDQWLGHSUHVVDQW
WULDORIDGHTXDWHGRVHDQGGXUDWLRQGXHWRLQWROHUDQFHWR
DQWLGHSUHVVDQWWKHUDS\PD\EHLQFOXGHGLIWKH\KDYH
GHPRQVWUDWHGLQWROHUDQFHWR tDQWLGHSUHVVDQWPHGLFDWLRQV
ZLWKLQRQHGLVFUHWHLOOQHVVHSLVRGHFXUUHQWRUDSUHYLRXVHSLV RGH
DVGHILQHGDERYH
)RUDQ\VXEMHFWFXUUHQWO\UHFHLYLQJDQWLGHSUHVVDQWPHGLFDWLRQ WKH
FOLQLFLDQPXVWGHWHUPLQHWKDWLQVXIILFLHQWEHQHILWLVEHLQJUHF HLYHGIURP
WKLVWUHDWPHQWDQGLWLVFOLQLFDOO\DSSURSULDWHWRGLVFRQWLQXH WKHH[LVWLQJ
DQWLGHSUHVVDQW
+$0',WHPÂ•DQGWRWDOVFRUHÂ• +$0'
6XEMHFWVDEOHWRFRPPLWWRSURWRFROVFKHGXOH 6XEMHFWDQGIDPLO \DJUHHPHQW
:LOOLQJWRSURYLGHLQIRUPHGDVVHQWDGROHVFHQWDQGLQIRUPHGFR QVHQW
IDPLO\IRUVXEMHFW\HDUVROGRUOHJDOUHTXLUHPHQWVRIWK HVWDWH
:LOOLQJWRSURYLGHLQIRUPHGFRQVHQWE\VXEMHFWÂ•\HDUVROGRU OHJDO
UHTXLUHPHQWVRIWKHVWDWH&RQVHQWDVVHQWGLVFXVVLRQ
6LJQHG+,3$$DXWKRUL]DWLRQE\VXEMHFWRUSDUHQWIRUVXEMHFW \HDUV
ROG+,3$$DXWKRUL]DWLRQ
,QWHULP,QFOXVLRQ&ULWHULD  'HWHUPLQDQW 
$WWKHHQGRIWKHEDVHOLQHYLVLW VXEMHFWPXVWKDYHD+$0'VF RUHRIÂ•
DQGFKDQJHLQVFRUHPD\QRWEHÂ•GHFUHDVHIURPWKDWVHHQ DWWKH
VFUHHQLQJYLVLW+$0'

([FOXVLRQ&ULWHULD

([FOXVLRQ&ULWHULD 'HWHUPLQDQW
6XEMHFWVGLUHFWO\DIILOLDWHGZLWKWKHVWXG\RUWKHLULPPHGLDWH IDPLOLHV
SDUHQWRUVLEOLQJZKHWKHUE\ELUWKRUOHJDODGRSWLRQ3K\VLFLDQLQWHUYLHZ
6XEMHFWVFXUUHQWO\RQFRQFXUUHQWPHGLFDWLRQOLVWHGDVH[FOXGHG RQWKH
&RQFRPLWDQW0HGLFDWLRQOLVW$S SHQGL['DQGRUXVHRIDQ
LQYHVWLJDWLRQDOGUXJZLWKLQ ZHHNVRIWKHEDVHOLQHYLVLW3K\VLFLDQHYDOXDWLRQDQGUHYLHZRI
PHGLFDOUHFRUG
$FWLYHVXEVWDQFHXVH 8ULQHGUXJWHVWDWVFUHHQLQJ
VHFRQGWHVWDOORZHGSULRUWR
UDQGRPL]DWLRQDVSHUPLWWHGE\
6SRQVRU
3ULRU706YDJXVQHUYHVWLPXODWLRQ916RU(&7 0HGLFDOKLVWRU \
&RQWUDLQGLFDWLRQWR05,RQO\IRU 6WUXFWXUDO+HDG05,VXEVHWVX EMHFWV 3K\VLFLDQHYDOXDWLRQPHGLFDO
KLVWRU\05,6DIHW\6FUHHQLQJ4XHVWLRQQDLUH7DEOHÂ±([FOXVLRQ&ULWHULD
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 30 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Contraindication to TMS  
Conductive, ferromagnetic, or other magnetic- sensitive metals implanted 
in the subjectâ€™s  head within 30 cm of the treatment coil excluding the 
mouth that cannot safely be removed. Examples include cochlear 
implants, implanted electrodes/stimulators, aneurysm clips or coils, 
stents, bullet fragments, jewelry and hair barrettes.  
Active or inactive implants (including device leads), including d eep 
brain stimulators, cochlear implants, and vagus nerve stimulators.  Physician evaluation and review of 
medical record   
Cardiac pacemakers, implanted medication pumps, intracardiac lines  Physician evaluation and review of 
medical record  
A true positive response to any question on the TASS questionnaire  Physician evaluation 
History of neurological disorder or insult including but not limited to the 
following that may increase risk of seizure:  
â€¢ Antecedent seizures  
â€¢ Any condition likely to be associated with increased intracranial 
pressure 
â€¢ Space occupying brain lesion 
â€¢ History of cerebrovascular accident  
â€¢ Transient ischemic attack within 2 years  
â€¢ Cerebral aneurysm  
â€¢ Dementia  
â€¢ Brain surgery  
â€¢ Head trauma with loss of consciousness for >5 minutes 
â€¢ History of stroke  
â€¢ History and/or family history of epilepsy  Physician evaluation and review of 
medical record  
Unstable medical conditions, including:  
â€¢ Hematological or infectious (e.g., human immunodeficiency 
virus-HIV) disorders. 
â€¢ History of autoimmune, endocrine, viral, or vascular disorder 
â€¢ Unstable cardiac disease, uncontrolled hypertension, or sleep apnea 
â€¢ Current anticoagulant, immune suppressive, and/or chemotherapy or those who have received any of these therapies within 3 months before enrollment in the study.  Physician evaluation; medical history 
Clinically significant laboratory abnormality, in the opinion of the Investigator  Physician review of screening laboratory tests  
Individuals diagnosed with the following conditions (current unless otherwise stated):  
â€¢ Depression secondary to a general medical condition, or substance induced: 
â€¢ Seasonal pattern of depression as defined by DSM-5 
â€¢ Any psychotic disorder (lifetime), including history of schizophrenia, schizoaffective disorder, other psychosi s, 
psychotic features in this or previous episodes, amnestic M.I.N.I. or M.I.N.I.  KID (age <18) 
to confirm DSM- 5 criteria 
 
Physician Examination and 
conference with family 
member/guardian to confirm 
findings (age <18  or legal 
requirements of the state ) 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/GLVRUGHU
x0HQWDOUHWDUGDWLRQ
x6XEVWDQFHGHSHQGHQFHRUDEXVHZLWKLQWKHSDVW\HDUH[FHSW
QLFRWLQHRUFDIIHLQH
x%LSRODUGLVRUGHU
x2EVHVVLYHFRPSXOVLYHGLVRUGHUOLIHWLPH
x3RVWWUDXPDWLFVWUHVVGLVRUGHUOLIHWLPH
x(DWLQJGLVRUGHUOLIHWLPH
$Q\SV\FKLDWULFGLVRUGHUZKLFKL QWKHMXGJHPHQWRIWKH,QYHVWL JDWRUPD\
KLQGHUWKHVXEMHFWLQFRPSOHWLQ JWKHSURFHGXUHVUHTXLUHGE\WKH VWXG\
SURWRFRO0,1,.,'DJHVXSWRRU
0,1,DJHV!WRFRQILUP
,ISDUWLFLSDWLQJLQSV\FKRWKHUDS\PXVWKDYHEHHQLQVWDEOHWUH DWPHQWIRU
DWOHDVWPRQWKVSULRUWRVFUHH QLQJLQWRWKHVWXG\ZLWKQRDQW LFLSDWLRQRI
FKDQJHLQWKHIUHTXHQF\RUIRFXVRIWKHUDSHXWLFVHVVLRQVRYHUW KH
GXUDWLRQRIWKHVWXG\3K\VLFLDQHYDOXDWLRQPHGLFDO
KLVWRU\
6LJQLILFDQWDFXWHVXLFLGHULVNGHILQHGDVIROORZV
x6XLFLGHDWWHPSWZLWKLQWKHSUHYLRXVPRQWKVWKDWUHTXLUHG
PHGLFDOWUHDWPHQWRU
x+LVWRU\RIDWWHPSWZLWKLQWKH SDVWPRQWKVRUÂ•VXLFLGH
DWWHPSWVLQWKHSDVWPRQWKVRU
x+DVDFOHDUFXWSODQIRUVXLFLGHDQGVWDWHVWKDWKHVKHFDQQRW
JXDUDQWHHWKDWKHVKHZLOOLQIRUPDIDPLO\PHPEHURUFDOOKLVK HU
SV\FKLDWULVWRUWKHLQYHVWLJDWRULIWKHLPSXOVHWRLPSOHPHQWWK H
SODQEHFRPHVVXEVWDQWLDOGXULQJWKHVWXG\RU
x,QWKH,QYHVWLJDWRUÂ¶VRSLQLRQLVOLNHO\WRDWWHPSWVXLFLGHZLW KLQ
WKHQH[WPRQWKV3K\VLFLDQHYDOXDWLRQ
0,1,0,1,.,'
$Q\RWKHUUHOHYDQWPHGLFDOSHUVRQDOLW\RUSV\FKRVRFLDOLVVXH VVSHFLILF
WRWKHVXEMHFWWKDWWKH3,GHWHUPLQHVWREHUHDVRQIRUH[FOXVLR QIURPWKH
VWXG\3K\VLFLDQHYDOXDWLRQPHGLFDO
KLVWRU\
3UHJQDQWRUVXVSHFWHGSUHJQDQF\ 8ULQHSUHJQDQF\WHVW
,IVH[XDOO\DFWLYHIHPDOHQRWRQDQDFFHSWHGPHWKRGRIELUWKF RQWURO6HH
$SSHQGL['&RQFRPLWDQW0HGLFDWLRQ/LVW
,QDELOLW\WRORFDWHDQGTXDQWLI\DPRWRUWKUHVKROG 0RWRU7KUHVK ROGGHWHUPLQDWLRQ
6XEMHFW5HFUXLWPHQW(QUROOPHQWDQG6FUHHQLQJ
6XEMHFW5HFUXLWPHQW
6HYHUDOUHVRXUFHVZLOOEHXWLOL]HGIRUUHFUXLWPHQWRISRWHQWLDO VXEMHFWVLQFOXGLQJ
xIURPZLWKLQWKHFOLQLFDODQGUHIHUUDOSUDFWLFHVRIWKHFOLQLFD OVWXG\VLWH
xUHIHUUDOVIURPRWKHUFDUHSURYLGHUVZLWKLQWKHWUHDWPHQWFRPPXQ LWLHV
xUDGLRDGYHUWLVHPHQWV
xLQYLWDWLRQOHWWHUVVHQWWRSDUHQWVRISRWHQWLDOO\HOLJLEOHVXEM HFWV
xSULQWDGYHUWLVHPHQWVLQFOXGLQJEXWQRWOLPLWHGWREURFKXUHVI O\HUV&UDLJÂ¶V/LVWDQGOLVWLQJVLQ
UHVHDUFKFODVVLILHGV
xWULDOOLVWLQJZLWK&OLQLFDO7ULDOVJRY
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/xWULDOOLVWLQJRQXQLYHUVLW\DQGFOLQLFDOVWXG\VLWHZHEVLWH
xVRFLDOPHGLD
$OODGYHUWLVLQJPDWHULDOVZLOOEHUHYLHZHGDQGDSSURYHGE\WKH VLWHÂ¶V,5%SULRUWRXVH

3RWHQWLDOO\LQWHUHVWHGDGROHVFHQWVDQGWKHLUIDPLOLHVPD\EHSU RYLGHGZLWKSULQWHGVXEMHFWHGXFDWLRQDO
PDWHULDOVWRDLGWKHPLQPDNLQ JDQLQIRUPHGGHFLVLRQUHJDUGLQJ WKHLUZLOOLQJQHVVWRSDUWLFLSDWHLQWKLV
VWXG\
6XEMHFW(QUROOPHQW
$WWKHWLPHRIWKHHQUROOPHQWYLVLWSRWHQWLDOVXEMHFWVDQGWKH LUSDUHQWVZLOOEHSU RYLGHGZLWKDZULWWHQ
FRS\RIWKHFXUUHQW,5%DSSURYHGLQIRUPHGFRQVHQWDVVHQWIRUPI URPWKHVLWHDWZKLFKWKH\ZLOOEH
UHFHLYLQJVWXG\WUHDWPHQWV$OODGROHVFHQWVDQGWKHLUJXDUGLDQV ZLOOEHSURYLGHGDFDUHIXODVVHQWDQG
FRQVHQWGLVFXVVLRQSULRUWRHQUROOPHQW'XHWRWKHQDWXUHRID VKDPFRQWUROOHGWULDODOOVXEMHFWVZLOOQHHG
WRXQGHUVWDQGWKDWGXULQJ3KDVH, RIWKHWULDOWKH\ZLOOEHUD QGRPL]HGWRHLWKHUWKHDFWLYHWUHDWPHQW
FRQGLWLRQRUWKHVKDPWUHDWPHQWFRQGLWLRQ7KH\ZLOODOVREHL QIRUPHGDERXWWKHRSSRUWXQLW\WRUHFHLYH
RSHQDFWLYH706WUHDWPHQWGXULQJ3KDVH,,LIWKH\GLGQRWUHFH LYHSURWRFROGHILQHGFOLQLFDOEHQHILWGXULQJ
3KDVH,)RUVXEMHFWVZKRUHDFKWKHDJHRIPDWXULW\\HDUVR UOHJDOUHTXLUHPHQWVRIWKHVWDWHGXULQJ
WKHLUSDUWLFLSDWLRQLQWKHVWXG\ZULWWHQFRQVHQWZLOOEHREWDL QHGIURPWKHVXEMHFWDWWKHQH[WYLVLW
IROORZLQJWKHLUELUWKGDWH
6XEMHFW6FUHHQLQJ
)ROORZLQJWKHLQIRUPHGFRQVHQWSURFHVVHQUROOHGVXEMHFWVZLOO EHJLQWKHVWXG\HOLJLELOLW\VFUHHQLQJ
SURFHVV9HULILFDWLRQRILQFOXVLRQDQGH[FOXVLRQZLOOEHFRPSOH WHGE\WKHVWXG\SK\VLFLDQWRHQVXUHWKDW
WKHVXEMHFWLVHOLJLEOHIRUWKHVWXG\DQGWKDWLWLVVDIHIRUW KHPWRSDUWLFLSDWH6XEMHFWVPXVWKDYH
GLVFRQWLQXHGDOODQWLGHSUHVVDQWVDQGSV\FKRWURSLFVIRUDWOHDVW RQHZHHNRUXQWLODOOWUDFHVDUHHOLPLQDWHG
IURPWKHVXEMHFWÂ¶VV\VWHPSULRUWRDGPLQLVWHULQJWKH+$0'
0$'56DQGDQ\RWKHUHIILFDF\
DVVHVVPHQW 
(DUO\:LWKGUDZDORI6XEMHFWV
:KHQDQG+RZWR:LWKGUDZ6XEMHFWV
6XEMHFWVPD\ZLWKGUDZYROXQWDULO \IURPWKHVWXG\DWDQ\WLPH7 KH\PD\EHZLWKGUDZQIURPWKHVWXG\E\
WKH,QYHVWLJDWRULIDVXEMHFW

xH[SHULHQFHVDVHL]XUH
xH[SHULHQFHVD'60FRQILUPHGWUHDWPHQWLQGXFHGPDQLD
xLVQRQFRPSOLDQWZLWKVWXG\SURFHGXUHVRU
xWKHUDQGRPL]DWLRQFRGHLVEURNHQIRUWKLVVXEMHFW

7KH,QYHVWLJDWRUPD\DOVRZLWKGUDZDVXEMHFWLIKHVKHEHOLHYHV WKDWIRUVDIHW\UHDVRQVLWLVLQWKHEHVW
LQWHUHVWRIWKHVXEMHFWWREHZLWKGUDZQ

'LVFRQWLQXDWLRQLQIRUPDWLRQ>HJ GDWHDQGWKHUHDVRQVIRUG LVFRQWLQXDWLRQ@PXVWEHUHFRUGHGLQWKH
VXEMHFWÂ¶V&5)LH6WXG\&RPSO HWLRQ)RUP6XEMHFWVZKRGLVFR QWLQXHSUHPDWXUHO\VKRXOGFRPSOHWHWKH
:HHNDVVHVVPHQWSURFHGXUHVZLWKLQGD\VIROORZLQJWKHLUODVW 706WUHDWPHQWVHVVLRQ6HHWKH
6FKHGXOHRI(YHQWVIRUWKHVSHFLILFSURFHGXUHVWREHSHUIRUPHG DWWKLVGLVFRQWLQXDWLRQYLVLW

6XEMHFWVZLWKGUDZQIURPWKHVWXG\GXHWRDQ$(ZLOOEHIROORZHG XSIRUGD\VRUXQWLOUHVROXWLRQ
6XEMHFWVZLWKGUDZQIURPWKHVWXG\ZLOOQRWEHUHSODFHGUHJDUGO HVVRIWKHUHDVRQIRUZLWKGUDZDO$QHIIRUW
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/ZLOOEHPDGHWRGHWHUPLQHZK\DVXEMHFWGRHVQRWUHWXUQIRUWKH UHTXLUHGYLVLWVRULVGURSSHGIURPWKH
VWXG\7KLVLQIRUPDWLRQZLOOVXEVHTXHQWO\EHUHFRUGHGRQWKHVX EMHFWÂ¶V&5)

6XEMHFWVZLOOEHHQFRXUDJHGWRUHPDLQFRPSOLDQWZLWKDOOH[SHFW HGVWXG\YLVLWV1RQDGKHUHQFHWR
H[SHFWHGVWXG\YLVLWVZLOOEHGRFXPHQWHGDQGPD\UHVXOWLQUHPR YDOIURPWKHVWXG\7KLVZLOOEHFOHDUO\
GLVFXVVHGGXULQJWKHFRQVHQWDVVHQWSURFHVVDQGUHLQIRUFHGWKUR XJKRXWWKHVWXG\WKURXJ KUHJXODUVFUHHQLQJ
IRULVVXHVZLWKFRPSOLDQFH
6WXG\'HYLFH
'HVFULSWLRQ
7KH1HXUR6WDU7067KHUDS\ÂŠ6\VWHPLVDFRPSXWHUL]HGHOHFWURPHFKDQLFDOLQVWUXPHQWWKDWSURG XFHVDQG
GHOLYHUVEULHIGXUDWLRQUDSLGO\DOWHUQDWLQJSXOVHGPDJQHWLF ILHOGVWRLQGXFHHOHFWULFDOFXUUHQWVLQ
ORFDOL]HGUHJLRQVRIWKHFHUHEUDOFRUWH[,WLVDQRQLQYDVLYH WRROXVHGIRUWKHWUHDWPHQWRIVXEMHFWVZLWK
0''ZKRKDYHQRWDFKLHYHGVXIILFLHQWFOLQLFDOEHQHILWIURPDQWL GHSUHVVDQWSKDUPDFRWKHUDS\7KH
1HXUR6WDU7067KHUDS\6\VWHPKDV EHHQ)'$FOHDUHGIRUXVHLQDG XOWVXEMHFWV1HXUR6WDU;3/25ÂŠLV
DFOLQLFDOUHVHDUFKRSWLRQIRUWKH1HXUR6WDU7067KHUDS\6\VWHP WKDWSURYLGHVIHDWXUHVQHFHVVDU\WR
FRQGXFWUDQGRPL]HGFRQWUROOHGWULDOVDQGRWKHU706UHVHDUFK7 KHDFWLYHWUHDWPHQWPRGDOLW\LV
HVVHQWLDOO\WKHVDPHIRUERWKWKH1HXUR6WDU7067KHUDS\6\VWHP DQG1HXUR6WDU;3/25

7KH1HXUR6WDU;3/257066\VWHPFRQVLVWVRIWKHIROORZLQJHTXLSP HQWDQGVRIWZDUH

x0RELOH&RQVROHLQFOXGHVSURFHVVRUPRGXOHSRZHUPRGXOHPDVW JDQWU\KDORDQGGLVSOD\DUP
x6\VWHP6RIWZDUHWKH;3/25RSWLR QDOVRLQFOXGHVDGHGLFDWHGV\V WHPVRIWZDUHDSSOLFDWLRQ
VRIWZDUHYHUVLRQRUJUHDWHUZLWKLWVRZQGHGLFDWHGGDWD EDVHRIVXEMHFWWUHDWPHQWKLVWRU\
7067UDN6WDUÂŠDSSOLFDWLRQDQG7UDN6WDUGDWDEDVHWKDWRSHUDWHVRQO\ZLWKWKH FRUUHVSRQGLQJ
;3/256RIWZDUHPDLQWDLQLQJLVRODWLRQVHFXULW\DQGGDWDLQWHJ ULW\RIWKHUHVHDUFK
x7067UDN6WDUÂŠ'DWD0DQDJHPHQW6\VWHPVRIWZDUH
x7KHUDS\&RLOVLQFOXGHGZLWKWKH;3/25RSWLRQLVDVHWRIWKUHH 706FRLOV
RDEOLQGHGVKDPRUSODFHERFRLOWKHVKDPFRLOLVDFRXVWLFDOO\P DWFKHGWRSURWHFWWKH
LQWHJULW\RIWKHEOLQG
RDEOLQGHGDFWLYHFRLODQG
RDVWDQGDUGWUHDWPHQWFRLOWKDWFDQEHXVHGIRUSHUIRUPLQJPRWRU WKUHVKROGOHYHO
GHWHUPLQDWLRQRURSHQODEHOWUHDWPHQW
x+HDG6XSSRUW6\VWHPLQFOXGHVODVHUSRVLWLRQLQJDLGDQGFRLOSR VLWLRQLQJJXLGH
x7UHDWPHQW&KDLU
x3RVLWLRQLQJ&XVKLRQVWRHQKDQFHFRPIRUWDQGSRVLWLRQLQJRIWKH VXEMHFWLQWKHUHTXLUHGSRVWXUH
IRUWKHGXUDWLRQRIWKHWUHDWPHQWVHVVLRQ
7KH1HXUR6WDU7067KHUDS\6\VWHPDOVRUHTXLUHVVXSSOLHVDQGGLV SRVDEOHVIRUHDFKWUHDWPHQWVHVVLRQ
x+HDG&XVKLRQ/LQHU
x+HDG6LGH3DG/LQHU
x+HDG3RVLWLRQLQJ6WUDSV
x(DUSOXJV
x6HQ6WDU
ÂŠ7UHDWPHQW/LQNDVLQJOHXVHPHGLFDOGHYLFH
x8VHG6HQ6WDU7UHDWPHQW/LQN5HWXUQER[
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/
6XEMHFW,GHQWLILFDWLRQ
(DFKVXEMHFWZLOOEHDVVLJQHGDXQLTXHVXEMHFWLGHQWLILFDWLRQX SRQVLJQLQJWKHLQIRUPHGFRQVHQWIRUP
7KLVQXPEHUZLOOFRQVLVWRIDQDVVLJQHGGLJLWVWXG\VLWHLGHQ WLILHUDQGDXQLTXHGLJLWVXEMHFW
LGHQWLILHU)RUH[DPSOHWKHILUVWVXEMHFWVFUHHQHGDWVLWH ZRXOGEHVXEMHFW
6XEMHFWVVKRXOGEHLGHQWLILHGWRWKH6SRQVRURQO\E\WKHLUDVVL JQHGQXPEHUDQGLQLWLDOVH[FHSWZKHUH
UHTXHVWHGRQWKH&5)VDQGVRXUFHGRFXPHQWV7KH,QYHVWLJDWRUPX VWPDLQWDLQDPDVWHUOLVWOLQNLQJVXEMHFW
QDPHVDQGWKHLGHQWLI\LQJLQIRUPDWLRQLQGLFDWHGDERYH
5DQGRPL]DWLRQ
$UDQGRPL]DWLRQVFKHGXOHZLOOEHJHQHUDWHGE\1HXURQHWLFVRUD GHVLJQDWHGFRQWUDFWUHVHDUFK
RUJDQL]DWLRQ6XEMHFWVZLOOQRWEHUDQGRPL]HGXQWLODOOHQWU\ LQFOXVLRQDQGH[FOXVLRQFULWHULDKDYHEHHQ
PHWDQGDOOSUHVWXG\SURFHGXUHVKDYHEHHQVDWLVIDFWRULO\FRPSO HWHG(OLJLEOHVXEMHFWVZLOOEHUDQGRPO\
DVVLJQHGWRUHFHLYHRQHRIWKHWZRWUHDWPHQWUHJLPHQVDFWLYH7 06WUHDWPHQWRUVKDP706WUHDWPHQW
DQGWKHQH[WDYDLODEOHUDQGRPL]DWLRQQXPEHUIRUWKHVXEMHFWÂ¶VV WUDWXPZLOOEHUHFRUGHGLQWKHVFUHHQLQJ
ORJDQGRQWKHVXEMHFWÂ¶V&5)5DQGRPL]DWLRQQXPEHUVPD\QRWEH UHDVVLJQHG$SHUPXWHGEORFN
SURFHGXUHZLOOEHXVHGWRUDQGRP O\DVVLJQWKHWUHDWPHQWFRQGLWL RQVZLWKDIL[HGEORFNVL]HIRUHDFK
VWUDWXP
0DVNLQJ
$OOVLWHSHUVRQQHOZLOOEHPDVNHGWRWKHWUHDWPHQWDVVLJQPHQWI RUHDFKVXEMHFW6SHFLILFDVSHFWVRIWKH
WULDOGHVLJQDUHLQWHQGHGWRRSWLPL]HWKHLQWHJULW\RIWKHPDVN LQJDQGDOOVWDIIZLOOEHWUDLQHGWRWKH
SURFHGXUHVIRUPDVNLQJGXULQJWKHVLWHLQLWLDWLRQYLVLW

,QDGGLWLRQWRWKRVHSURFHGXUHVHDFK,QYHVWLJDWRUZLOOEHSURY LGHGZLWKLQGLYLGXDOO\VHDOHGDQGQXPEHUHG
HQYHORSHVFRUUHVSRQGLQJWRVXEMHFWUDQGRPL]DWLRQQXPEHUV,QW KHFDVHRIDQHPHUJHQF\DQHQYHORSH
PD\EHRSHQHGWRLGHQWLI\WKH706WUHDWPHQWDVVLJQPHQWIRUDSD UWLFXODUVXEMHFW,QDOOFLUFXPVWDQFHV
WKH,QYHVWLJDWRUZLOOQRWLI\1HXURQHWLFVSULRUWRXQPDVNLQJWKH 706WUHDWPHQWIRUDQ\VXEMHFWLISRVVLEOH
,QWKHHYHQWWKDWWKHHPHUJHQF\ FLUFXPVWDQFHVSUHFOXGHILUVWQR WLI\LQJ1HXURQHWLFVLPPHGLDWHO\WKH
,QYHVWLJDWRUVKRXOGFRQWDFW1HXURQHWLFVZLWKLQRQHEXVLQHVVGD\ DQGSURYLGHWKHUHDVRQVIRUXQPDVNLQJ
DQGGDWHRIRSHQLQJRIWKHHQYHORSH PXVWEHGRFXPHQWHGLQWKHV XEMHFWÂ¶VILOHV

7KHXQPDVNLQJPXVWDOVREHGRFXPHQWHGRQWKH$GYHUVH(YHQWSDJH RIWKH&5)DQGLQWKHVXEMHFWÂ¶V
VRXUFHGRFXPHQWV$GGLWLRQDOO\WKH,QYHVWLJDWRUPXVWVXEPLWD ZULWWHQH[SODQDWLRQGHVFULELQJWKH
XQPDVNLQJZLWKLQZRUNLQJGD\V$ OORWKHUUDQGRPL]DWLRQHQYHOR SHVPXVWEHUHWXUQHGXQRSHQHGWR
1HXURQHWLFVDWWKHFRPSOHWLRQRIWKHWULDO
3UHSDUDWLRQDQG$GPLQLVWUDWLRQRI,QYHVWLJDWLRQDO'HYLFH
$GPLQLVWUDWLRQRI706WUHDWPHQWZLOOEHFRQVLVWHQWZLWKSURFHGX UHVRXWOLQHGLQWKH1HXUR6WDUÂŠ8VHU
0DQXDODQG8VHUWUDLQLQJGRFXPHQWDWLRQ

0RWRU7KUHVKROG'HWHUPLQDWLRQ3URFHGXUHÂ±SHU1HXUR6WDU8VHU0D QXDO
6XEMHFWVLQ3KDVH,UDQGRPL]HGWRDFWLYHWUHDWPHQWVZLOOUHFHLY HWUHDWPHQWSDUDPHWHUVWKDWKDYHEHHQ
VDIHO\DQGIHDVLEO\XWLOL]HGLQDGXOWUDQGRPL]HGFRQWUROOHGWU LDOVDQGLQWKH:DOOHWDORSHQODEHO
WULDOLQDGROHVFHQWV6WLPXODWL RQZLOORFFXUDWDPD[LPXPRI PDJQHWLFILHOGLQWHQVLW\UHODWLYHWRWKH
VXEMHFWÂ¶VUHVWLQJPRWRUWKUHVKROG07DWSXOVHVSHUVHFRQG +]IRUVHFRQGVZLWKDQLQWHUWUDLQ
LQWHUYDORIVHFRQGV'XULQJWK HWUHDWPHQWIRUWKHILUVWZHH NRQO\WKHLQWHQVLW\RIWKHPDJQHWLFILHOG
FDQEHUHGXFHGDVQHHGHGWR IRUWROHUDELOLW\8SZDUGWL WUDWLRQZLWKJRDORIUHWXUQWRPD[LPXP
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/LQWHQVLW\QRWWRH[FHHG07ZLOORFFXUDVWROHUDWHGE\HD FKVXEMHFWE\WKHHQGRIWKHILUVWZHHNRI
WUHDWPHQW7UHDWPHQWVHVVLRQVZLOOODVWIRUPLQXWHVW UDLQVWRSURYLGHDWRWDORISXOVHVSHU
WUHDWPHQWVHVVLRQ8SWRDWRWDO RIWUHDWPHQWVZLOOEHFRPS OHWHGZLWKLQZHHNVRIWUHDWPHQWLQLWLDWLRQ

7UHDWPHQW
6XEMHFWVLQ3KDVH,UDQGRPL]HGWRVKDPWUHDWPHQWVZLOOKDYHLGH QWLFDOVFKHGXOHVV\VWHPDWLFDVVHVVPHQWV
DQGDWUHDWPHQWDSSURDFKWRDFWLYHWUHDWPHQW1HLWKHUWKHVXEM HFWQRU,QYHVWLJDWRUV ZLOONQRZZKHWKHUWKH
WUHDWPHQWLVDFWLYHRUVKDPLQQDWXUH7KHVKDPFRLOZLOOEHL GHQWLFDOLQLWVDSSHDUDQFHWRWKHDFWLYHFRLO
)XUWKHUPRUH1HXURQHWLFV,QFKDVFUHDWHGDQDFRXVWLFPDWFKLQJ SURILOHWKDWUHQGHUVWKHÂ³VRXQGÂ´RIWKH
WUHDWPHQWVYLUWXDOO\LQGLVWLQJXLVKDEOHWRVXEMHFWVRUUHVHDUFKH UV7KHDFRXVWLFVLJQDOFUHDWHVDSDLQOHVV
SHUFXVVLYHVHQVDWLRQWKDWZLOOEHIHOWE\WKHVXEMHFWDQGZLOO DVVLVWLQVLPXODWLQJWKHDFWLYHFRQGLWLRQ
6XEMHFWVLQ3KDVH,,ZLOOUHFHLYHWUHDWPHQWWKDWLVLGHQWLFDOL QVFKHGXOHDQGSDUDPHWHUVWRWKDWRI3KDVH,
ZLWKWKHH[FHSWLRQWKDWWKHNQRZQDFWLYHWKHUDS\FRLOZLOOEHX VHGIRUDOOWUHDWPHQWV8SWRDWRWDORI
WUHDWPHQWVZLOOEHFRP SOHWHGZLWKLQZHHNV
6XEMHFWVLQ3KDVH,,,ZLOOEHPRQLWRUHGIRUV\PSWRPUHHPHUJHQF H,QWKHHYHQWWKDWWKHVXEMHFWÂ¶V&*,6
VFRUHZRUVHQVE\SRLQWRUPRUH IURPWKHYDOXHREVHUYHGDW3KD VH,,,HQWU\WKHQWKHVXEMHFWPXVWEH
UHVFKHGXOHGIRUUHSHDWFOLQLFDODVVHVVPHQWZLWKLQZHHN,IW KLVV\PSWRPFKDQJHLVFRQILUPHGDWWKDW
YLVLWWKHQWKHVXEMHFWLVFRQVLGHUHGWRKDYHPHWFULWHULDIRU FOLQLFDOGHWHULRUDWLRQ706UHLQWURGXFWLRQ
WUHDWPHQWVKRXOGRFFXUZLWKWKHNQRZQDFWLYHFRLOXVLQJWKHVDP HSURWRFROSDUDPHWHUV$0RWRU
7KUHVKROGGHWHUPLQDWLRQPXVWDOVREHSHUIRUPHGLPPHGLDWHO\SULR UWRDGPLQLVWUDWLRQRIWKHILUVW706
WUHDWPHQWWRDVXEMHFWLQDQ\706WUHDWPHQWEORFN'XULQJHDFK DFWLYH706UHWUHDWPHQWEORFNVXEMHFWV
DUHDVVHVVHGHYHU\RWKHUZHHNZLWKWKHVDPHHIILFDF\PHDVXUHVX VHGLQWKH:HHNYLVLWDQGWKH&6656
'XULQJD706UHWUHDWPHQWEORFN706VKRXOGEHGLVFRQWLQXHGZKHQ WKH&*,6VFRUHKDVUHWXUQHGWRWKH
YDOXHREVHUYHGDW3KDVH,,,HQWU\ 6XEMHFWVPXVWEHZLWKGUDZQI URPWKHVWXG\LIWKH\PHHWFULWHULDIRU
UHODSVHDVGHILQHG

x0HHWLQJGLDJQRVWLFFULWHULDIRUPDMRUGHSUHVVLRQFRQILUPHGRQ WZRRFFDVLRQVZLWKLQDWZRZHHN
SHULRGRU
x)DLOXUHWRH[SHULHQFHV\PSWRPDW LFLPSURYHPHQWE\UHVWRUDWLRQRI &*,6VFRUHWRLWV3KDVH,,,
HQWU\YDOXHXSRQWKHFRPSOHWLRQRIDQ706UHWUHDWPHQWEORFN
3DFNDJLQJDQG/DEHOLQJ
7KH1HXUR6WDU;3/25ÂŠ7KHUDS\6\VWHPZLOOEHFOHDUO\ODEHOHGZLWKWKHIROORZLQJZDUQ LQJ

Â³&$87,21Â±,QYHVWLJDWLRQDO'HYLFH/LPLWHGE\)HGHUDORU8QLWH G6WDWHVODZWRLQYHVWLJDWLRQDOXVHÂ´
%OLQGLQJRI6WXG\
7KHEOLQGHG706FRLOVZLOODUULYHIURP1HXURQHWLFVDQGZLOOEH LGHQWLFDOLQDSSHDUDQFHDQGODEHOHG
JHQHULFDOO\HJ&RLO;&RLO<7KHGHYLFHZLOOUHFRJQL]H RQHFRLODVDFWLYHDQGWKHRWKHUFRLODVVKDP
2QFHDVXEMHFWKDVEHHQUDQGRPL]HGWKHGHYLFHZLOOÂ³OLQNÂ´WKH VXEMHFWÂ¶VWUHDWPHQWZLWKWKHFRUUHVSRQGLQJ
FRLO7KHGHYLFHZLOOUHPDLQLQDFWLYHLIWKHÂ³LQFRUUHFWÂ´FRLO LVXVHGIRUDVXEMHFWDGGLQJDQDGGLWLRQDO
VDIHJXDUGIRUHDFKVXEMHFWDQGW KHLQWHJULW\RIWKHVWXG\DQGD OORZLQJWKHVWXG\WUHDWHUVWRUHPDLQEOLQGHG
WRWKHQDWXUHRIWKHVXEMHFWÂ¶VWUHDWPHQWDVVLJQPHQW 
6XEMHFWVZLOOEHUDQGRPO\DVVLJQHGWRDFRLODQGZLOOUHFHLYHD OOWUHDWPHQWVGXULQJ3KDVH,RIWKHWULDO
XVLQJWKLVFRLO1HLWKHUWKHVXEMHFWQRUWKHVWXG\VWDIILQFO XGLQJWKRVHDGPLQLVWHULQJ706WUHDWPHQWVDQG
WKRVHDGPLQLVWHULQJPRRGFRJQLWLYHVDIHW\DQGLPDJLQJDVVHVV PHQWVZLOONQRZZKHWKHUWKHVXEMHFWLV
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/UHFHLYLQJDFWLYHRUVKDPWUHDWPHQW6XEMHFWVDQG3DUHQWVLIV XEMHFW\HDUVROGRUGRHVQRWPHHWWKH
ORFDORUVWDWHOHJDODJHUHTXLUH PHQWZLOOFRPSOHWHD3UH3RVW 7UHDWPHQW([SHFWDWLRQVDQG([SHULHQFH
4XHVWLRQQDLUH35(7((4$35(7((43DQG32677((4$32677((4 3WKDWTXHULHVWKHLU
LQLWLDOH[SHFWDWLRQVRIWULDORXWFRPHDQGILQDOLPSUHVVLRQRIW KHWULDO
,Q3KDVH,,DQG ,,,DOOWUHDWPHQWVZLOO EHSURYLGHGZLWKWKHN QRZQDFWLYHFRLO
7RPLQLPL]HDQ\VRXUFHRIELDVXQEOLQGLQJRIWKHVWXG\ZLOOQR WEHGRQHXQWLODOOVXEMHFWVKDYHFRPSOHWHG
DOOVWXG\SKDVHV+RZHYHUXQEOLQGLQJZLOORFFXULIWKH'DWDD QG6DIHW\0RQLWRULQJ%RDUGFRQVLVWHQW
ZLWKWKHLUDVVLJQHGFKDUWHUDQGDVVRFLDWHGVWRSSLQJUXOHVGHWH UPLQHVWKDWLWQHFHVVDU\WRGRVR
$VDQDGGLWLRQDOPHDVXUHWRHQVXUHWKHLQWHJULW\RIWKHEOLQGHG FRLODVVLJQPHQWWKHVWXG\FRLOVDWHDFK
ORFDWLRQPD\EHUHWULHYHGE\1HXURQHWLFVVWXG\SHUVRQQHODQGQH ZVWXG\FRLOVUHDVVLJQHG
5HFHLYLQJ6WRUDJH'LVWULEXWLRQDQG5HWXUQ
5HFHLSWRI,QYHVWLJDWLRQDO'HYLFHV
1HXUR6WDU;3/25ÂŠ7067KHUDS\6\VWHPZLOOEHGHOLYHUHGWRWKH,QYHVWLJDWRUDQGL QVWDOOHGE\
1HXURQHWLFV

8SRQUHFHLSWRIWKH1HXUR6WDUD QGVWXG\WUHDWPHQWVXSSOLHVDQ LQYHQWRU\ZLOOEHSHUIRUPHGDQGDGHYLFH
DFFRXQWDELOLW\ORJFRPSOHWHGE\GH VLJQDWHGVWXG\VWDIIDWHDFK VLWH7KHGHVLJQDWHGVWXG\VWDIIZLOOFRXQW
DQGYHULI\WKDWWKHVKLSPHQWFRQWDLQVDOOWKHLWHPVQRWHGLQWK HVKLSSLQJLQYRLFH$Q\GLVFUHSDQFLHVRU
GDPDJHGRUXQXVDEOHGHYLFHVLQDJLYHQVKLSPHQWZLOOEHGRFXPHQ WHGLQWKHGHYLFHDFFRXQWDELOLW\ORJ
7KH,QYHVWLJDWRUDWHDFKVWXG\VLWHZLOOQRWLI\1HXURQHWLFVLPP HGLDWHO\RIDQ\GLVFUHSDQFLHVRUGDPDJHG
RUXQXVDEOHSURGXFWV
6WRUDJH
7KHVXSSOLHVDQGGLVSRVDEOHVUHTXLUHGIRUHDFKWUHDWPHQWZLOOE HVWRUHGLQDVXSSO\VWDWLRQVHSDUDWHIURP
FOLQLFDOSUDFWLFHVWRFNDWHDFKVLWH
'LVWULEXWLRQRI6WXG\'HYLFH
6XEMHFWVLQ3KDVH,ZLOOEHUDQGRPO\DVVLJQHGWRRQHRIWKHEOL QGHGWUHDWPHQWFRLOVDWWLPHRIHQUROOPHQW
DVRXWOLQHGLQSURWRFROVHFWLRQ$OOVXEMHFWVLQ3KDVH,, DQG,,,ZLOOEHWUHDWHGZLWKWKHNQRZQDFWLYH
QRQEOLQGHGWKHUDS\FRLO$OOVXEMHFWVZLOOEHWUHDWHGXVLQJD QHZVLQJOHXVHWUHDWPHQWGLVSRVDEOHRU
6HQ6WDUÂŠ7UHDWPHQW/LQNIURPWKHLUWUHDWPHQWVLWHDWWKHVWDUWRIHYHU \QHZWUHDWPHQW7KHWUHDWPHQW
SDFNVDQG6HQ6WDU7UHDWPHQW/LQNVZLOOEHVWRUHGLQDQDUHDWKD WLVVHSDUDWHIURPFOLQLFDOSUDFWLFHVWRFN
5HJXODUUHFRQFLOLDWLRQRI6HQ6WDU7UHDWPHQW/LQNVUHFHLYHGIURP 1HXURQHWLFV6HQ6WDUVXVHGGXULQJVWXG\
WUHDWPHQWVDQG6HQ6WDUVUHPDLQLQJZLOOEHSHUIRUPHG7KLVUHF RQFLOLDWLRQRIWKHLQYHQWRU\ZLOOEHORJJHG
LQWKH'HYLFH$FFRXQWDELOLW\ /RJVLJQHGDQGGDWHG$Q\GLVFU HSDQFLHVQRWHGZLOOEHGRFXPHQWHG
1HXURQHWLFVZLOOEHQRWLILHGDQGDQLQYHVWLJDWLRQZLOOEHFRQG XFWHGWRGHWHUPLQHWKHFDXVHRIWKH
GLVFUHSDQF\$Q\6HQ6WDUVGLVSRVHGRIIRUDQ\UHDVRQRWKHUWKD QXVHIRUWKHVWXG\ZLOOEHGRFXPHQWHGLQ
WKH'HYLFH$FFRXQWDELOLW\/RJDWWKHWLPHRIGLVSRVDO
5HWXUQRU'HVWUXFWLRQRI6WXG\'HYLFH
7KH1HXUR6WDUÂŠGHYLFHVSXUFKDVHGIURP1HXURQHWLFV,QFZLOOUHPDLQDWWKHVW XG\VLWHVDWWKHFRPSOHWLRQ
RIWKHVWXG\1HXUR6WDUGHYLFHVDQGRU;3/25VWKDWDUHORDQHG WRWKHVWXG\VLWHIRUSXUSRVHVRI
SDUWLFLSDWLQJLQWKLVVWXG\ZLOOEHUHWXUQHGWR1HXURQHWLFVDW FRQFOXVLRQRIWKHVWXG\E\1HXURQHWLFV
SHUVRQQHO6HQ6WDUVÂŠWKDWDUHUHPDLQLQJLQWKHVLWHVWXG\UHVHDUFKLQYHQWRU\DWWKH FRPSOHWLRQRIWKHVWXG\
ZLOOEHSDFNDJHGDQGUHWXUQHGWR1HXURQHWLFV
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/6WXG\3URFHGXUHV
6WXG\2YHUYLHZ
$GROHVFHQWVZLOOEHVFUHHQHGDQGHQUROOHGLQWKHVWXG\DQGUDQG RPL]HGLQDEOLQGHGPDQQHUWRHLWKHUWKH
DFWLYHWUHDWPHQWRUVKDPWUHDWPHQWJURXS1HLWKHUWKHVXEMHFWV QRUWKHLQYHVWLJDWRUVZLOONQRZZKHWKHU
WKHWUHDWPHQWVDUHDFWLYHRUVKD PLQQDWXUH$OOVXEMHFWVZLOO KDYHEDVHOLQHPRRGVDIHW\DQGFRJQLWLYH
DVVHVVPHQWV6XEMHFWVDWVLWHVFRQGXFWLQJWKH6WUXFWXUDO+HDG 05,VXEVHWZLOOKDYHEDVHOLQHLPDJLQJ
$OOVXEMHFWVZLOOWKHQXQGHUJR7 06WUHDWPHQWVZLWKLQWKHZ HHNWLPHIUDPH0RRGVDIHW\DQG
FRJQLWLYHDVVHVVPHQWVZLOOEHSHUIRUPHGDWUHJXODULQWHUYDOV WKURXJKRXWWKHVWXG\VHH$SSHQGL[$IRU
VFKHGXOHRIHYHQWV$IWHUWKHILQDOWUHDWPHQWLHWUHDWPHQ WRUDWHDUO\ZLWKGUDZDOWKHPRRGDQG
FRJQLWLYHDVVHVVPHQWVZLOOEH SHUIRUPHGIRUDOOVXEMHFWV

7KHWUHDWPHQWDQGDVVHVVPHQWVFKHGXOHVIRU3KDVH,DUHLGHQWLFD OIRUERWKWKHDFWLYHDQGWKHVKDP
WUHDWPHQWFRKRUWV)RUVXEMHFWVLQWKH6WUXFWXUDO05,VXEVHW 05,VFDQVZLOODOVRRFFXUDIWHUWKHILQDO
WUHDWPHQWIRU3KDVHV,DQG,,DQGDJDLQDWWKHPRQWKIROORZX SYLVLW

6XEMHFW&RPSOLDQFH0RQLWRULQJ
1RQDGKHUHQFHWRWKHDVVLJQHGWUHDWPHQWUHJLPHQLVGHILQHGDVP LVVLQJÂ•WUHDWPHQWVLQGDLO\VHTXHQFH
RUPLVVLQJPRUHWKDQRIWKHWRWDOQXPEHURIWUHDWPHQWVHVVL RQVRFFXUULQJGXULQJWKHZHHNVRIDFXWH
WUHDWPHQWGRHVQRWLQFOXGHWDSHUWUHDWPHQWVDVRXWOLQHGLQWK HVFKHGXOHRIHYHQWVLHFRPSOLDQFH
 WRWDOWUHDWPHQWV+RZHYHULIWKHVXEMHFWGRHVPLVVDWU HDWPHQWWKHVXEMHFWPXVWQRWJRPRUHWKDQ
FDOHQGDUGD\VZLWKRXWDWUHDWPHQWVHVVLRQ7UHDWPHQWVPLVVHGG XULQJWKHWDSHUYLVLWVDUHFRQVLGHUHG
SURWRFROGHYLDWLRQV6XEMHFWVZ KRDUHXQDEOHWRFRPSO\ZLWKWK LVVFKHGXOHPD\EHZLWKGUDZQIURPWKH
LQYHVWLJDWLRQDOWUHDWPHQWSRUWL RQRIWKHVWXG\,IDVXEMHFWU HFHLYHVPRUHWKDQWKHSUHVFULEHGQXPEHURI
SXOVHVLHSXOVHVRIJRRGFRQWDFWWKLVZRXOGEHFRQVLG HUHGDQRYHUGRVHDQGGRFXPHQWHGRQWKH
6$(IRUPDQGUHSRUWHGWR1HXURQHWLFV
3ULRUDQG&RQFRPLWDQW7KHUDS\
5HDVRQDEOHHIIRUWVZLOOEHPDGHWRGHWHUPLQHDOOVRPDWLFWKHUDS LHVIRUGHSUHVVLRQUHFHLYHGE\WKHVXEMHFW
LQWKHSDVW\HDUV$OORWKHUPH GLFDWLRQVDQGWKHUDSLHVUHFHL YHGZLWKLQVL[PRQWKVRIVWXG\HQUROOPHQW
ZLOODOVREHGHWHUPLQHG$OOUHOHYDQWLQIRUPDWLRQZLOOEHUHFR UGHGRQWKHVXEMHFWV&5)7KH$75ZLOOEH
XVHGLQWKLVVWXG\WRYHULI\WKHLQFOXVLRQFULWHULDSHUWDLQLQJ WRWUHDWPHQWUHVLVWDQFHDQGLQWROHUDQFH6HH
6WXG\5HIHUHQFH0DQXDOIRUGHWDLOVRIWKHDGPLQLVWUDWLRQRIWKH $75
3HUPLWWHG&RQFRPLWDQW7KHUDS\
=DOHSORQ]ROSLGHPRU]RSLFORQH GRVHQLJKWO\DVQHHGHGIRU WUHDWPHQWHPHUJHQWLQVRPQLDRU
ORUD]HSDPXSWRPJGDLO\IRUWUHDWPHQWHPHUJHQWDQ[LHW\PD \EHDGPLQLVWHUHGIRUXSWRGRVHV
GXULQJ3KDVH,DQGDQDGGLWLRQDOGRVHVGXULQJ3KDVH,,)RU 3KDVH,,,WKHVHPHGLFDWLRQVPD\EH
DGPLQLVWHUHGIRUXSWRGD\VRQÂ” RFFDVLRQV7KHXVHRIDO WHUQDWLYHK\SQRWLFVRUDQ[LRO\WLF
FRPSRXQGVUHTXLUHVSULRUDSSURYDOIURPWKH6SRQVRU+RUPRQDOF RQWUDFHSWLYHVDUHDOORZHGLIWKHVXEMHFW
KDVEHHQRQDVWDEOHGRVHIRUDWOHDVWPRQWKV6KRUWWHUPWU HDWPHQWVIRUKHDGDFKHVDOOHUJLHVFROGVDQG
IOXV\PSWRPVZLOOEHDOORZHGGXULQJWKHVWXG\SURYLGHGWKHPHGL FDWLRQVXWLOL]HGKDYHQRHVWDEOLVKHG
SV\FKRWURSLFHIIHFWVWKDWZRXOGEHH[SHFWHGWRFRQIRXQGLQWHUSU HWDWLRQRIVWXG\RXWFRPHPHDVXUHV
7KHVHPHGLFDWLRQVPD\LQFOXGHQRQVHGDWLQJRYHUWKHFRXQWHUR USUHVFULSWLRQDQWLKLVWDPLQHVDQDOJHVLFV
DQGGHFRQJHVWDQWV$OOTXHVWLRQVUHJDUGLQJWKHDFFHSWDELOLW\R IVSHFLILFPHGLFDWLRQVPXVWEHDSSURYHGE\
WKH6SRQVRU
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 38 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Prohibited  Concomitant Therapy  
Any medication administered for the treatment of any psychiatric or neurologic disorder or any other 
known CNS active drugs, including herbal, over -the-counter, and homeopathic medications, MAOIs, 
other antidepressants,  antipsychotics, stimulants and mood stabilizers are prohibited during this study 
(See Appendix D, Concomitant Medication Exclusion List ).  Use of Zaleplon, zolpidem, zopi clone or 
lorazepam  for more than the permitted days (see above) or beginning a new regimen of hormonal 
contraception may  lead to excluding the subject from the study.
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/
3KDVHVÂ±5DQGRPL]H G7ULSOH%OLQGHG
6WDWLVWLFDO3ODQ
6DPSOH6L]HDQG3RZHU&DOFXODWLRQ
7KHUHDUHQRODUJHUDQGRPL]HGFRQWUROOHGWULDOVRIWKHXVHRI WUDQVFUDQLDOPDJQHWLFVWLPXODWLRQ706LQ
WKHWUHDWPHQWRIDGROHVFHQWPDMRUGHSUHVVLYHGLVRUGHUWKDWFDQ EHXVHGWRHVWLPDWHHIIHFWVL]H7KHUHIRUH
VHYHUDOGLIIHUHQWVRXUFHVRIHYLGHQFHZHUHXVHGWRHVWLPDWHWKH H[SHFWHGHIIHFWVL]HRIWUHDWPHQWDV
SURSRVHGLQWKLVSURWRFRO)LUVW HYLGHQFHZDVUHYLHZHGIURPW KHVWXG\E\:DOODQGFROOHDJXHVZKR
UHSRUWHGSUHOLPLQDU\GDWDIURPDVPDOOSDWLHQWSRSXODWLRQRIDG ROHVFHQWVWUHDWHGZLWKWKH1HXUR6WDU706
7KHUDS\6\VWHPLQDQRSHQODEHO VWXG\GHVLJQ:DOO7KL VVWXG\LVHVSHFLDOO\UHOHYDQWEHFDXVHLWLV
WKHRQO\DYDLODEOHHYLGHQFHXVLQJWKHVSHFLILF706GHYLFHLH WKH1HXUR6WDU7067KHUDS\6\VWHPWKDW
ZLOOEHXWLOL]HGLQWKH1HXUR6WDU706$GROHVFHQW0''5&7DQGL WXVHGWKHLGHQWLFDOVWLPXODWLRQ
SDUDPHWHUVDQGGXUDWLRQRIWUHDWPHQWSURSRVHGLQWKLVVWXG\SUR WRFRO,QWKDWUHSRUWHLJKWDGROHVFHQW
SDWLHQWVSDUWLFLSDWHGZKRKDGSUHYLRXVO\IDLOHGWREHQHILWIURP WUHDWPHQWZLWKRUPRUHDQWLGHSUHVVDQW
PHGLFDWLRQVDQGZHUHFXUUHQWO\LQVWDEOHWUHDWPHQWZLWKDVLQJO HLQHIIHFWLYHVHOHFWLYHVHURWRQLQUHXSWDNH
LQKLELWRU665,DQWLGHSUHVVDQWPHGLFDWLRQ6HYHQRISDWLHQW VDJHV\HDUVFRPSOHWHGDOO
WUHDWPHQWVLQWKLVVWXG\7KHSULPDU\RXWFRPHPHDVXUHZDVWKH &KLOGUHQÂ¶V'HSUHVVLRQ5DWLQJ6FDOH
5HYLVHG&'565ZKLFKVKRZHGVLJ QLILFDQWLPSURYHPHQWIURPEDVH OLQHPHDQ>6'@>@DW
WUHDWPHQW>@3 WUHDWPHQW>@3 WUHDWPHQW>@3
DQGDWPRQWKIROORZXS >@3

8VLQJWKLVGDWDWKHPHDQFKDQJH LQ&'565WRWDOVFRUHZDVHVWL PDWHGWREHDSSUR[LPDWHO\ZLWKD
VWDQGDUGGHYLDWLRQRI,WLVSUHVXPHGWKDWDWUHDWPHQWGLI IHUHQFHRISRLQWVRQWKH&'565VFDOH
EHWZHHQUDQGRPL]HGWUHDWPHQWFRQGLWLRQVPD\EHDQWLFLSDWHGLQD VKDPFRQWUROOHGVWXG\DQGWKDWD
FRQVHUYDWLYHHVWLPDWHIRUDSRROHGVWDQGDUGGHYLDWLRQLVS RLQWVZKLFKUHVXOWVLQDQHVWLPDWHG
VWDQGDUGL]HGHIIHFWVL]HRI7KLVLVFRQVLGHUHGWREHWKH XSSHUERXQGRIDQH[SHFWHGPDJQLWXGHRI
WUHDWPHQWEHQHILWLQDQDGROHVFHQWGHSUHVVLRQVWXG\SRSXODWLRQ 8QGHUWKHVHDVVXPSWLRQVLWLVSUHVXPHG3KDVH,
:HHN5DQGRPL]HG7063KDVH,,,
PRQWKIROORZXSZLWK706
UHWUHDWPHQWDVQHHGHGIRU
FOLQLFDOGHWHULRUDWLRQ
3KDVH,,
ZHHNRSHQODEHO706
$EVHQFHRI3URWRFRO'HILQHG
&OLQLFDO%HQHILWÂ±GLVFRQWLQXH
IURPWKHVWXG\3URWRFROGHILQHG&OLQLFDO
%HQHILWSURFHHGWR3KDVH3URWRFROGHILQHG&OLQLFDO
%HQHILWSURFHHGWR3KDVH
$EVHQFHRI3URWRFRO
'HILQHG&OLQLFDO%HQHILW
SURFHHGWR3KDVH,,
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/WKDWDVDPSOHVL]HRIDSSUR[LPDWHO\1 SDWLHQWVSHUWUHDWPHQW JURXSZLWKDQDOSKDOHYHO ZRXOG
SURYLGHDSSUR[LPDWHO\SRZHU WRGHWHFWDWUHDWPHQWGLIIHUHQF HEHWZHHQDFWLYHDQGVKDP706JURXSV

$QRWKHULPSRUWDQWVRXUFHRIHYLGHQFHWRFRQVLGHULQHVWLPDWLQJ DQHIIHFWVL]HIRUWKLVVWXG\FDQEHGHULYHG
IURPUDQGRPL]HGFRQWUROOHGWULDOHYLGHQFHIURPWKHVWXG\RIDQW LGHSUHVVDQWPHGLFDWLRQVWKDWDUH)'$
DSSURYHGDVWUHDWPHQWVIRUDGROH VFHQWSDWLHQWVZLWKPDMRUGHSUH VVLYHGLVRUGHU7KHUHOHYDQWPHGLFDWLRQV
WRFRQVLGHULQFOXGHWKHPHGLFDWLRQVIOXR[HWLQH(PVOLHHWDO DQGHVFLWDORSUDP(PVOLHHW
DO5HSOLFDWHGVWXGLHVRIWKHDQWLGHSUHVVDQWIOXR[HWLQ HKDYHVKRZQDFWLYHYHUVXVVKDPWUHDWPHQW
GLIIHUHQFHVXVLQJWKH&'565WKDWUDQJHIURPDSSUR[LPDWHO\WR SRLQWVZLWKDVVRFLDWHGSRROHG
VWDQGDUGGHYLDWLRQVRIDSSUR[LPDWHO\WRSRLQWV(VWLPDWHG VWDQGDUGL]HGHIIHFWVL]HVLQWKHVHVWXGLHV
DUHUHSRUWHGDVPRGHUDWHO\ODUJHDSSUR[LPDWHO\(PVOLHH WDO5HVXOWVRIVLPLODUO\
GHVLJQHGVWXGLHVRIHVFLWDORSUDPVXJJHVWDORZHUHVWLPDWHGVWDQ GDUGL]HGHIIHFWVL]HRIDSSUR[LPDWHO\
(PVOLHHWDO

,QDGGLWLRQWRWKHVHGDWDWKHUHVXOWVRIDODUJHIHGHUDOO\VX SSRUWHGPXOWLVLWHVWXG\RIWKHXVHRI
DQWLGHSUHVVDQWPHGLFDWLRQIRUWKHWUHDWPHQWRIDGROHVFHQWPDMRU GHSUHVVLRQDUHDOVRUHOHYDQWWRFRQVLGHU
7KLVVWXG\ZDVQRWVSHFLILFDOO\GLUHFWHGDWWKHTXHVWLRQRIDQW LGHSUHVVDQWPHGLFDWLRQPRQRWKHUDS\DORQH
UDWKHUWKHGHVLJQZDVLQWHQGHGWRH[DPLQHWKHHIIHFWLYHQHVVRI WKHFRPELQDWLRQRIDQWLGHSUHVVDQW
PHGLFDWLRQZLWKFRJQLWLYHEHKDYLRUWKHUDS\&%71HYHUWKHOHVV H[DPLQDWLRQRIWKHPHGLFDWLRQDORQH
WUHDWPHQWFRQGLWLRQLQWKLVVWXG\SURYLGHVLPSRUWDQWVXSSRUWLYH LQIRUPDWLRQLQDQHVWLPDWLRQRIWKH
DQWLFLSDWHGVWDQGDUGL]HGHIIHFWVL]HLQDGROHVFHQWV7KH7UHDW PHQWRI$GROHVFHQW'HSUHVVLRQ6WXG\
7$'60DUFKHWDOH[DPLQHGWKHEHQHILWRIWKHXVHRI IOXR[HWLQHDORQH&%7DORQHRUWKH
FRPELQDWLRQRIWKHWZRYHUVXVDSODFHERFRQGLWLRQ,QWKDWUHS RUWWKHXVHRIIOXR[HWLQHDORQHYHUVXV
SODFHERZDVREVHUYHGWRGHPRQVWUDWHDVWDQGDUGL]HGHIIHFWVL]H RIVLPLODULQPDJQLWXGHWRWKHUHVXOWV
RIWKH(PVOLHDQGFROOHDJXHVVWXGLHVGHVFULEHGDERYH(PVOLHH WDO,WVKRXOGEHQRWHG
KRZHYHUWKDWWKHVHVWXGLHVZLWKDQWLGHSUHVVDQWPHGLFDWLRQXWLO L]HGDWUHDWPHQWQDwYHVWXG\SRSXODWLRQ
H[FOXGLQJSDWLHQWVZLWKWUHDWPHQWUHVLVWDQWGHSUHVVLRQ
%DVHGRQWKHDJJUHJDWHHYLGHQFHGHVFULEHGKHUHLWLVDQWLFLSDW HWKDWWKLVVWXG\LIHIIHFWLYHLQ
GHPRQVWUDWLQJWKHVXSHULRULW\RI1HXUR6WDU7067KHUDS\
ÂŠFRPSDUHGWRVKDP706LQDGROHVFHQWSDWLHQWV
ZLWKWUHDWPHQWUHVLVWDQWPDMRUGHSUHVVLYHGLVRUGHUPD\EHH[SH FWHGWRGHPRQVWUDWHDVWDQGDUGL]HGHIIHFW
VL]HRIDSSUR[LPDWHO\WR$ VDVWDQGDORQHDQDO\VLV LWLVWKHUHIRUHH[SHFWHGWKDWDVDPSOHVL]H
RISDWLHQWVSHUWUHDWPHQWDUPDWDQDOSKDOHYHORIVK RXOGSURYLGHJUHDWHUWKDQSRZHUWR
GHWHFWDVWDWLVWLFDOO\VLJQLILFDQWGLIIHUHQFHEHWZHHQWKHWUHDW PHQWJURXSV+RZHYHUDVQRWHGIXUWKHU
EHORZHIILFDF\DOVRPD\EHHVWDEOLVKHGE\DQDO\VLVRIWKHDGRO HVFHQWVWXG\GDWDXVLQJDIUHTXHQWLVW
DSSURDFKZKLFKERUURZVGDWDIURPWZRSULRUDGXOW5&7VLQPDMRU GHSUHVVLRQXVLQJWKH1HXUR6WDU706
7KHUDS\6\VWHP

$QDO\VLV3ODQ
7KLVVWXG\LQDGROHVFHQWSDWLHQWVLVDUDQGRPL]HGSDUDOOHOJUR XSFRPSDULVRQRIWUHDWPHQWZLWK706DV
FRPSDUHGWRDVKDPFRQWURO,WZLOOEHFRQGXFWHGDWDSSUR[LPDWH O\VLWHVLQWKH8QLWHG6WDWHVDQG
&DQDGDZLWKLQGHSHQGHQWUDQGRPL]DWLRQSURWRFROVZLWKLQHDFKVL WHXVLQJDSHUPXWHGEORFNGHVLJQWR
LPSURYHEDODQFHZLWKLQVLWH7KHSULPDU\RXWFRPHLVWKHODVWSR VWWUHDWPHQWV\PSWRPVFRUH/9
PHDVXUHGXVLQJWKHSULPDU\HIILFDF\RXWFRPHPHDVXUHHIILFDF\Y DULDEOHDQGSRLQWRIGHFODUDWLRQDUH
EOLQGHGWRWKH,QYHVWLJDWRUIRUHDFKVXEMHFW7KHDQDO\VLVZL OOEHSHUIRUPHGRQWKHVWULFWLQWHQWLRQWR
WUHDWVDPSOHRIDOOHYDOXDEOHVXEMHFWVPHDQLQJWKRVHVXEMHFWV ZLWKDEDVHOLQHDQGDWOHDVWRQHSRVW
EDVHOLQHREVHUYDWLRQDYDLODEOHIRUDQDO\VLV

Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 41 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Poorly recruiting sites, defined as those with fewer than 2 randomization blocks, will be pooled into one 
or more pseudo- sites for purposes of analysis.  To ensure that nearly all sites will be of adequate size we 
will adopt a strict closure policy for sites that do not show early signs of enrollment success.  With 16 sites, the average number of subjects per site is approximately 18,  so there may be a few sites with fewer 
than 2 randomization blocks.   A site that has not randomized at least 2 subject s in the first quarter of their 
enrollment may be closed.  Then if as many as 2 sites are closed, and one poorly performing site eludes 
closure, there will be no more than one pseudo-site comprising a total of no more than 2 subjects from the 
closed site and approximately 11 from the poorly performing site, or no more than 13 subject s in all (i.e. 
<5% of the total sample). 
 
As noted elsewh ere in this protocol, the sites will remain blinded to which efficacy measure has been 
declared as the primary outcome and to the point of efficacy declaration in order to improve the studyâ€™s 
signal detection ability. Point of declaration and the primary outcome measure will be documented in the 
study master file prior to unblinding of the dataset. The null hypothesis will be tested in an analysis of 
covariance of the LV, using baseline score, and AT R medication resistance level as fixed effect 
covariates, adjusting for site differences using a random effect.  As discussed elsewhere, the AT R 
medication resistance levels will group subjects categorically by number of medications which have 
shown an adequate degree of resistance for that subject .  These resistance levels will be grouped into two 
categories in statistical model, 0 -1 in the current episode or 2-4 in the current episode, unless the final 
distribution of ATR scores in the study population suggests another allocation would be more statisticall y 
appropriate.  All tests are two -sided, at the 5% level. The primary outcome should be available and 
meaningful for nearly all subjects, so the main analysis will be by strict intention -to-treat as defined 
above. An analysis of observed cases only will be  performed as a secondary outcome measure.  A site by 
treatment interaction analysis will be done as a secondary analysis to see if there is significant 
heterogeneity in the effect of TMS across sites.  In particular, we will examine site- specific treatmen t 
effects (with confidence intervals) to test for evidence of true reversal of effect.  
 
Secondary outcomes include other continuous measures, and within- subject dichotomous variables as 
outlined in the efficacy variables described elsewhere in this protoco l. The treatment effect null 
hypothesis will be tested by logistic regression on treatment group assignment with adjustment for site and ATR medication resistance level. In addition, the longitudinal symptom scores will be analyzed with 
a general linear model adjusting for baseline scores and AT R medication resistance level, using a 
saturated means model for time since baseline, with treatment effect parameterized by a linear effect in 
time. The correlation of scores within individuals over time will be han dled by allowing a within- subjects 
residual covariance matrix selected by exploration of the sample semi -variogram, as described by Diggle, 
Liang and Zeger. If this exploration reveals that a mixed model approach will fit the covariance structure 
better, random effects will be included in the model.  As in the main analysis, site by treatment 
interactions will be tested.  
 
In addition to testing the hypothesis noted above in the study alone, a meta- analysis will be used to 
establish evidence of efficacy.  Specifically, in addition to the evidence to be obtained in this study 
protocol, there are already two large, randomized, multisite sham-controlled studies of the use of the 
NeuroStar TMS Therapy
Â® System in adult patients (ages 18 -70 years of age) with major depressive 
disorder.  T hese data are statistically important to consider in the interpretation of the data to be collected 
in the adolescent study population using the NeuroStarÂ® TMS device.  Therefore, a frequentist  analysis 
will be used to demonstrate the effectiveness of the NeuroStar TMS Therapy System across ages 12 -70 by  
borrowing data from the two adult studies to be used in a meta- analysis with the adolescent study data .  
This approach effectively allows meaningful computational us e of the preponderamce of  adult study 
evidence with the adolescent study data to permit a â€œsample -sparingâ€ adolescent study design.  T his 
approach is clinically justified by the substantial evidence of safety and effectiveness already shown in the adult pa tient population, the biological and clinical continuity of the disease state from adolescence to 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 42 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  adulthood, the shared mechanism of action of transcranial magnetic stimulation across age groups, and 
because of the significant unmet need in treatment options available for adolescent patients with major 
depressive disorder. 
 
Details of the statistical approach to be used in the meta- analysis are contained in the blinded statistical 
plan associated with this study protocol.  The meta- analysis will include data from all three studies.  The 
model for this analysis will include the following terms: treatment (active vs. sham), baseline score (continuous), medication resistance level as determined using the Antidepressant Treatment Record 
(ATR), (ATR=1 â€˜Loâ€™ vs. AT R=2-4 â€˜Hiâ€™), and Study (adolescent study (IDE G120121), and the two adult 
studies combined (Oâ€™Reardon, et al, 2007 and George, et al, 2010) as fixed effects, and, interaction terms for â€œstudy-by- treatmentâ€ and â€œATR medication resistance level -by-treatmentâ€.  A random effect of â€œsite 
nested within studyâ€ will also be included to assess any potential site effects.  
 
Based on this meta -analysis, there are 3 essential criteria to declare success and conclude that the 
evidence rejects the null hypothesis of no di fference between active TMS and sham TMS in adolescent 
patients with treatment resistant major depressive disorder.  These criteria are:  
 
 
1) The main effect of treatment on the primary efficacy variable of mean change from baseline on 
the HAMD24 in the adolescent/adult studies meta -analysis will be statistically significant, and 
fall below the specified alpha level of 0.05,  
2) There will be no statistically significant evidence of interaction between Study and Treatment on the primary efficacy outcome variable at the pre- specified alpha level > 0.10,  
3) The study -specific treatment effect observed for the primary efficacy outcome variable in the 
adolescent study as a stand -alone analysis will reside between the ranges of 1.7 points to 5.5 
points on the HAMD24, and t o meet the maximum Type I error rate of 15%.  
 
 
The criteria above are clinically justified based on the results using the HAMD24 outcome measure in the prior adult stud ies which ranges from 1.7 to 2.5  (Oâ€™Reardon, et al, 2007; George, et al, 2010) .  The 
maximum Type I error rate of 15% for the adolescent data alone  is justified given the large dataset 
available  in adults (N=491 ) and that adult and adolescent populations should respond simi larly to TMS 
Therapy.  Simulations using data from the adult studies and N=100 adolescents, shows that with a type I error rate of 5%, the observed HAMD24 mean difference between active and sham treatment would need to be 2.67, which would require a result greater than what it would need to achieve had it been 
considered alone.   For this reason, the 15% type I error rate for the adolescent data is justified.  
 
 
If the criteria described above for pooling the adolescent study with the adult studies are not satisfied, the 
adolescent study must stand alone.  If the results of the analysis of the adolescent study shows a 
statistically significant treatment group difference in favor of the active treatment at a pre- specified alpha 
level = 0.05, then this study alone will be sufficient to establish efficacy in the adolescent population. 
 A listing of the efficacy outcome measures and their intended sequence of testing in priority order are 
listed here. Note that the point of declaration of efficacy for the primary outcome measure is concealed 
from the Investigator and hence, is not specifically noted in this listing. All tests are to be performed on the intent to treat sample unless specifically noted.  Please refer to the Schedule of Events for a listing of study timing for collection of primary and secondary outcome measures. 
 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/7DEOH3ULRULWL]HG2UGHURI7HVWLQJRI3ULPDU\DQG6HFRQGDU\ 2XWFRPH0HDVXUHV

3ULPDU\(IILFDF\2XWFRPH0HDVXUH 'HILQLWLRQV
+$0'WRWDOVFRUHLQWHQWWRWUHDW
VDPSOHXVLQJODVWSRVWWUHDWPHQWVFRUH+$0'WRWDOVFRUHFKDQJHIURPEDVHOLQHYDOXH>%OLQGHG
SRLQWRIGHFODUDWLRQRIHIILFDF\IRUSULPDU\RXWFRPHPHDVXUHLQFOXGHGLQVWDWLVWLFDOVXSSOHPHQW@
6HFRQGDU\(IILFDF\2XWFRPH
0HDVXUHV
&RQWLQXRXVRXWFRPHV
+$0'0$'56&'5654,'6
$5&*,6WRWDOVFRUHLQWHQWWRWUHDW
VDPSOHXVLQJODVWSRVWWUHDWPHQWVFRUH>%OLQGHGSRLQWRIGHFODUDWLRQRIHIILFDF\IRUVHFRQGDU\
RXWFRPHPHDVXUHVLQFOXGHGLQVWDWLVWLFDOVXSSOHPHQW@
5HVSRQGHUFDWHJRULFDORXWFRPH
+$0'DQG,WHPYHUVLRQV
0$'56
&'5654,'6$65
&*,6
)RU+$0'0$'56&'565DQG4,'6$65
SURSRUWLRQRISDWLHQWSRSXODWLRQDFKLHYLQJDQHQGRIDFXWH
SKDVHWRWDOVFRUHUHGXFWLRQRI!FRPSDUHGWREDVHOLQH
VFRUH
)RU&*,6(QGRIDFXWHWUHDWPHQWVFRUHRIRU
)DFWRUVFRUHVGHULYHGIURPWKH+$0'
LQFOXGLQJXVLQJWKHODVWSRVWWUHDWPHQW
YDOXH
$Q[LHW\6RPDWL]DWLRQ
&RUH)DFWRU0DLHU
*LEERQV
5HWDUGDWLRQ
6OHHS


$Q[LHW\6RPDWL]DWLRQVXPRILWHPV
&RUH)DFWRUVXPRILWHPV0DLHUVXPRILWHPV
*LEERQVVXPRILWHPV
5HWDUGDWLRQVXPRILWHPV
6OHHSVXPRILWHPV
5HPLWWHUFDWHJRULFDORXWFRPH
+$0'DQG,WHPYHUVLRQV
0$'56&'565
&*,6
)RU+$0'(QGRIDFXWHWUHDWPHQWVFRUH
)RU+$0'(QGRIDFXWHWUHDWPHQWVFRUH)RU0$'56(QGRIDFXWHWUHDWPHQWVFRUH
)RU&'565(QGRIDFXWHW UHDWPHQWWRWDOVFRUH
)RU&*,6(QGRIDFXWHWUHDWPHQWVFRUHRU
7KHLQWHJULW\RIWKHPDVNLQJRIWKHHIILFDF\WUHDWPHQWFRQGLWLR QVZLOOEHHYDOXDWHGE\H[SORUDWRU\
DQDO\VHVRIWKHHIILFDF\PHDVXUHVZLWKVXEMHFWVJURXSHGE\SURP LQHQWVHOIUHSRUWHGVSRQWDQHRXVDGYHUVH
HYHQWV,QDGGLWLRQVXEMHFWVDQG3DUHQWVZLOOFRPSOHWHD3UH 3RVW7UHDWPHQW([SHFWDWLRQVDQG
([SHULHQFH4XHVWLRQQDLUH35(7((4$35(7((43DQG32677((4$ 32677((43WKDW
TXHULHVWKHLULQLWLDOH[SHFWDWLRQVRIWULDORXWFRPHDQGILQDOL PSUHVVLRQRIWKHWULDO
1HXURFRJQLWLYHVDIHW\RXWFRPHPHDVXUHVZLOOEHFRPSDUHGIURPHQ GRIHDFKSKDVHWR3KDVH,EDVHOLQH
DQGSUHYLRXVSKDVHFRPSOHWLRQDVVHVVPHQWV
6DIHW\DQG$GYHUVH(YHQWV
$GYHUVH(YHQW'HILQLWLRQV
$QDGYHUVHHYHQW LVDQ\XQWRZDUGXQGHVLUHGRUXQSODQQHGHYHQWLQWKHIRUPRI VLJQVV\PSWRPVGLVHDVH
RUODERUDWRU\RUSK\VLRORJLFDOR EVHUYDWLRQVRFFXUULQJLQDSHUV RQZKRKDVUHFHLYHGWUHDWPHQWZLWKD
1HXURQHWLFVGHYLFHRULQD1HXURQHWLFVFOLQLFDOVWXG\7KHHYHQ WQHHGQRWEHFDXVDOO\UHODWHGWRWKH
1HXURQHWLFVGHYLFHRU1HXURQHWLFVFOLQLFDOWULDO$Q$(LQFOXGH VEXWLVQRWOLPLWHG WR
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 44 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL   
â€¢ Any clinically significant worsening of a pre-existing condition; 
â€¢ An AE occurring from overdose (i.e., a dose higher than that described in the protocol) of a 
Neuronetics device, whether accidental or intentional; 
â€¢ An AE occurring from abuse (e.g., use for non- clinical reasons) of a Neuronetics device;  
â€¢ An AE that has been associated with the discontinuation of the use of a Neuronetics device;  a 
preexisting condition  is a clinical condition (including a condition being treated) that is diagnosed 
before an informed consent form is signed  and is documented as part of the subjectâ€™s medical history.  
 The questions concerning whether the condi tion existed before the start of the active phase of the study 
and whether it has increased in severity and/or frequency will be used to determine whether an event is a 
treatment -emergent AE (TEAE). An AE is considered to be treatment emergent if (1) it was not present 
when the active phase of the study began and is not a chronic condition that is part of the subjectâ€™s 
medical history, or (2) it was present at the start of the active phase of the study or as part of the subjectâ€™s 
medical history, but the se verity or frequency increased during the active phase. 
 
The treatment phase of the study begins at the time of the first administration of a TMS treatment (active 
or sham).   A serious adverse event  (SAE) is defined by Neuronetics as an AE that: 
 
â€¢ Results in  death: 
â€¢ Is life threatening (see below) 
â€¢ Requires inpatient hospitalization or prolongation of an existing hospitalization  
â€¢ Results in a substantial disruption of a person's ability to conduct normal life functions, i.e., the 
adverse event resulted in a significant, persistent or permanent change, impairment, damage or 
disruption in the patient's  body function/ structure, physical activities and/or quality of life  
â€¢ Necessitates medical or surgical intervention to preclude such impairment  
â€¢ Results in a congenital anomaly or birth defect 
 
Additionally, important medical events  that may not result in death, be life-threatening, or require 
hospitalization, may be considered SAEs, based upon appropriate medical judgment.  Life threatening refers to  immediate risk  of death as the event occurred or use or continued use of the 
device or other medical product might have resulted in the death per the reporter. A life- threatening event 
does not include an event that, had it occurred in a more severe form, might have cau sed death, but as it 
actually occurred, did not create an immediate risk of death.  
 Hospitalization  is to be considered only as an admission. Hospitalization or prolongation of a 
hospitalization constitutes an AE to be classified as serious.  
 
Note that hospitalization s planned before the start of the study, for a preexisting condition that has not 
worsened , do not constitute an SAE (e.g., elective hospitalization for a total knee replacement due to a 
preexisting condition of osteoarthritis of the knee that has not worsened during the study). 
 An adverse event of special interest is a device- specific adverse event designated by Neuronetics for 
transmission in the same time frame as an SAE, even if it does not meet serious reporting criteria.  For this protocol, seizure should be reported as an adverse event of special interest. 
 
If there is any doubt whether the information constitutes an SAE, the information should be treated as an SAE for the purpose of this study. 
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/
7LPLQJIRU5HSRUWLQJRI6HU LRXV$GYHUVH(YHQWV
$Q\6$(UHJDUGOHVVRIFDXVDOUHODWLRQVKLSPXVWEHUHSRUWHGLP PHGLDWHO\WRWKH1HXURQHWLFVPHGLFDO
PRQLWRUZLWKLQRQHEXVLQHVVGD\E\ID[LQJDFRPSOHWHGVHULRXV DGYHUVHHYHQWIRUPWRWKHID[WHOHSKRQH
QXPEHUOLVWHGLQ6HFWLRQRIWKLVSURWRFRODQGWKHQFRQILUPL QJE\WHOHSKRQHWKDWWKHID[ZDVUHFHLYHG
&RPSOLDQFHZLWKWKLVWLPHUHTXLUHPHQWLVHVVHQWLDOVRWKDWWKH 6SRQVRUPD\FRPSO\ZLWKLWVUHJXODWRU\
REOLJDWLRQV
)ROORZXSLQIRUPDWLRQUHODWLQJWRDQ6$(PXVWEHUHSRUWHGWRWK H1HXURQHWLFVPHGLFDOPRQLWRUZLWKLQ
RQHEXVLQHVVGD\DIWHUWKHLQIRUPDWLRQLVUHFHLYHGE\WKH,QYHV WLJDWRUE\ID[LQJDFRPSOHWHGVHULRXV
DGYHUVHHYHQWIRUPWRWKHID[WHOHSKRQHQXPEHUOLVWHGLQ6HFWLR QRIWKLVSURWRFRODQGFRQILUPLQJE\
WHOHSKRQHWKDWWKHID[ZDVUHFHLYHG7KHVXEMHFWVKRXOGEHREVH UYHGDQGPRQLWRUHGFDUHIXOO\XQWLOWKH
FRQGLWLRQUHVROYHVRUVWDELOL]HVRULWVFDXVHLVLGHQWLILHG
$Q\HPHUJHQF\PXVWEHUHSRUWHGWR1HXURQHWLFVLPPHGLDWHO\ZLWK LQRQHEXVLQHVVGD\E\FRQWDFWLQJWKH
PHGLFDOPRQLWRUOLVWHGLQWKHIURQWRIWKLVSURWRFRO6HFWLRQ 

)RUDOORWKHULQTXLULHVDQGLQIRUPDWLRQDERXWWKLVVWXG\FRQWD FWWKH1HXURQHWLFVUHSUHVHQWDWLYHLGHQWLILHG
LQ6HFWLRQRIWKLVSURWRFRO
5HSRUWDEOH(YHQWV
$Q$(RU6$(FDQRFFXUIURPWKH WLPHWKDWWKHVXEMHFWVLJQVWKH LQIRUPHGFRQVHQWIRUPWRGD\VIURP
WKHVXEMHFWÂ¶VODVWVWXG\YLVLWUHJDUGOHVVRIUHODWLRQVKLSWRWK HSURWRFRORU706GHYLFH7KLVLQFOXGHVHYHQWV
WKDWHPHUJHGXULQJWKHSUHVWXG\VFUHHQLQJSKDVH$OO$(VDQG6 $(VZLOOEHUHFRUGHGRQVRXUFH
GRFXPHQWVDQGUHFRUGHGRQWKHVXE MHFWÂ¶V&5)V$OO$(VDQG6$(V WKDWRFFXUDIWHUWKHSUHVWXG\VFUHHQLQJ
SHULRGZLOOEHUHFRUGHGRQWKHVXEMHFWÂ¶V&5)VZKLFKZLOOEHSU RYLGHGWRWKH6SRQVRU7KH1HXURQHWLFV
PHGLFDOPRQLWRUZLOOLQVWUXFWWKH,QYHVWLJDWRUWRIROORZDOO$( V6$(VDQGRWKHUUHSRUWDEOHHYHQWVXQWLO
WKHHYHQWKDVVXEVLGHGRUYDOXHVKDYHUHWXUQHGWREDVHOLQHRU LQFDVHRISHUPDQHQWLPSDLUPHQWXQWLOWKH
FRQGLWLRQVWDELOL]HV
7KH,QYHVWLJDWRUZLOOSURYLGHDOOUHOHYDQWGRFXPHQWDWLRQSHUWDL QLQJWRDQ6$(HJDGGLWLRQDOODERUDWRU\
WHVWVFRQVXOWDWLRQUHSRUWVGLVFKDUJHVXPPDULHVSRVWPRUWHPUH SRUWVHWFWR1HXURQHWLFVLQDWLPHO\
PDQQHU5HSRUWVUHODWLYHWRWKHVXEMHFWÂ¶VVXEVHTXHQWFRXUVHPX VWEHVXEPLWWHGWRWKH1HXURQHWLFVXQWLO
WKHHYHQWKDVVXEVLGHGRULQF DVHRISHUPDQHQWLPSDLUPHQWXQW LOWKHFRQGLWLRQVWDELOL]HV
2WKHULQIRUPDWLRQUHSRUWDEOHW R1HXURQHWLFVZKLOHQRWPHHWLQJ WKHGHILQLWLRQRIDQ$(LVUHSRUWDEOHWR
1HXURQHWLFVZLWKWKHWLPHOLQHVVRIDQ6$(7KLVLQFOXGHV
x6HL]XUH
x3UHJQDQF\RFFXUULQJGXULQJWKHVWXG\SHULRGLQZKLFKWKHVXEMHF WZDVH[SRVHGWRWKH706GHYLFH
x2YHUGRVHHJDGRVHKLJKHUWKDQWKDWSUHVFULEHGE\DKHDOWKF DUHSURIHVVLRQDOIRUFOLQLFDOUHDVRQV
ZLWKRUZLWKRXW$(V
x$EXVHHJXVHIRUQRQFOLQLFDOUHDVRQVZLWKRUZLWKRXWDQ$ (
x,QDGYHUWHQWRUDFFLGHQWDOH[SRVXUHZLWKRUZLWKRXWDQ$(
x'HYLFHPDOIXQFWLRQWKDWZRXOGOLN HO\UHVXOWLQGHDWKVHULRXVL QMXU\RURWKHUVLJQLILFDQWDGYHUVHHYHQW
5HSRUWLQJ3URFHGXUHV
$WHDFKUHTXLUHGVWXG\YLVLWDOO$(VWKDWKDYHRFFXUUHGVLQFH WKHSUHYLRXVYLVLWZLOOEHUHFRUGHGLQWKH
DGYHUVHHYHQWUHFRUGRIWKHVXEMHFWÂ¶V&5)7KHLQIRUPDWLRQUHFR UGHGVKRXOGEHEDVHGRQWKHVLJQVRU
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/V\PSWRPVGHWHFWHGGXULQJWKHSK\VLFDOH[DPLQDWLRQDQGFOLQLFDO HYDOXDWLRQRIWKHVXEMHFW,QDGGLWLRQWR
WKHLQIRUPDWLRQREWDLQHGIURPWKRVHVRXUFHVWKHVXEMHFWVKRXOG EHDVNHGWKHIROORZLQJQRQVSHFLILF
TXHVWLRQ+RZKDYH\RXEHHQIHHOLQJVLQFH\RXUODVWYLVLW"6 LJQVDQGV\PSWRPVVKRXOGEHUHFRUGHG
XVLQJVWDQGDUGPHGLFDOWHUPLQRORJ\
7KHIROORZLQJ$(LQIRUPDWLRQPXV WEHLQFOXGHGZKHQDSSOLFDEOH WKHVSHFLILFFRQGLWLRQRUHYHQWDQG
GLUHFWLRQRIFKDQJHZKHWKHUWKHFRQGLWLRQZDVSUHH[LVWLQJLH DQDFXWHFRQGLWLRQSUHVHQWDWWKHVWDUWRI
WKHVWXG\RUKLVWRU\RIDFKURQLFFRQGLWLRQDQGLIVRZKHWKH ULWKDVZRUVHQHGHJLQVHYHULW\DQGRU
IUHTXHQF\WKHGDWHVDQGWLPHVRIRFFXUUHQFHVHYHULW\FDXVDO UHODWLRQVKLSWRWKHLQYHVWLJDWLRQDOGHYLFH
DFWLRQWDNHQDQGRXWFRPH
&DXVDOUHODWLRQVKLSRSWLRQVDQGGHILQLWLRQVDUHDVIROORZV
x'HILQLWHO\UHODWHG (YHQWFDQEHIXOO\DWWULEXWDEOHWRDGPLQLVWUDWLRQRIWKHLQYH VWLJDWLRQDOGHYLFH
x3UREDEO\UHODWHG (YHQWLVPRVWOLNHO\WREHH[SODLQHGE\DGPLQLVWUDWLRQRIWKH LQYHVWLJDWLRQDOGHYLFH
UDWKHUWKDQWKHVXEMHFWÂ¶VFOLQLFDOVWDWHRURWKHUDJHQWVWKHUDS LHV
x3RVVLEO\UHODWHG (YHQWLVDVOLNHO\H[SODLQHGE\DGPLQLVWUDWLRQRIWKHLQYHVWL JDWLRQDOGHYLFHDVE\WKH
VXEMHFWÂ¶VFOLQLFDOVWDWHRURWKHUDJHQWVWKHUDSLHV
x3UREDEO\QRWUHODWHG (YHQWLVPRVWOLNHO\WREHH[SODLQHGE\WKHVXEMHFWÂ¶VFOLQLFD OVWDWHRURWKHU
DJHQWVWKHUDSLHVUDWKHUWKDQWKHLQYHVWLJDWLRQDOGHYLFH
x'HILQLWHO\QRWUHODWHG (YHQWFDQEHIXOO\H[SODLQHGE\WKHVXEMHFWÂ¶VFOLQLFDOVWDWH RURWKHU
DJHQWVWKHUDSLHVUDWKHUWKDQWKHLQYHVWLJDWLRQDOGHYLFH
:KHQDVVHVVLQJWKHUHODWLRQVKLSEHWZHHQDQLQYHVWLJDWLRQDOSURG XFWSURWRFRODQGDQ$(WKHIROORZLQJ
SDUDPHWHUVDUHFRQVLGHUHG
x7HPSRUDOUHODWLRQVKLSEHWZHHQWKHLQYHVWLJDWLRQDOGHYLFHSURWRF RODQGWKH$(
x%LRORJLFSODXVLELOLW\RIUHODWLRQVKLS
x6XEMHFWVÂ¶XQGHUO\LQJFOLQLFDOVWDWHRUFRQFRPLWDQWDJHQWVWKHUD SLHV
x:KHUHDSSOLFDEOHZKHWKHUWKH$(DEDWHVRQGLVFRQWLQXDWLRQRIW KHLQYHVWLJDWLRQDOGHYLFH
GHFKDOOHQJH
x:KHUHDSSOLFDEOHZKHWKHUWKH$(UHDSSHDUVRQUHSHDWH[SRVXUHW RWKHLQYHVWLJDWLRQDOGHYLFH
UHFKDOOHQJH
6$(VWKDWDUHQRWLQYHVWLJDWLRQD OGHYLFHUHODWHGPD\QHYHUWKHOH VVEHFRQVLGHUHGE\WKHSDUWLFLSDWLQJ
,QYHVWLJDWRURUWKHPHGLFDOPRQLWRURUGHVLJQHHWREHUHODWHG WRWKHFRQGXFWRIWKHFOLQLFDOVWXG\LHWR
DVXEMHFW
VSDUWLFLSDWLRQLQWKHVWXG\
$GYHUVH(YHQW5HSRUWLQJ3HULRG
)RUWKLVVWXG\WKHWUHDWPHQWIROORZXSSHULRGIRUDGYHUVHHYHQ WVLVGHILQHGDVGD\VIROORZLQJWKHODVW
VWXG\YLVLW)ROORZXSZLOOEHGRFXPHQWHGLQWKHVXEMHFWVVWXG \ILOH
8QEOLQGLQJ3URFHGXUHV%UHDNLQJWKH%OLQG
:KLOHWKHVDIHW\RIWKHVXEMHFWDOZD\VFRPHVILUVWLWLVVWLOO LPSRUWDQWWRVHULRXVO\FRQVLGHULIXQEOLQGLQJ
WKHVWXG\WKHUDS\LVQHFHVVDU\WRHQVXUHDVXEMHFWÂ¶VVDIHW\, QWKHHYHQWRIDVHULRXVDGYHUVHGHYLFHHIIHFW
WKH,QYHVWLJDWRUZLOOFDUHIXOO\DVVHVVZKHWKHUEUHDNLQJWKHEOL QGZLOOFULWLFDOO\DIIHFWKRZDVXEMHFWLV
WUHDWHGLQUHVSRQVHWRWKHDGYHUVHHIIHFWDQGZKHWKHUWKLVNQRZ OHGJHRXWZHLJKVWKHLPSOLFDWLRQVWRWKH
VFLHQWLILFVRXQGQHVVRIWKHVWXG\,QWKHFDVHRIPRVWVHULRXV DGYHUVHHIIHFWVWUHDWPHQWZRXOGEH
GLVFRQWLQXHGDQGV\PSWRPVWUHDWHGV\PSWRPDWLFDOO\LUUHVSHFWLYH RIWKHNQRZOHGJHRIZKHWKHUWKH
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/WUHDWPHQWUHFHLYHGZDVDFWLYHRUVKDPLQQDWXUH,QWKHVHLQVW DQFHVKDYLQJWKLVLQIRUPDWLRQZRXOGQRW
VLJQLILFDQWO\DOWHUWKHWUHDWPHQWRIWKHDGYHUVHHIIHFWV

$VDQDGGLWLRQDOVDIHJXDUGDJDLQVWELDVWKH'60%KDVEHHQFKDU JHGZLWKPDNLQJWKHILQDO
UHFRPPHQGDWLRQVIRUEUHDNLQJW KHVWXG\EOLQG,IWKH'60%UHFR PPHQGVXQPDVNLQJWKHVWXG\
1HXURQHWLFV,QFZLOOEHFRQWDFWHGDQGWKHNH\WRDFWLYHRUVK DPWUHDWPHQWZLOOEHREWDLQHG1RWDWLRQ
UHJDUGLQJWKHQDWXUHRIWKHWUHDWPHQWWKHVXEMHFWKDGEHHQUHFH LYLQJZLOOEHGRFXPHQWHGLQWKHVXEMHFWÂ¶V
VRXUFHGRFXPHQW

,IWKHGHFLVLRQWREUHDNWKHEOLQGLVPDGHLPPHGLDWHO\XSRQOHD UQLQJRIWKHDGYHUVHHYHQWWKLVLQIRUPDWLRQ
ZLOOEHUHSRUWHGWRWKH)'$DQGUHYLHZLQJ,5%DWWKHWLPHRILQ LWLDODGYHUVHHYHQWUHSRUWLQJ,IWKH
XQEOLQGLQJRFFXUVDIWHUWKHLQLWLDOUHSRUWLQJWKH)'$ZLOOEH QRWLILHGRIWKHDFWLR QZLWKLQWHQZRUNLQJ
GD\VIURPWKHWLPHRIEUHDNLQJWKHEOLQG7KHUHYLHZLQJ,5%ZL OOEHQRWLILHGDFFRUGLQJWRWKHLUUHSRUWLQJ
JXLGHOLQHVLIWKHGHFLVLRQLVPDGHWREUHDNWKHVWXG\EOLQGDIW HUWKHLQLWLDOUHSRUWLQJ

,IXQEOLQGLQJRFFXUVDWRQHVLWHWKHRWKHUVLWHV:,//127EHJ LYHQWKHUDQGRPL]DWLRQNH\XQOHVV
GLUHFWHGWRGRVRE\WKH)'$1HXU RQHWLFV,QFUHYLHZLQJ,5% RUWKH'60%
6WRSSLQJ5XOHV
6SHFLILFRFFDVLRQVZKHQVWXG\WUH DWPHQWPD\EHVWRSSHGDUHH[SO DLQHG6HFWLRQLQWKHGLVFXVVLRQRI
$QWLFLSDWHG5LVNV

%HFDXVHRIWKHDQWLFLSDWHGORZOHYHORIDGYHUVHHYHQWVRI706 WKH'60%ZLOOEHFKD UJHGZLWKUHYLHZLQJ
DGYHUVHHYHQWVDWOHDVWHYHU\VL[PRQWKV6HULRXVDGYHUVHHYHQW VZLOOEHUHYLHZHGRQDPRQWKO\EDVLV
XQOHVVDPRUHXUJHQWUHYLHZLVUHTXHVWHG2QO\XQGHUH[WUHPHF LUFXPVWDQFHVRULILWZHUHGHWHUPLQHGWKDW
DKLJKOHYHORIVLGHHIIHFWVZDVGXHWR706ZRXOGWKH'60%EH FKDUJHGZLWKEUHDNLQJWKHVWXG\PDVN
0HGLFDO0RQLWRULQJ
7KHUHJXODWRU\VSRQVRUKDVRYHUVLJKWIRUWKHRYHUDOOVDIHW\RI WKHVWXG\7KLVVDIHW\PRQLWRULQJZLOO
LQFOXGHFDUHIXODVVHVVPHQWDQGDSSURSULDWHUHSRUWLQJRIDGYHUVH HYHQWVDVQRWHGDERYHDVZHOODVWKH
FRQVWUXFWLRQDQGLPSOHPHQWDWL RQRIDGDWDDQGVDIHW\PRQLWRULQJ SODQ0HGLFDOPRQLWRULQJZLOOLQFOXGHD
UHJXODUDVVHVVPHQWRIWKHQXPEHUDQGW\SHRIVHULRXVDGYHUVHHY HQWV
'DWDDQG6DIHW\0RQLWRULQJ%RDUG
$'DWDDQG6DIHW\0RQLWRULQJ%RD UGZLOOEHDVVHPEOHGWRRYHUVHH WKHVDIHW\RIWKHVWXG\VXEMHFWVDQG
WKHVFLHQWLILFYDOLGLW\DQGLQWHJULW\RIGDWDFROOHFWHGDVSDUW RIWKHVWXG\7KLV'60%ZLOOLQFOXGH
PHPEHUVIURPDFDGHPLFVLWHVLQGHSHQGHQWRIWKHVWXG\VLWHVDQG ZLOOFRQVLVWRIDWOHDVWRQHQRQVWXG\
ERDUGFHUWLILHGSV\FKLDWULVWDQGRQHELRVWDWLVWLFLDQ

7KHUHVSRQVLELOLWLHVDQGGHFLVLRQSRLQWVIRUWKH'60%ZLOOEHF DSWXUHGLQWKH'60%FKDUWHU
'DWD+DQGOLQJDQG5HFRUG.HHSLQJ
&RQILGHQWLDOLW\
,QIRUPDWLRQDERXWVWXG\VXEMHFWVZLOOEHNHSWFRQILGHQWLDODQG PDQDJHGDFFRUGLQJWRWKHUHTXLUHPHQWVRI
WKH+HDOWK,QVXUDQFH3RUWDELOLW\DQG$FFRXQWDELOLW\$FWRI +,3$$7KRVHUHJXODWLRQVUHTXLUHD
VLJQHGVXEMHFWDXWKRUL]DWLRQLQIRUPLQJWKHVXEMHFWRIWKHIROOR ZLQJ

3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/x:KDWSURWHFWHGKHDOWKLQIRUPDWLRQ3+,ZLOOEHFROOHFWHGIURP VXEMHFWVLQWKLVVWXG\
x:KRZLOOKDYHDFFHVVWRWKDWLQIRUPDWLRQDQGZK\
x:KRZLOOXVHRUGLVFORVHWKDWLQIRUPDWLRQ
x7KHULJKWVRIDUHVHDUFKVXEMHFWWRUHYRNHWKHLUDXWKRUL]DWLRQ IRUXVHRIWKHLU3+,
,QWKHHYHQWWKDWDVXEMHFWUHYRNHVDXWKRUL]DWLRQWRFROOHFWRU XVH3+,WKHLQYHVWLJD WRUE\UHJXODWLRQ
UHWDLQVWKHDELOLW\WRXVHDOOLQIRUPDWLRQFROOHFWHGSULRUWRW KHUHYRFDWLRQRIVXEMHFWDXWKRUL]DWLRQ)RU
VXEMHFWVZKRKDYHUHYRNHGDXWKRUL]DWLRQWRFROOHFWRUXVH3+, DWWHPSWVVKRXOGEHPDGHWRREWDLQ
SHUPLVVLRQWRFROOHFWDWOHDVWYLWDOVWDWXVORQJWHUPVXUYLYDO VWDWXVWKDWWKHVXEMHFWLVDOLYHDWWKHHQGRI
WKHLUVFKHGXOHGVWXG\SHULRG
6RXUFH'RFXPHQWV
6RXUFHGDWDFRPSULVHDOOLQIRUPDWLRQRULJLQDOUHFRUGVRIFOLQL FDOILQGLQJVREVHUYDWLRQVRURWKHUDFWLYLWLHV
LQDFOLQLFDOWULDOQHFHVVDU\IRUWKHUHFRQVWUXFWLRQDQGHYDOXD WLRQRIWKHWULDO6RXUFHGDWDDUHFRQWDLQHGLQ
VRXUFHGRFXPHQWV([DPSOHVRIWKH VHRULJLQDOGRFXPHQWVDQGGDW DUHFRUGVLQFOXGHKRVSLWDOUHFRUGV
FOLQLFDODQGRIILFHFKDUWVOD ERUDWRU\QRWHVPHPRUDQGDVXEMHF WVÂ¶GLDULHVRUHYDOXDWLRQFKHFNOLVWV
SKDUPDF\GLVSHQVLQJUHFRUGVUHFRU GHGGDWDIURPDXWRPDWHGLQVWU XPHQWVFRSLHVRUWUDQVFULSWLRQVFHUWLILHG
DIWHUYHULILFDWLRQDVEHLQJDFFXUDWHDQGFRPSOHWHPLFURILFKHV SKRWRJUDSKLFQHJDWLYHVPLFURILOPRU
PDJQHWLFPHGLD[UD\VVXEMHFWILOHVDQGUHFRUGVNHSWDWWKH SKDUPDF\DWWKHODERUDWRULHVDQGDWPHGLFR
WHFKQLFDOGHSDUWPHQWVLQYROYHGLQWKHFOLQLFDOWULDO:KHQDSSO LFDEOHLQIRUPDWLRQUHFRUGHGRQWKH&5)
VKDOOPDWFKWKHVRXUFHGDWDUHFRUGHGRQWKHVRXUFHGRFXPHQWV
&DVH5HSRUW)RUPV
7KH6SRQVRUZLOOSURYLGHFDVHUHS RUWIRUPV&5)VIRUHDFKVXEM HFWHQUROOHGLQWRWKHVWXG\WRHQVXUH
FRQVLVWHQWGDWDFROOHFWLRQ

'DWDZLOOEHFDSWXUHGDWHDFKSDUWLFLSDWLQJVLWHE\TXDOLILHGV WXG\VWDIIZKRZLOOSHUIRUPSULPDU\GDWD
FROOHFWLRQIURPVRXUFHGRFXPHQWUHYLHZVWRFDVHUHSRUWIRUPV& 5)'DWDZLOOEHFROOHFWHGIRUWKLVVWXG\
XWLOL]LQJRQHRUDFRPELQDWLRQRIWKHIROORZLQJ PHWKRGV
'DWDPD\EHWUDQVFULEHGIURPWKH(OHFWURQLF0HGLFDO5HFRUG(05 DQHOHFWURQLFVRXUFHWKDW 
PXVWEHDYDLODEOHIRUUHYLHZRQW RWKH&5)$FRS\RIWKH(05 ZLOOEHSULQWHGDQGSODFHGLQWKH
VXEMHFWVFDVHILOHDVVRXUFHGRFXPHQWDWLRQ
'DWDPD\EHFDSWXUHGGLUHFWO\RQWRWKH&5)DQGWUDQVFULEHGLQWR WKH('&V\VWHPE\1HXURQHWLFV
%87SDSHUGRFXPHQWDWLRQPXVWEHUHWDLQHGDQGDYDLODEOHIRUUHYL HZ
'DWDUHSRUWHGLQWKH&5)VKRXOGEHFRQVLVWHQWZLWKWKHVRXUFHG RFXPHQWVRUWKHGLVFUHSDQFLHVVKRXOGEH
H[SODLQHG

'DWD0DQDJHPHQW
1HXURQHWLFVDQGRU6WXG\6LWHVZLOOHQWHUGDWDIURPWKH&5)VLQ WRDQHOHFWURQLFGDWDFDSWXUH('&
V\VWHPWKDWLVFRPSOLDQWZLWK &)5&RGHRI)HGHUDO5HJXODWL RQV3DUW)'$)RRGDQG'UXJ
$GPLQLVWUDWLRQUHTXLUHPHQWV(GLWFKHFNVHOHFWURQLFTXHULHV DQGDXGLWWUDLOVDUHEXLOWLQWRWKHV\VWHPWR
HQVXUHDFFXUDWHDQGFRPSOHWHGDWDFROOHFWLRQDQGVHFXULW\'DW DZLOOEHWUDQVPLWWHGYLDWKHLQWHUQHWWRD
FHQWUDOKRVWLQJVLWHXWLOL]LQJVWDWHRIWKHDUWHQFU\SWLRQPHF KDQLVPVWRHQVXUHVHFXULW\DQG
FRQILGHQWLDOLW\

'HWDLOVRIWKHVWXG\WUHDWPHQWVLQFOXGLQJWUHDWPHQWSDUDPHWHUV VXFKDV07IRUHDFKVXEMHFWZLOOEH
UHWDLQHGZLWKLQWKH706GHYLFHE\WKH;3/25VRIWZDUH,QDGGLW LRQDSULQWHGUHSRUWRIWKHWUHDWPHQWV
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/ZLOOEHVWRUHGDVSDUWRIWKHVXEMHFWÂ¶VVRXUFHGRFXPHQWV'HWD LOVIURPWKHVWXG\WUHDWPHQWVZLOOEHHQWHUHG
LQWR('&

&DVHILOHVZLOOEHFUHDWHGIRUHDFKVXEMHFWZKHUHFRPSOHWHG&5) VZLOOEHVWRUHG

'DWD6HFXULW\DQG&RQILGHQWLDOLW\
'DWDEDVHDQG:HEVHUYHUVZLOOEHVHFXUHGWKURXJKFRQWUROOHGSK\ VLFDODFFHVV)RUVHFXULW\UHDVRQVDQGLQ
FRPSOLDQFHZLWKUHJXODWRU\JXLGHOLQHV('&V\VWHPDFFHVVLVJUD QWHGWRWKHXVHUZKRRZQVWKHVLJQRQ
LGHQWLILFDWLRQDQGSDVVZRUGLQXVH$FFHVVFRGHVDUHQRQWUDQV IHUUDEOH3HUVRQQHOZKRKDYHQRW
XQGHUJRQHWUDLQLQJPD\QRWDFFHVVWKHVWXG\H&5)Â¶VXQWLODSSURS ULDWHWUDLQLQJLVFRPSOHWHGDQG
GRFXPHQWHG7KHH&5)GDWDHOHPHQWVGRQRWUHVLGHRQWKHXVHUV ZRUNVWDWLRQWKH\DUHWUDQVPLWWHGWRD
VHFXUHFHQWUDOGDWDEDVHKRVWVLWHDVIRUPVDUHFRPSOHWHGRUX SGDWHG3URWRFROVSHFLILHGVRXUFH
GRFXPHQWVHJKRVSLWDOGLVFKDUJHVXPPDULHVRSHUDWLYHSURFHGX UDOUHSRUWVZLOOEHUHWULHYHGDV
QHFHVVDU\&RSLHVRIDOOVWXG\UHODWHGGRFXPHQWDWLRQZLOOEHU HWDLQHGDWWKHVLWH

&DVHILOHVZLOOEHORFDWHGLQDVHFXUHGDUHDDWHDFKVWXG\VLWH $OOFRPSOHWHG&5)VZLOOEHGHLGHQWLILHG
DQGVXEMHFWVZLOOEHUHIHUUHGWRXVLQJRQO\WKHLUDVVLJQHGVWXG \VXEMHFWLGHQWLILHUDQGLQLWLDOV,QIRUPDWLRQ
VWRUHGLQWKHVRXUFHGRFXPHQWVZLOOEHVDIHJXDUGHGDFFRUGLQJW RLQVWLWXWLRQDOJXLGHOLQHV

'DWD4XDOLW\$VVXUDQFH'DWD&ODULILFDWLRQ3URFHVV
7KH('&GDWDEDVHZLOOKDYHFRQVLVWHQF\FKHFNVSURJUDPPHGLQWRW KHV\VWHPWRDVVLVWWKH6SRQVRUZLWK
LQIRUPLQJLQYHVWLJDWRUVRISRWHQWLDOGDWDLVVXHVDVWKHGDWDHQ WU\SURJUHVVHV7KHH[FHSWLRQORJIRUHQWULHV
ZLOOEHUHYLHZHGE\WKH6SRQVRUWRLGHQWLI\SRWHQWLDOWUDLQLQJ DQGRUGDWDLQWHJULW\LVVXHV1HXURQHWLFV
RUGHVLJQHHZLOOSHUIRUPVLWHPRQLWRULQJLQFOXGLQJUHYLHZRI WKH&5)VZLWKYHULILFDWLRQWRWKHVRXUFH
GRFXPHQWDWLRQWRYHULI\DFFXUDF\RI&5)GDWD'XULQJPRQLWRULQJ YLVLWVWKHVLWHZLOOPDNHWKHLU
FRPSXWHUDQGRUKLJKVSHHGLQWHUQHWDFFHVVDYDLODEOHWRWKHVWX G\PRQLWRUVRWKDWKHRUVKHPD\YHULI\WKH
GDWDHQWULHVZLWKWKHVRXUFHGRFXPHQWDWLRQDVQHHGHG,IGDWDL QWHJULW\LVVXHVDUHVXVSHFWHGWKH\ZLOOEH
UHSRUWHGWRWKH6SRQVRULPPHGLDWHO\

5HTXHVWIRUGDWDFODULILFDWLRQRUFRUUHFWLRQZLOOEHIRUZDUGHG WRWKHVWXG\VLWHIRUUHVROXWLRQ
5HFRUGV5HWHQWLRQ
7KHVLWH3,VZLOOPDLQWDLQUHFRUGVDQGHVVHQWLDOGRFXPHQWVUHOD WHGWRWKHFRQGXFWRIWKHVWXG\7KHVHZLOO
LQFOXGHVXEMHFWFDVHKLVWRULHVDQGUHJXODWRU\GRFXPHQWV5HFRU GVZLOOEHUHWDLQHGSHUORFDOUHJXODWLRQV
DQGORFDOVLWHSROLF\DQGDOVRLQDFFRUGDQFHZLWKSDUW&)5 FZKLFKVWDWHVÂ³IRUDSHULRGRI
\HDUVIROORZLQJWKHGDWHDPDUNHWLQJDSSOLFDWLRQLVDSSURYHGIR UWKHGUXJGHYLFHIRUWKHLQGLFDWLRQIRU
ZKLFKLWLVEHLQJLQYHVWLJDWHGRULIQRDSSOLFDWLRQLVWREH ILOHGRULIWKHDSSOLFDWLRQLVQRWDSSURYHGIRU
VXFKLQGLFDWLRQXQWLO\HDUVDIWHUWKHLQYHVWLJDWLRQLVGLVFR QWLQXHGDQGWKH)'$LVQRWLILHGÂ´
)XUWKHUPRUH1HXURQHWLFVZLOOEHQRWLILHGLQZULWLQJRIWKHUHO RFDWLRQRIDQ\VWXG\UHODWHGUHFRUGV
6WXG\0RQLWRULQJ$XGLWLQJDQG,QVSHFWLQJ
6WXG\0RQLWRULQJ3ODQ
7KLVVWXG\ZLOOEHPRQLWRUHGE\1HXURQHWLFVRUGHVLJQHHDFFRUGL QJWRWKHPRQLWRULQJSODQLQFOXGHGLQWKH
VWXG\UHIHUHQFHPDQXDO
3URWRFRO  1HXUR6WDUÂŠ706$GROHVFHQW0''5&7
3DJHRI  
 5HYLVLRQ&$XJ 
&21),'(17,$/
$XGLWLQJDQG,QVSHFWLQJ
7KHVLWHLQYHVWLJDWRUZLOOSHUPLWVWXG\UHODWHGPRQLWRULQJDXG LWVDQGLQVSHFWLRQVE\WKH,5%WKH
6SRQVRUDQGJRYHUQPHQWUHJXODWRU\DJHQFLHVRIDOOVWXG\UHODW HGGRFXPHQWVHJVRXUFHGRFXPHQWV
UHJXODWRU\GRFXPHQWVGDWDFROOHFWLRQLQVWUXPHQWVVWXG\GDWD HWF7KHVLWHLQYHVWLJDWRUVZLOOHQVXUHWKH
FDSDELOLW\IRULQVSHFWLRQVRIDSSOLFDEOHVWXG\UHODWHGIDFLOLWL HVHJSKDUPDF\GLDJQRVWLFODERUDWRU\
HWF
3DUWLFLSDWLRQDVDQLQYHVWLJDWRULQWKLVVWXG\LPSOLHVDFFHSWDQ FHRISRWHQWLDOLQVSHFWLRQE\JRYHUQPHQW
UHJXODWRU\DXWKRULWLHVDQGDSSOLFDEOHFRPSOLDQFHRIILFHV
(WKLFDO&RQVLGHUDWLRQV
7KLVVWXG\LVWREHFRQGXFWHGD FFRUGLQJWR8QLWHG6WDWHVDQG&D QDGLDQJRYHUQPHQWUHJXODWLRQVDQG
,QVWLWXWLRQDOUHVHDUFKSROLFLHVDQGSURFHGXUHV

$OWKRXJKWKLVVWXG\LVFRQVLGHUHGPRUHWKDQPLQLPDOULVNWRDGR OHVFHQWV706WUHDWPHQWVRIIHUDSRWHQWLDO
GLUHFWEHQHILWIRUWKHLQGLYLGXDOVXEMHFW,QDGGLWLRQWKHVF KHGXOHRIPRRGDVVHVVPHQWVDQGGDLO\
DVVHVVPHQWGXULQJWKHLQWHUYHQWLRQDOSRUWLRQRIWKHVWXG\IRUD Q\DGYHUVHHYHQWVKDVEHHQGHYHORSHGIRU
WKHSXUSRVHRIPRQLWRULQJWKHVXEMHFW
VZHOOEHLQJ

7KLVSURWRFRODQGDQ\DPHQGPHQWVZLOOEHVXEPLWWHGWRDSURSHUO \FRQVWLWXWHGORFDO,5%LQDJUHHPHQW
ZLWKORFDOUHTXLUHPHQWVIRUIRUPDODSSURYDORIWKHVWXG\DWHD FKSDUWLFLSDWLQJVLWH7KHGHFLVLRQRIWKH
,5%FRQFHUQLQJWKHFRQGXFWRIW KHVWXG\ZLOOEHGRFXPHQWHGLQZ ULWLQJWRWKHUHJXODWRU\VSRQVRUEHIRUH
FRPPHQFHPHQWRIWKLVVWXG\

$OOIDPLOLHVDQGVXEMHFWVIRUWKLVVWXG\ZLOOEHSURYLGHGDFRQ VHQWDVVHQWIRUPGHVFULELQJWKLVVWXG\DQG
SURYLGLQJVXIILFLHQWLQIRUPDWLRQIRUVXEMHFWVWRPDNHDQLQIRUP HGGHFLVLRQDERXWWKHLUSDUWLFLSDWLRQLQWKLV
VWXG\7KLVFRQVHQWDVVHQWIRUPZLOOEHVXEPLWWHGZLWKWKHSUR WRFROIRUUHYLHZDQGDSSURYDOE\WKHVLWH
,5%IRUWKHVWXG\7KHIRUPDOFRQVHQWRIDVXEMHFWXVLQJWKH DSSURYHG,5%FRQVHQWDVVHQWIRUPPXVWEH
REWDLQHGEHIRUHWKDWVXEMHFWXQGHUJRHVDQ\VWXG\SURFHGXUH7K LVIRUPPXVWEHVLJQHGDQGGDWHGE\WKH
VXEMHFWWKHVXEMHFWÂ¶VOHJDOO\DXWKRUL]HGUHSUHVHQWDWLYHDQGW KHLQGLYLGXDOREWDLQLQJLQIRUPHG
FRQVHQWDVVHQW

Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 51 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  20 References  
 
American Academy of Child and Adolescent Psychiatry.  (2001) Practice parameter for the assessment 
and treatment of children and adolescents with  suicidal behavior. American Academy of Child and 
Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry.40(7 Suppl):24S-51S 
Bloch, Y., et al., (2008) Repetitive transcranial magnetic stimulation in the treatment of depression in 
adolescents: An open- label study. Journal of ECT. 24(2): 156-159 
Brent, D., et al., (2008) Switching to another SSRI or to venlafaxine with or without cognitive behavioral 
therapy for adolescents with SSRI -resistant depression: The TORDIA randomized controlled trial. JAMA 
- Journal of t he American Medical Association . 299(8): 901-913. 
Carpenter L.L. et al.(2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, 
naturalistic, observational study of acute  treatment outcomes in clinical practice. Depress An xiety. 
29(7):587-96.  
Cheung, A., et al., (2008 ) Pediatric prescribing practices and the FDA Black -box warning on 
antidepressants. Journal of developmental and behavioral pediatrics : JDBP. 29(3): p. 213-5. 
Craig, A.D.,(2010). The sentient self. Brain stru cture & function. 214(5-6): 563-77 
Croarkin, P.E., et al. (2010). The emerging role for repetitive transcranial magnetic stimulation in 
optimizing the treatment of adolescent depression. Journal of ECT. 26 (4): 323-329. 
Dunner D.L., et al (2014) A multisite , naturalistic, observational study of transcranial magnetic 
stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow -up period. J Clin Psychiatry. 75(12):1394-401.  
George, M.S., et al.(2010) Daily left prefrontal transcranial magnetic stimulation therapy for major 
depressive disorder: A sham-controlled randomized trial. Archives of General Psychiatry. 67 (5): 507-516. 
Gibbons, R.D., et al., (2007) Early evidence on the effects of regulators' suicidality warnings on SSRI 
prescriptions and suicide in children and adolescents. The American journal of psychiatry . 164(9): 1356-
63. 
Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: 
a comprehensive summary of safety experience from acute exposure, extended exposure, and during 
reintroduction treatment. J Clin Psychiatry.69(2):222-32. 
Janicak PG, et al. (2013). Transcranial magnetic stimulation (TMS) for major depression: a multisite, 
naturalistic , observational study of quality of life outcome measures in clinical practice. CNS Spectr. 
18(6):322-32.  
Libby, A.M., et al., (2007) Decline in treatment of pediatric depression after FDA advisory on risk of 
suicidality with SSRIs. The American journal o f psychiatry. 164(6): 884-91. 
Loo, C., T. McFarquhar, and G. Walter, (2006). Transcranial magnetic stimulation in adolescent 
depression. Australas Psychiatry. 14(1): 81-5. 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 52 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Maalouf, F.T. and D.A. Brent, (2010), Pharmacotherapy and psychotherapy of pediatric depression . 
Expert opinion on pharmacotherapy. 11(13): 2129-40. 
March, J.S., et al. (2007)  The Treatment for Adolescents with Depression Study (TADS): Long- term 
effectiveness and safety outcomes. Archives of General Psychiatry. 64(10): 1132-1144. 
March, J.S., (2004)Fluoxetine, cognitive- behavioral therapy, and their combination for adolescents with 
depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. 
Journal of the American Medical Association. 292 (7): 807-820. 
O'Reardon, J.P., et al., ( 2007) Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute 
Treatment of Major Depression: A Multisite Randomized Controll ed Trial. Biological psychiatry . 62(11): 
1208-1216. 
Rappaport, N., et al., (2006) Treating p ediatric depression in primary care: coping with the patients' blue 
mood and the FDA's black box. The Journal of pediatrics. 148 (5):567-8 
Rossi S, et al. (2009) Safety of TMS Consensus Group. Safety, ethical considerations, and application 
guidelines for t he use of transcranial magnetic stimulation in clinical practice and research. 
ClinNeurophysiol. 120(12):2008-39. 
Walkup, J.T., (2010) Treatment of depressed adolescents. American Journal of Psychiatry. 167 (7): p. 734-
737. Wall, C.A., et al.(2011) Adjuncti ve use of repetitive transcranial magnetic stimulation in depressed 
adolescents: A prospective, open pilot study. Journal of Clinical Psychiatry. 72(9):  1263-1269. 
Walter, G., et al., (2001) Transcranial magnetic stimulation in young persons: a review of known cases . 
Journal of child and adolescent psychopharmacology. 11(1): 69-75. 
Wassermann, E.M., et al (1998) . Risk and safety of repetitive transcranial magnetic stimulation: report 
and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial 
Magnetic Stimulation, June 5-7, 1996. Electroencephalography and clinical neurophysiology. 108(1):  1-
16. 
 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 53 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Appendix A. Phase I Schedule of Events  
Phase 1-Week  
Prestudy 6-Week  
Acute Treatment  3-Week  
Post-Treatment Taperm 
Week Wk â€“ 2 to -1a 
(Screening)  Wk 0a 
(Baseline)  Wk 1b Wk 2b Wk 3b Wk 4b Wk 5 b Wk 
6b,c/ET Wk 1  Wk 2  Wk 3  
Day(s) -7a 0a 1-5 8-12 15-19 22-26 29-35 36-42 43-49 50-56 57-63 
Informed Consent /Assent/HIPAA  X           
Psychiatric/ Medical History/TASS X           
Antidepressant Treatment  Record 
(ATR) X           
M.I.N.I. / M.I.N.I. KID X           
Pre/Post -TEEQ-Pd  X      X    
Pre/Post -TEEQ-A  X      X    
Efficacy Assessmentse            
HAMD 24/MADRSf X X    Xd  Xc,e   Xe 
CDRS-R X X    Xd  Xc,e   Xe 
CGI-S X X    Xd  Xc,e   Xe 
QIDS-A17-SR X X    Xd  Xc,e   Xe 
Neuropsychological Assessmentse            
NIH Toolbox Cognition Battery    X       Xc,e    
Safety Assessments             
Physical examination  X           
Vital Signs   X      Xc    
YMRSe  X          
C-SSRSe X X Xe Xe Xe Xe Xe Xc,e Xe Xe Xe 
Laboratory determinationsg X           
Urine drug screen  X           
Pregnancy testh X           
Structural MRIi X       X    
Audiometry assessment   X      Xc    
Adverse Eventsj X ---------------------------------------------------------------------------------------------------------------------------------------------------X 
Prior/Concomitant Treatmentk X ---------------------------------------------------------------------------------------------------------------------------------------------------X 
Motor Threshold Determinationl Xl           
TMS Treatment Sessionb 
(daily Ã— 5 weekdays/week)    X---Xb X---Xb X---Xb X---Xb X---Xb X---Xb    
Post-Treatment Taper TMS 
Session(s)m 
(3X/Wk1, 2X/Wk 2, 1X/Wk 3)          X X X 
a. A minimum of 7 days may elapse between the screening and baseline visits; a maximum of 5 days may elapse between the baseline visit and the first treatment day of Week 1.   
All baseline assessments must be completed and laboratory results received before 1st TMS treatment.  
b. The first visit during each week of treatment should occur on a Monday, with daily treatment sessions occurring on Monday through Friday of each week.  
c. Subjects who prematurely discontinue should complete all Week 6 procedures within 2 days after their last TMS treatment session.  
d. If subject <18 yrs of age or the legal age requirement of the state  
e. Efficacy ,  neuropsychological  and safety  assessments to be performed after last TMS treatment session on last day of the treatment week when assessments are required . Y-
MRS to be completed if symptom indicating mania occurs.  If positive, a M.I.N.I./M.I.N.I. KID must be repeated to determine if subject meets full DSM -5 criteria for mania or 
hypomania.  If positive, subject to be discontinued from the study and followed clinically . 
f. Subject must have been off of any antidepressants for at least one week.  
g. Laboratory  determinations to include standard hematology, and blood chemistry.  
h. If subject is female of childbearing potential, a urine pregnancy test will be performed in the office at screening . 
i. Performed on a subset of subjects at participating sites,  
j. Adverse events occurring prior to randomization will be recorded as part of each patientâ€™s medical history. Those AEs occurring following the first TMS treatment session 
through 30 days after last study visit  will be collected . 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 54 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  k. Medication treatment for emergent insomnia and emergent anxiety is permitted (refer to protocol for usage allowance).  Refer to Appendix D for the Concomitant Medication List.  
l. In addition to the indicated day, Motor Threshold Determination (MT) may be repeated at any time during the course of the active TMS treatment sessions based on clinical 
assessment of the supervising physician.   Justification for the additional MT must be documented and pre- approved by the Sponsor when possible.    
m. Taper occurs only if exiting the study or transitioning  directly to Phase III.   
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 55 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Appendix B. Phase II Schedule of Events 
Phase 6-Week  
Open Label Acute Treatment  3-Week  
Post-Treatment Taper  i  
Week Wk 1b Wk 2b Wk 3b Wk 4b Wk 5b Wk 6b,c/ET Wk 1  Wk 2  Wk 3  
Day(s) 1-5 8-12 15-19 22-26 29-35 36-42 43-49 50-56 57-63 
Informed Consent/Assent  X a         
Efficacy Assessmentsd          
HAMD 24/MADRS     Xd  Xc,d   X 
CDRS-R    Xd  Xc,d   X 
CGI-S    Xd  Xc,d   X 
QIDS-A17-SR    Xd  Xc,d   X 
Neuropsychological Assessmentsd          
NIH Toolbox Cognition Battery       Xc,d    
Safety Assessments           
Vital Signs       Xc    
C-SSRSd Xd Xd Xd Xd Xd Xc,d Xd Xd Xc,d 
YMRSd      Xc,d    
Structural MRIe      X    
Audiometry assessment       Xc    
Adverse Eventsf X ------------------------------------------------------------------------------------------------------------X 
Concomitant Treatmentg X ------------------------------------------------------------------------------------------------------------X 
Motor Threshold Determination  Xh         
TMS Treatment Sessiona 
(daily Ã— 5 weekdays/week)  X---Xb X---Xb X---Xb X---Xb X---Xb X---Xb    
Post-Treatment Taper TMS Session(s)i 
(3X/Wk1, 2X/Wk 2, 1X/Wk 3)        X X X 
a. An Informed Consent /Assent for this study must be signed prior to initiating any study -related procedures.  
b. The first visit during each week of treatment should occur on a Monday, with daily treatment sessions occurring on Monday through Friday of each week.  
c. Subjects who prematurely  discontinue should complete all Week 6 procedures within 2 days after their last TMS treatment session.  
d. Efficacy , neuropsychological and safety assessments to be performed after last TMS treatment session on last day of the treatment week when assessments are 
required.   YMRS to be completed if symptom indicating mania occurs.  If positive, a M.I.N.I./M.I.N.I.-KID must be repeated to determine if subject meets full DSM -5 
criteria for mania or hypomania.  If positive, subject to be discontinued from the stud y and followed clinically . 
e. Performed on a subset of subjects at participating sites  
f. Adverse events occurring prior to randomization will be recorded as part of each subjectâ€™s medical history. Those AEs occurring following the first TMS treatment 
session through 30 days after last study visit  will be collected.  
g. Medication treatment for emergent insomnia and emergent anxiety is permitted (refer to protocol for usage allowance).  Refer to Appendix D for 
the Concomitant Medication List . 
h. Motor Threshold Determination (MT) is to be performed prior to the administration of the first  active TMS treatment session.  In addition, MT may 
be repeated at any time during the course of the active TMS treatment sessions based on clinical assessment of the supervising physician.   
Justification for the additional MT must be documented and pre- approved by the Sponsor when possible.  
i. Taper occurs at end of acute treatment and prior to entry into Phase III. . 
,
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 56 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Appendix C. Phase III Schedule of Events 
Phase 6-Month  
Long- term follow up  
Timepoint  Month 1  Month 2 Month 3 Month 4 Month 5 Month 6/ ETb 
Day(s) Taper -30 Day 60 Day 90 Day 120 Day 150 Day 180 
Informed Consent/Assent  Xa      
Efficacy Assessmentsc,h       
HAMD 24/MADRS    X   X 
CDRS-R   X   X 
CGI-S X X X X X X 
QIDS-A17-SR X X X X X X 
Neuropsychological Assessments       
NIH Toolbox Cognition Battery       X 
Safety Assessments        
Vital Signs      X 
YMRSd       
C-SSRSe       
Structural MRIf      X 
Audiometry Assessmentg      X 
Adverse Eventsh,i X ------------------------------------------------------------------------------------------------------------------ X 
Concomitant Treatmenth,j X ------------------------------------------------------------------------------------------------------------------X 
Motor Threshold Determinationk       
TMS Retreatment,c, ,e,l 
(5x/week for 6 weeks)  
See protocol text for description of 
retreatment parameters        
a. An Informed Consent /Assent for this study must be signed prior to initiating any study -related procedures.  
b. Subjects who prematurely discontinue should complete all Month 6 procedures within 2 days after their last TMS treatment session.  
c. TMS retreatment s should begin on a Monday, with daily treatment sessions occurring on Monday through Friday of each week.   All efficacy and 
safety assessments must be completed prior to the start of retreatment.  Efficacy assessments must be completed every other week during each 
TMS retreatment with the assessment beings conducted after the last treatment for the two week block.  TMS treatment to stop when t he CGI-S 
value returns to the Phase III entry score or a full 6 weeks of TMS treatment has been comp leted.  A 3 week taper should follow each retreatment 
session. TMS retreatment can occur multiple times if symptom re- emergence occurs.  
d. Y-MRS to be completed if symptom indicating mania occurs.  If positive, a M.I.N.I./M.I.N.I. KID must be repeated to determine if subject meets full 
DSM-5 criteria for mania or hypomania.  If positive, subject to be discontinued from the study and followed clinically.   
e. C-SSRS to be performed after last TMS retreatment session on last day of the retreatment week.   
f. Performed on a subset of subjects at participating sites.  
g. Audiometry assessments must be performed immediately prior to the start of the TMS retreatment and at the completion of the retreatment course.   
h. Efficacy assessments to be performed the end of each month for monthly visits.  Subjects will be called to assess safety and well -being between 
visits at approximately 2 weeks post previous months visit.  
i. Those AEs occurring following informed consent signature through 30 days after the last st udy visit will be collected.  
j. Medication treatment for emergent insomnia and emergent anxiety is permitted (refer to protocol for usage allowance).   
k. A Motor Threshold Determination (MT) is to be performed prior to the administration of the first TMS treatment in each treatment course.   In 
addition, motor threshold may be repeated at any time during the course of the active TMS treatment sessions based on clinical assessment of the supervising p hysician.  
l. TMS retreatment  is to occur if the CGI -S increases by 1 from the score at entry into Phase III and is confirmed one week later.  
 
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 57 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  Appendix D . Concomitant Medication List  
   
CONCOMITANT MEDICATION LIST  
 
This list should not be considered exhaustive. In general, drugs that are categorized into one of the 
drug categories listed in the table below should be treated similarly.  Contact Neuronetics if questions 
arise. 
 
CLASS:      Drug PRN Chronic  
ANTIASTHMA DRUGS    
  Theo -Dur (theophylline)  N N 
 Bronchodilators    
  Alupent (metaproterenol), Proventil (albuterol), Ventolin (albuterol)  Y Y 
 Steroids    
  Inhaled (Beclovent [beclomethasone], Azmacort [triamcinolone], 
Vanceril [beclomethasone])  Y Y 
  Oral C N 
 Leukotriene antagonists    
  Accolate (zafirlukast), Zyflo (zileuton), Singulair (monoleukast)  N Y 
     
ANTICOAGULANTS    
  Coumadin (warfarin)  N Y  
(w/ stable 
protime) 
     
ANTICHOLINGERGICS    
  Cogentin (benztropine), Artane (trihexyphenidyl), etc.  N N 
  Phenylpropanolamine (PPA) and pseudoephedrine  N N 
     
ANTIHISTAMINE and DECONGESTANTS    
 Sedating    
  Anticholinergic (Benadryl [diphenhydramine], chlorpheniramine, 
brompheniramine, Atarax [hydroxyzine]) (not for psychiatric indications)  N N 
 Non-sedating    
  Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)  Y Y 
  Hismanal (astemizole)  N N 
     
ANTI-INFECTIVE AGENTS    
 Antibacterial antibiotics (Penicillin, sulfa, etc.)  Y Y 
 Antifungal agents  (ketoconazole, fluconazole, etc.)    
  Topical creams and ointments  Y Y 
  Oral antifungals (single -dose for vaginitis OK)  Y N 
 Antiviral agents    
  Zovirax (acyclovir), Famvir (famcyclovir), Valtrex (valacyclovir)  Y Y 
  Antiretroviral drugs (e.g. AZT, protease inhibitors)  N N 
     
ANTI-NEOPLASTIC AGENTS  N N 
     
SKELETAL MUSCLE RELAXANTS    
  Lioresal (baclofen), Flexeril (cyclobenzaprine), Parafon Forte N N 
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 58 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  CLASS:      Drug PRN Chronic  
(chlorzoxazone), Robaxin (methocarbamol), Soma (carisoprodol)  
ANALGESICS AND ANTIPYRETICS    
  Nonsteroidal anti -inflammatory agents (aspirin, ibuprofen, naproxen)  Y Y 
  Opiate Agonists / Partial Agonists (including Ultram [tramadol])  N N 
  Miscellaneous analgesics & antipyretics (acetaminophen, paracetamol)  Y Y 
 
CARDIOVASCULAR DRUGS (All drugs in this category must be stable for at least 3 months)  
CARDIAC DRUGS    
  Calcium Channel Blockers  for coronary disease or angina (see also 
"Antihypertensives") (Calan [verapamil], Cardizem [diltiazem], Norvasc 
[amlodipine], Procardia [nifedipine])  N Y 
 Antiarrhythmics    
  Cordarone (amiodarone), lidocaine (note: local anesthesia injection OK), 
Mexitil (mexiletine), Norpace (disopyramide), Procan (procainamide), 
quinidine, Tambocor (flecainide)  N N 
  Digoxin (blood levels must be monitored)  N Y 
     
ANTI-HYPERTENSIVE AGENTS  (All anti -hypertensives must be stable dose x 1 month)  
  ACE Inhibitors (Vasotec, Capoten, Zestril)  N Y 
  Angiotensin receptor blockers (Cozaar)  N Y 
  Calcium Channel Blockers  N Y 
  Diuretics  Y Y 
  Phentolamine  N N 
Beta-Adrenergic Blockers (see also  Anti-Migraine )   
  Low lipid solubility/CNS penetration  (Corgard [nadolol], Tenormin 
[atenolol])  Y Y 
  High lipid solubility/CNS penetration  (Inderal [propranolol], Lopressor 
[metaprotereno]), (low lipid solubility preferred)  Y Y 
 Peripherally -acting alpha adrenergic agents    
  Cardura (doxazosin), Hytrin (terazosin), Minipress (prazosin)  Y Y 
 Centrally -acting alpha adrenergic agents    
  Aldomet (methyldopa), Catapres (clonidine)  N N 
 All others  (quanethidine , reserpine, etc.)  N N 
     
ANTILIPEMIC AGENTS    
  Niacin (no slow -release preparations), Lipitor (atorvastatin), Lopid 
(gemfibrozil), Mevacor (lovastatin), Zocor (simvastatin)  N Y 
     
VASODILATING AGENTS    
  Hydralazine  N Y 
  minoxidil  (topical OK)  N C 
     
ANTI-CONVULSANTS  N N 
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 59 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  CLASS:      Drug PRN Chronic  
PSYCHOTHERAPEUTIC AGENTS    
  Antidementia drugs (donepezil, etc.), Antidepressants, Antipsychotics 
(Thorazine, Prolixin, etc.), Miscellaneous Psychotherapeutic Agents  N N 
 Anxiolytics (per protocol)  Y N 
 Stimulants  N  
 Sedatives and Hypnotics    
  Barbiturates, Benzodiazepines  (except those allowed per the protocol) , 
Other hypnotic agents  N N 
  Ambien (zolpidem; per protocol), chloral hydrate (per protocol), Sonata 
(zaleplon; per protocol), Lunesta (eszopiclone; per protocol), Rozerem 
(ramelteon; per protocol)  Y N 
     
ANTIMANIC AGENTS    
  Anticonvulsants, lithium  N N 
     
HORMONES & SYNTHETIC SUBSTITUTES    
  Corticosteroids (methylprednisolone, prednisone)  Y C 
  Mineralocorticoids (Florinef [fludrocortisone])  N C 
  Topical steroids (creams, ointments, eyedrops)  Y Y 
  pregnenolone  N N 
 Androgens  N N 
  DHEA, testosterone, danazol  N N 
 Contraceptives    
  Hormonal (dose must be stable for at least 3 months) : Oral, Vaginal 
Ring, Patch, Injections, Norplant (levonorgestrel)   N Y 
  Intrauterine device  Y Y 
  Latex condom , diaphragm and or cervical cap with spermicide  Y Y 
 Estrogen replacement  (postmenopausal, stable dose for â‰¥3 months)  N Y 
 Thyroid (stable dose for â‰¥3 months and thyroid function tests within normal 
limits .  Clinical significance to be determined by the physician ) N Y 
     
ANTIDIABETIC AGENTS    
  Oral hypoglycemic agents  N Y 
  Insulinâ€™s  Y Y 
   
DERMATOLOGIC AGENTS    
  Topical steroid preparations, Rogaine (topical minoxidil), Miscellaneous 
creams, ointments, etc.  Y Y 
     
VITAMINS  Y Y 
   
OVER-THE-COUNTER SUPPLEMENTS    
  chromium picolinate, DHEA, melatonin, pregnenolone, St. Johnâ€™s Wort  N N 
     
 
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 60 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  CLASS:      Drug PRN Chronic  
GASTROINTESTINAL DRUGS    
  Cisapride (propulsid)  Y Y 
 Antiemetics    
  Over -the-counter (e.g., Emetrol [dextrose], Coke syrup)  Y Y 
  Phenothiazines & related drugs (Compazine [prochloroperazine ], 
Phenergan [promethazine], Reglan [metoclopramide], Tigan 
[trimethobenzamide]), Anzemet (dolasetron), Kytril (granisetron), Zofran 
(ondansetron)  C N 
  Marinol (dronabinol),  N N 
 Antacids    
  AlternaGel (aluminum hydroxide), Amphojel  (aluminum hydroxide), 
Basaljel (aluminum carbonate), Bicitra (sodium citrate), Maalox (calcium carbonate), MagOX (magnesium oxide), Mylanta (magnesium 
hydroxide), Tums (calcium carbonate), UroMag (magnesium oxide)  Y Y 
 Antidiarrhea agents    
  Arco-Lase  (trizyme), Furoxone (furazolidone), Motofen (difenoxin), 
Sandostatin (octreotide acetate)  N N 
  Imodium (loperamide), Lomotil (diphenoxylate), Pepto -Bismol (bismuth 
subsalicylate)  Y N 
 Cathartics & Laxatives    
  Colace (docusate), enemas, Metamucil, Perdiem, Senokot, Soflax, 
Unifibre  Y Y 
  Dialose (docusate)  Y Y 
 Antisecretory agents    
 H2 Blockers  N N 
  Axid (nizatidine), Pepcid (famotidine), Zantac (ranitidine)  Y Y 
 Proton pump inhibitors    
  Prevacid (lansoprazole), Prilosec (omeprazole)  Y Y 
 Miscellaneous gastrointestinal drugs    
  Carafate (sucralfate)  Y Y 
  Reglan (metoclopramide)  N N 
  Levsin (L -hyoscyamine sulfate)  Y Y 
     
ANTI-MIGRAINE    
  DHE 45 (dihydroergotamine), Imitrex (sumatriptan), methysergide, 
Midrin (isometheptene mucate), Zomig (zolmitriptan)  N C 
  Fiorinal (butalbital, ASA, caffeine), Cafergot (ergotamine)  Y C 
  Nonsteroidal anti -inflammatory drugs (ibuprofen, naproxen, Toradol, 
etc.) Y Y 
 Beta-blocking drugs    
  Corgard (nadolol), Tenormin (atenolol), Other beta-blockers (e.g., 
Inderal [propranolol])  Y Y 
     
SKIN & MUCOUS MEMBRANE AGENTS  Y Y 
     
  
Protocol 44-02219-000  NeuroStarÂ® TMS Adolescent MDD RCT  
Page 61 of 61    
                           Revision C,  31 Aug 2015   
CONFIDENTIAL  CLASS:      Drug PRN Chronic  
MISCELLANEOUS DRUGS    
  Acutane, All over -the-counter diet pills,  Ionamin (phentermine resin), 
Lioresal  (baclofen), Wellbutrin (bupropion), Zyban (bupropion)  N N 
  Allopurinol, colchicine  Y Y 
  Fosamax (alendronate)  N Y 
  Gold compounds, hydroxychloroquine, and methotrexate for severe 
arthritis  N C 
  Smoking cessation aids (Nicorrette, nicotine patches)  C C 
  Chantix (varenicline)  N N 
     
ENDNOTES    
N = Never to be used in this study.  
Y = Can be used in this study for either PRN or Chronic use as indicated in the table.  
C = Call for Sponsor approval.  Approval for these medications is generally granted if the patient is 
otherwise acceptable, including stable medical condition, no undue risk, no other "marginal" considerations in the medical history or concomitant medications. Or may be used during the long- term 
maintenance phase with certain restrictions.  
 
 
 